1 C C JC20 Rec'd PCT/PTO 2 0 MAR 2002

FORM-PTO-1390 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE ATTORNEY'S DOCKET NUMBER (Rev. 9-2001) TRANSMITTAL LETTER TO THE UNITED STATES 003300-920 DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) **CONCERNING A FILING UNDER 35 U.S.C. 371** unassigned INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/SE00/02082 26 October 2000 28 October 1999 TITLE OF INVENTION **NOVEL COMPOUNDS** APPLICANT(S) FOR DO/EO/US THOMAS BRODIN, PIA J. KARLSTRÖM, LENNART G. OHLSSON, JESPER M. TORDSSON, PHILIP P. KEARNEY and BO H. K. NILSON Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: \boxtimes This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 冈 This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), 3. (9) and (21) indicated below. 4. The US has been elected by the expiration of 19 months from the priority date (Article 31). \boxtimes 5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)) a. is attached hereto (required only if not communicated by the International Bureau). \boxtimes has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). 7 Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. \boxtimes have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). \boxtimes 9. An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 20 below concern/document(s) or information included: 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. A FIRST preliminary amendment. 14. A SECOND or SUBSEQUENT preliminary amendment. 15. A substitute specification. 16. A change of power of attorney and/or address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 18. A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). \boxtimes Other items or information: A certified copy of Swedish Application No. 9903895-2, filed 28 October 1999, was submitted during 20. the international phase of examination. Thus the claim for priority has been perfected.



21839

u.s. APPLICATION NO. (If kn unassigned	··1·0·7·0·8 86 3	9 INTERNATIONAL APPL PCT/SE00/02				RNEY'S DOCKET NUMBER
21. A The following	g fees are submitted:			CALC	CULATIONS	PTO USE ONLY
Basic National Fee (37 CFR 1.492(a)(1)-(5)):			 			
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to U.S. PATENT AND TRADEMARK						
OFFICE and International Search Report not prepared by the EPO or JPO						
International preliminary examination fee (37 CFR 1.482) not paid to U.S. PATENT AND TRADEMARK OFFICE but International Search Report prepared by the EPO or JPO						
International preliminary examination fee (37 CFR 1.482) not paid to U.S. PATENT AND TRADEMARK OFFICE						
but international search fee (37 CFR 1.445(a)(2)) paid to U.S. PATENT AND TRADEMARK OFFICE\$740.00 (958)						
International preliminary examination fee (37 CFR 1.482) paid to U.S. PATENT AND TRADEMARK OFFICE						
but all claims did n	ot satisfy provisions of PCT A		·			
I TRADEMARK OFFI	ninary examination fee (37 CF ICE Ified provisions of PCT Article					
und un ciamis satis						
		APPROPRIATE BASI		\$	1,040.00	
Surcharge of \$130.00 (months from the earlies	154) for furnishing the path of t claimed priority date (37 CF	r declaration later than R 1.492(e)).	20 🗆 30 🗆	L.		
Claims	Number Filed	Number Extra	Rate			
Total Claims	57 -20 =	37	X\$18.00 (966)	\$	666.00	
Independent Claims	1 -3 =	0	X\$84.00 (964)	\$		
Multiple dependent clain	n(s) (if applicable)		+ \$280.00 (968)	\$		
	**************************************	TOTAL OF ABOVE	CALCULATIONS =	\$ '	1,706.00	
Reduction for ½ for filin	g by small entity, if applicable	(see below).	+	\$		-
			SUBTOTAL =	\$ 1	1,706.00	
Processing fee of \$130.00 (156) for furnishing the English translation later than 20 30 30 months from the strong fee of saliest claimed priority date (37 CFR 1.492(1)).			\$			
		TOTAL	NATIONAL FEE =	\$ 1	,706.00	
Fee for recording the end an appropriate cover she	closed assignment (37 CFR 1 eet (37 CFR 3.28, 3.31). \$40	.21(h)). The assignment r	nust be accompanied by	\$	40.00	·
•			EES ENCLOSED =	\$ 1	746.00	
					nount to be	
					refunded:	\$
a. Small entity	status is hereby claimed.			<u>.</u>	chargeu.	
S S	ne amount of \$1,746.00	to cover the above fe	es is enclosed.			
	e my Deposit Account No. <u>02</u>			ve fees.	A duplicate of	copy of this sheet
d.						
NOTE: Where an	NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.				137(a) or (b))	
SEND ALL CORRESPONDENCE TO:						
Benton S. Duffett, Jr. BURNS, DOANE, SWECKER & MATHIS, L.L.P. P.O. Box 1404						
Alexandria, Virginia 22313-1404 (703) 836-6620 Benton S. Duffett, Jr. NAME						
			2,030 EGISTRATION NUMBER		March 20,	2002



Patent Attorney's Docket No. <u>003300-920</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Thomas BRODIN et al.) Group Art Unit: Not yet assigned
Serial No.: 10/088,639) Examiner: Not yet assigned
Filed: March 20, 2002) Confirmation No.: 7152
For: NOVEL COMPOUNDS) ATTENTION: BOX SEQUENCE

REPLY

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notification of Defective Response dated August 20, 2002, please amend the above-identified application as follows:

IN THE SPECIFICATION:

In compliance with 37 C.F.R. § 1.823(a), please insert the attached paper copy of the "Sequence Listing" after the last page of the above-identified application to replace the Sequence Listing previously filed on July 19, 2002.

Patent

Serial No.: 10/088,639

Attorney's Docket No. 003300-920

REMARKS

The paper copy of the Sequence Listing for the subject application, is by this amendment, added after the last page of the application to replace the Sequence Listing previously filed on July 19, 2002.

Favorable consideration on the merits is respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Deborah H. Yellin

Registration No. 45,904

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: September 16, 2002



#4.

Patent Attorney's Docket No. <u>003300-920</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Thomas Brodin et al.) Group Art Unit: Not yet assigned
Serial No.: 10/088,639) Examiner: Not yet assigned
Filed: March 20, 2002) ATTENTION: BOX SEQUENCE
For: NOVEL COMPOUNDS) Confirmation No.: 7152

REPLY

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In response to the Notification of Missing Requirements Under 35 U.S.C. 371 dated May 20, 2002, please amend the above-identified application as follows:

IN THE SPECIFICATION:

In compliance with 37 C.F.R. §1.823(a), please insert the attached paper copy of the "Sequence Listing" after the last page of the above-identified application to replace the Sequence Listing identified on pages 1-22 after the Figures.

Serial No.: 10/088,639

Atty. Dkt. No.: 003300-920

REMARKS

The paper copy of the Sequence Listing for the subject application, is by this amendment, added after the last page of the application to replace the Sequence Listing identified on pages 1-22 after the Figures.

Favorable consideration on the merits is respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Deborah H. Yellu

Registration No. 45,904

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: July 19, 2002



Patent Attorney's Docket No. <u>003300-920</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Thomas Brodin <i>et al</i> .) Group Art Unit: Not yet assigned
Serial No.: 10/088,639) Examiner: Not yet assigned
·)
Filed: March 20, 2002) ATTENTION: BOX SEQUENCE)
For: NOVEL COMPOUNDS) Confirmation No. 7152

DECLARATION PURSUANT TO 37 C.F.R. §§1.821-1.825

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

I, Deborah H. Yellin, declare as follows:

- 1. That the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same in compliance with §1.821(f).
- That the submission, filed in accordance with 37 C.F.R. §1.821(g)[or (h)], herein does not include new matter [or go beyond the disclosure in the international application].
- 3. That the substitute copy of the computer readable form, submitted in accordance with 37 C.F.R. §1.825(d), is identical to that originally filed.

looseese oszooz

Serial No.: 10/088,639 Atty. Dkt. No. 003300-920

I hereby declare that all statements made herein of my own knowledge are true and that all statements were made on information and belief and are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

	July 19, 2002	
Date		

Registration No. 45,904

JC13 Rec'd PCT/PTO 2 0 MAR 2002

Patent Attorney's Docket No. <u>003300-920</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)	BOX PCT
THOMAS BRODIN et al.)	Attention: DO/EO/US
Application No.: (Unassigned))	Group Art Unit: (unassigned)
Filed: March 20, 2002)	Examiner: (unassigned)
For: NOVEL COMPOUNDS)	

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

This is a national phase filing of International Application No. PCT/SE00/02082, filed October 26, 2000.

Please amend the Application as indicated.

IN THE ABSTRACT:

Please add the Abstract of the Disclosure that is provided on a separate sheet.

IN THE CLAIMS:

Kindly replace Claim 17, 22 to 24, 28 to 30, 32 to 40, 45 to 48, 51 and 52 as follows:

17. (Amended) A target structure displayed in, or on the surface of, tumour cells, said target structure

- a) having the ability of being specifically blocked by and to specifically block the binding structure of an antibody as defined in claim 1, and other binding structures with similar binding properties,
 - b) being displayed in, and on the surface of, human gastrointestinal epithelial cells,
- c) having substantial homology with $\alpha 6$ and/or $\beta 4$ integrin chains or variants thereof, representing a shared or unique epitope,
 - d) being highly expressed on the surface of tumour cells, and
 - e) being a target for cytotoxic effector mechanisms.
- 22. (Amended) A target structure according to claim 17, which is expressed homogenously in human colonic epithelial cells and less in pancreatic duct and bile duct cells.
- 23. (Amended) A target structure according to claim 17, the expression of which is correlated to gastrointestinal epithelial differentiation.
- 24. (Amended) A target structure according to claim 17, which comprises essentially the amino acid sequence of $\alpha 6$ integrin shown in SEQ ID NO: 3 and/or of $\beta 4$ integrin shown in SEQ ID NO: 4, and/or one or more fragments, and/or variants or splice variants, and or subunits, thereof.

- 28. (Amended) A target structure according to claim 24 recognised, exclusively or not, in its non-reduced form by the binding structure comprised by the antibody, or a derivative or a fragment thereof, having a binding structure for a target structure displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells, said binding structure comprising the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23-33 (CDR1), 49-55 (CDR2), 88-98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158-162 (CDR1), 177-193 (CDR2), 226-238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties.
- 29. (Amended) A substance which binds to the target structure as defined in claim 17, which substance is an organic chemical molecule or a peptide.
- 30. (Amended) A substance, which is an anti-idiotype of a binding structure to said target structure as defined in claim 17.
- 32. (Amended) A substance which blocks the function of the target structure as defined in claim 17, which substance is an organic chemical molecule or a peptide.

10088639 . 032002

- 33. (Amended) A binding structure which recognizes a target structure as defined in claim 17, and which is of an organic chemical nature.
- 34. (Amended) A pharmaceutical composition comprising as an active principle an antibody as defined in claim 1.
- 35. (Amended) A pharmaceutical composition comprising as an active principle a target structure as defined in claim 17.
- 36. (Amended) A pharmaceutical composition comprising as an active principle a substance as defined in claim 29.
- 37. (Amended) A vaccin composition comprising as an active principle an antibody as defined in claim 1.
- 38. (Amended) A method of therapy for treating conditions based on an antiangiogenic mechanism, whereby an antibody as defined in claim 1 is administered to a human subject.
- 39. (Amended) A method of treating human metastatic diseases, wherein an antibody as defined in claim 1 is administered to a human subject.

- 40. (Amended) A method of in vitro histopathological diagnosis and prognosis of human malignant desease, whereby a sample is contacted with an antibody as defined in claim 1 and an indicator.
- 45. (Amended) A method for in vitro diagnosis and prognosis of human malignant disease, whereby concentrations in bodily fluids of an antigen comprising a target structure as defined in claim 17.
- 46. (Amended) A method for in vitro diagnosis and prognosis of human malignant disease, whereby concentrations in bodily fluids of an antibody as defined in claim 1 is assayed.
- 47. (Amended) A method for in vitro diagnosis and prognosis of human malignant disease, whereby concentrations in bodily fluids of a complex of a) an antigen comprising a target structure, as defined in claim 17 is assayed, and b) an antibody, or a derivative or a fragment thereof, having a binding structure for a target structure displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells, said binding structure comprising the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23-33 (CDR1), 49-55 (CDR2), 88-98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158-162 (CDR1), 177-193

Application No. (<u>Unassigned</u>) Attorney's Docket No. <u>003300-920</u> Page 6

(CDR2), 226-238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties, is assayed.

- 48. (Amended) A method for in vivo diagnosis and prognosis of human malignant disease, whereby the localisation of an antibody, as defined in claim 1, to tumour deposits in a human subject is determined.
 - 51. (Amended) A method according to claim 48 which is quantitative.
- 52. (Amended) A method for therapy of human malignant disease, whereby an antibody, as defined in claim 1, is administered to a human subject.

Please add the following new Claims 53 to 57.

- 53. (New) A vaccin composition comprising as an active principle a target structure as defined in claim 17.
- 54. (New) A vaccin composition comprising as an active principle a substance as defined in claim 29.

- 55. (New) A method of therapy for treating conditions based on an antiangiogenic mechanism, whereby a target structure as defined in claim 17 is administered to a human subject.
- 56. (New) A method of therapy for treating conditions based on an antiangiogenic mechanism, whereby a substance as defined in claim 29 is administered to a human subject.
- 57. (New) A method for in vitro diagnosis and prognosis of human malignant disease, whereby concentrations in bodily fluids of a complex of a) a target structure, as defined in claim 29, is assayed, and b) an antibody or a derivative or a fragment thereof, having a binding structure for a target structure displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells, said binding structure comprising the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23-33 (CDR1), 49-55 (CDR2), 88-98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158-162 (CDR1), 177-193 (CDR2), 226-238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties, is assayed.

Application No. (<u>Unassigned</u>) Attorney's Docket No. <u>003300-920</u> Page 8

REMARKS

The present Amendment modifies the claim format only so as to eliminate the use of multiple dependency.

An Information Disclosure Statement is being filed concurrently herewith.

The examination and allowance of the Application are respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By

Benton S. Duffett, Jr. Registration No. 22,030

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: March 20, 2002

JC13 Rec'd PCT/PTO 2 0 MAR 2002

Application No. (Unassigned)
Attorney's Docket No. 003300-920
Mark-up of Abstract - Page 1 of 1

Attachment to Preliminary Amendment dated March 20, 2002

Abstract of the Disclosure

An antibody, or a derivate or a fragment thereof, having a binding structure for a target structure is described. The antibody is displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells. Said binding structure comprises the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23-33 (CDR1), 49-55 (CDR2), 88-98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158-162 (CDR1), 177-193 (CDR2, 226-238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties. There is also described a target structure displayed in, or on the surface of tumour cells, vaccine compositions, pharmaceutical compositions as well as methods related to human malignant diseases.

JC13 Rec'd PCT/PTO 2 0 MAR 2002

Application No. (Unassigned) Attorney's Docket No. 003300-920 Mark-up of Claims - Page 1 of 6

- 17. (Amended) A target structure displayed in, or on the surface of, tumour cells, said target structure
- a) having the ability of being specifically blocked by and to specifically block the binding structure of an antibody as defined in [any one of claims 1-14] claim 1, and other binding structures with similar binding properties,
 - b) being displayed in, and on the surface of, human gastrointestinal epithelial cells,
- c) having substantial homology with $\alpha 6$ and/or $\beta 4$ integrin chains or variants thereof, representing a shared or unique epitope,
 - d) being highly expressed on the surface of tumour cells, and
 - e) being a target for cytotoxic effector mechanisms.
- 22. (Amended) A target structure according to [any one of claims 17-21] claim 17, which is expressed homogenously in human colonic epithelial cells and less in pancreatic duct and bile duct cells.
- 23. (Amended) A target structure according to [any one of claims 17-22] claim 17, the expression of which is correlated to gastrointestinal epithelial differentiation.
- 24. (Amended) A target structure according to [any one of claims 17-23] claim 17, which comprises essentially the amino acid sequence of α6 integrin shown in SEQ ID

Application No. (Unassigned) Attorney's Docket No. 003300-920 Mark-up of Claims - Page 2 of 6

Attachment to Preliminary Amendment dated March 20, 2002 Mark-Up Copy of Claims 17, 22 to 24, 28 to 30, 32 to 40, 45 to 48, 51 and 52 NO: 3 and/or of β4 integrin shown in SEQ ID NO: 4, and/or one or more fragments, and/or variants or splice variants, and or subunits, thereof.

- 28. (Amended) A target structure according to [any one of claims 24-27] claim 24 recognised, exclusively or not, in its non-reduced form by the binding structure comprised by the antibody [as defined in any one of claims 1-16], or a derivative or a fragment thereof, having a binding structure for a target structure displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells, said binding structure comprising the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23-33 (CDR1), 49-55 (CDR2), 88-98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158-162 (CDR1), 177-193 (CDR2), 226-238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties.
- 29. (Amended) A substance which binds to the target structure as defined in [any one of claims 17-28] claim 17, which substance is an organic chemical molecule or a peptide.

Application No. (Unassigned) Attorney's Docket No. 003300-920 Mark-up of Claims - Page 3 of 6

- 30. (Amended) A substance, which is an anti-idiotype of a binding structure to said target structure as defined in [any one of claims 17-28] claim 17.
- 32. (Amended) A substance which blocks the function of the target structure as defined in [any one of claims 17-28] claim 17, which substance is an organic chemical molecule or a peptide.
- 33. (Amended) A binding structure which recognizes a target structure as defined in [any one of claims 17-28] claim 17, and which is of an organic chemical nature.
- 34. (Amended) A pharmaceutical composition comprising as an active principle an antibody as defined in [any one of claims 1-16] claim 1.
- 35. (Amended) A pharmaceutical composition comprising as an active principle a target structure as defined in [any one of claims 17-28] claim 17.
- 36. (Amended) A pharmaceutical composition comprising as an active principle a substance as defined in [any one of claims 29-32] <u>claim 29</u>.

Application No. (Unassigned) Attorney's Docket No. 003300-920 Mark-up of Claims - Page 4 of 6

- 37. (Amended) A vaccin composition comprising as an active principle an antibody as defined in [any one of claims 1-16, or a target structure as defined in any one of claims 17-28, or a substance as defined in any one of claims 29-32] claim 1.
- 38. (Amended) A method of therapy for treating conditions based on an antiangiogenic mechanism, whereby an antibody as defined in [any one of claims 1-16, or a target structure as defined in any one of claims 17-28, or a substance as defined in any one of claims 29-32,] claim 1 is administered to a human subject.
- 39. (Amended) A method of treating human metastatic diseases, wherein an antibody as defined in [any one of claims 1-16] claim 1 is administered to a human subject.
- 40. (Amended) A method of in vitro histopathological diagnosis and prognosis of human malignant desease, whereby a sample is contacted with an antibody as defined in [any one of claims 1-17] claim 1 and an indicator.
- 45. (Amended) A method for in vitro diagnosis and prognosis of human malignant disease, whereby concentrations in bodily fluids of an antigen comprising a target structure as defined in [any one of claims 17-28] claim 17.

Application No. (Unassigned)
Attorney's Docket No. 003300-920
Mark-up of Claims - Page 5 of 6

- 46. (Amended) A method for in vitro diagnosis and prognosis of human malignant disease, whereby concentrations in bodily fluids of an antibody as defined in [any one of claims 1-16] claim 1 is assayed.
- 47. (Amended) A method for in vitro diagnosis and prognosis of human malignant disease, whereby concentrations in bodily fluids of a complex of a) an antigen comprising a target structure, as defined in [any one of claims 17-28, or a structure, as defined in any one of claims 29-32,] claim 17 is assayed, and b) an antibody, [as defined in any one of claims 1-16,] or a derivative or a fragment thereof, having a binding structure for a target structure displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells, said binding structure comprising the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23-33 (CDR1), 49-55 (CDR2), 88-98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158-162 (CDR1), 177-193 (CDR2), 226-238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties, is assayed.

Application No. (Unassigned) Attorney's Docket No. 003300-920 Mark-up of Claims - Page 6 of 6

- 48. (Amended) A method for in vivo diagnosis and prognosis of human malignant disease, whereby the localisation of an antibody, as defined in [any one of claims 1-16] claim 1, to tumour deposits in a human subject is determined.
- 51. (Amended) A method according to [any one of claims 48-50] claim 48 which is quantitative.
- 52. (Amended) A method for therapy of human malignant disease, whereby an antibody, as defined in [any one of claims 1-16] claim 1, is administered to a human subject.

WO 01/30854

15

20

25

30

JC13 Rec'd PCT/PTO 2 0 MAR 2002

10/poto

NOVEL COMPOUNDS

The present invention is related to an antibody, or a derivate, or a fragment thereof, having a binding structure for a target structure displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells; and to a target structure displayed in, or on the surface of tumour cells; vaccine compositions; pharmaceutical compositions; as well as methods related to human malignant diseases.

10 BACKGROUND OF THE INVENTION

Surgery is the primary treatment of colorectal cancer leading to five-year survival rates of 90 to 40 percent depending on the state of tumour progression from Dukes Stage A to C. Conventional adjuvant therapy that includes radiation therapy and chemotherapy has been able to reduce the death rates further by approximately 30 percent (1). Despite these achievements cancer of the colon and rectum is one of the major causes of death in human cancer. Immunological therapy has been extensively attempted. However, colon cancer has generally been resistant to immunotherapy and is considered to be of low immunogenicity. Patients with colon cancer neither respond to IL-2 treatment or adoptive transfer of in vitro cultured tumour infiltrating lymphocytes otherwise active in patients with immunogenic malignancies such as melanoma. Most encouraging however, Riethmüller et al. reported a 32 percent decreased seven-year death rate for Dukes Stage C colorectal cancer treated after primary tumour resection with a naked murine mAb directed to a tumour and normal epithelial associated antigen (Ep-CAM) (2), indicating that other immunotherapeutic modalities could be effective.

A significant improvement of adjuvant immunotherapy and of the treatment of more advanced stages of cancer

PCT/SE00/02082

5

10

15

20

25

30

35

2

should require a more potent effector mechanism than provided by a naked mAb. In principle, an increased potency should require an increased tumour selectivity of the targeting antibody.

The limited number of colon cancer associated antigens defined today have been discovered using hybridoma produced murine mAbs resulting from xenogenic immunisations with human tumours (3).

The use of large phage display libraries for the identification of novel tumour-associated antigens can be expected to significantly speed up the process of finding target molecules useful for tumour immunotherapy and diagnosis. Such identification of target molecules could be accomplished by the selection and screening of antibody phage libraries on cultured tumour cells and tissue sections to generate specific reagents defining in vitro and in vivo expressed antigens (4). The phage display technology has been established as an efficient tool to generate monoclonal antibody reagents to various purified antigens, and the construction and successful selection outcome from immune, naive and synthetic antibody phage libraries have been described in several studies (5).

Non-immune libraries are favourable with respect to their general applicability, making unique libraries for every single target unnecessary. On the other hand, sufficiently large and high quality non-immune libraries are difficult to construct and a target discovery process using these libraries should require efficient subtractive selection methods when based on complex antigens.

A phage library of a more moderate size has now been constructed from a near human primate immunised with complex human antigens. This represents an approach that takes advantage of an in vivo pre-selected repertoire. Such libraries should be enriched for specificities to tumour specific epitopes in a reduced background reactivity to xenogeneic antigens (6). Furthermore, as

PCT/SE00/02082

5

10

15

20

25

30

35

3

compared to the mouse, primate antibodies demonstrating close sequence homology with human antibodies should not be immunogenic in man (7).

Novel primate antibodies from a phage library that define selectively expressed colon cancer associated antigens have now been identified. The therapeutic potential, demonstrated by T cell mediated killing of cultured colon cancer cells coated with two of these antibodies fused to engineered superantigens, is comparable with superantigens fused to murine Fab fragment specific for colon cancer associated antigens such as EP-CAM, for which there has previously been established the therapeutic capacity in experimental systems (8).

There is also provided a method for efficient positive and subtractive cell selection of phage antibodies that should facilitate future identification of novel phenotype specific antigens including tumour associated antigens using antibodies from large phage libraries.

BRIEF SUMMARY OF THE INVENTION

The present invention is related in a first aspect to an antibody, or a derivative or a fragment thereof, having a binding structure for a target structure displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells, said binding structure comprising the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23-33 (CDR1), 49-55 (CDR2), 88-98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158-162 (CDR1), 177-193 (CDR2), 226-238 (CDR3) of the amino acid sequence shown in NO: 2, or other binding structures with similar unique binding properties.

WO 01/30854 PCT/SE00/02082

4

In one embodiment the antibody is phage selected. In another embodiment the sequences are of Macaca fascicularis origin. A further embodiment of the invention is a derivative of said antibody, which derivative is of human origin. The sequences preferably have an identity of at least 84% to corresponding sequences of human origin. Preferably, the antibody has low immunogenicity or non-immunogenicity in humans.

In a further embodiment, the antibody has been derivatised by genetically linking to other polypeptides, and/or by chemical conjugation to organic or non-organic chemical molecules, and/or by di-, oligo- or multimerisation.

10

20

25

30

In still a further embodiment, said antibody is genetically linked or chemically conjugated to cytotoxic polypeptides or to cytotoxic organic or non-organic chemical molecules.

In a further embodiment, said antibody is genetically linked or chemically conjugated to biologically active molecules.

In still a further embodiment, said antibody is genetically linked or chemically conjugated to immune activating molecules.

In another embodiment, said antibody has been changed to increase or decrease the avidity and/or affinity thereof.

In still another embodiment, said antibody has been changed to increase the production yield thereof.

In a further embodiement, said antibody has been changed to influence the pharmacokinetic properties thereof.

In still a further embodiment, said antibody has been changed to give new pharmacokinetic properties thereto.

In a further embodiment, said antibody is labeled and the binding thereof is inhibited by an unlabeled form of said antibody and not by other binding structures, and

PCT/SE00/02082

10

15

20

25

30

35

5

not inhibiting the binding of other binding structures having other specificities.

A further embodiment is an antibody, the binding structure of which recognizes a non-reduced form of $\alpha 6\beta 4$ integrin.

In another aspect the invention relates to a target structure displayed in, or on the surface of, tumour cells, said target structure

- a) having the ability of being specifically blocked by and to specifically block the binding structure of an antibody as defined in any one of claims 1-14, and other binding structures with similar binding specificities,
- b) being displayed in, and on the surface of, human questrointestinal epithelial cells,
- c) having substantial homology with $\alpha 6$ and/or $\beta 4$ integrin chains or variants thereof, representing a shared or unique epitope,
- d) being highly expressed on the surface of tumour cells, and
 - e) being a target for cytotoxic effector mechanisms.

By substantial homology in this context is meant homology in those parts of the target structure which are relevant for the binding of the antibody.

In one embodiment of said target structure, the binding structure is labeled and the binding thereof is inhibited by an unlabeled form of said binding structure and not by other binding structures, and not inhibiting the binding of other binding structures having other binding specificies.

In a further embodiment of said target structure said binding structure comprises one or more of the complementarity determining region (CDR) sequences comprising essentially the amino acids number 23-33, 49-55, 88-98, 158-162, 177-193, 226-238 of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties.

10

15

20

25

30

35

6

In still a further embodiment of said target structure said binding structure is an antibody, which antibody in a further embodiment comprises the variable region of a light chain comprising essentially the amino acids number 1-109 of the amino acid sequence shown in SEQ ID NO:2, and the variable region of a heavy chain comprising essentially the amino acids number 128-249 of the amino acid sequence shown in SEQ ID NO: 2.

Said target structure is in a further embodiment expressed homogenously in human colonic epithelial cells and less in pancreatic duct and bile duct cells.

In still a further embodiment, the expression of said target structure is correlated to gastrointestinal epithelial differentiation.

In another embodiment, said target structure comprises the amino acid sequence of $\alpha6\beta4$ integrin, of which the $\alpha6$ part is shown in SEQ ID NO: 3 and the $\beta4$ part is shown in SEQ ID NO: 4. Another embodiment of the target structure comprises homo- or heteromonomers or homo- or heteromultimers of said $\alpha6\beta4$ integrin and/or of said one or more fragments and/or variants and/or subunits thereof. Preferably, said target structure has an apparent molecular weight in its non-reduced form of from 90 to 140 kDa, most preferred fro 80 to 160 kDa.

In still further embodiments the target structure compirses a peptide or polypeptide(s) comprising essentially any one of the amino acid sequences shown in SEQ ID NOs: 5-51, or comprises a molecule complexed to said polypeptide(s).

In the case of a target structure comprising amino acid sequences from the $\alpha 6\beta 4$ integrin, said target structure may in a further embodiment be recognised, exclusively or not, in its non-reduced form by the binding structure comprised by the antibody as defined above.

The invention relates in a further aspect to a substance which binds to the target structure as defined

10

15

20

25

30

7

above, which substance is an organic chemnical molecule or a peptide. In one embodiment, said substance is an anti-idiotype of said target structure. Said anti-idiotype may be specifically blocked by and specifically block a binding structure having similar binding specificity for said target structure.

In a still further aspect, the invention relates to a substance that blocks the function of the target structure as defined above, which substance is an organic molecule or a peptide.

In another aspect, the invention relates to a binding structure which recognises a target structure as defined above and which is of an organic chemical nature.

In a further aspect, the invention relates to a pharmaceutical compositin comprising as an active principle an antibody as defined above, or a target structure as defined above, or a substance as defined above.

In still a further aspect, the invention is related to a vaccine composition comprising as an active principle abn antibody as defined above, or a target structure as defined above, or a substance as defined above.

In a further aspect, the invention is related to a method of therapy for treating conditions based on an anti-angiotenic mechanism, whereby an antibody as defined above, or a target structure as defined above, or a substance as defined above, is administered to a human subject.

In another aspect, the invention is related to a method of treating human metastatic diseases, wherein an antibody as defined above is administered to a human subject.

In a further aspect the invention is related to a
method of in vitro histopathological diagnosis and
prognosis of human malignant disease, whereby a sample is

WO 01/30854 PCT/SE00/02082

8

contacted with an antibody as defined above and an indicator.

5

10

15

20

25

30

35

Embodiments of said method comprise tumour typing, tumour screening, tumour diagnosis and prognosis, and monitoring premalignant conditions.

In still a further aspect, the invention is related to a method for in vitro diagnosis and prognosis of human malignant disease, whereby concentrations in bodily fluids of an antigen comprising a target structure, as defined above, or an anti-idiotype of said target structure, as defined above, is assayed.

A further aspect of the invention is related to a method for in vitro diagnosis and prognosis of human malignant disease, whereby concentrations in bodily fluids of an antibody as defined above is assayed.

A still further aspect of the invention is related to a method for in vitro diagnosis and prognosis of human malignant disease, whereby concentrations in bodily fluids of a complex of a) an antigen comprising a target structure, as defined above, or an anti-idiotype of said target structure, as defined above, and b) an antibody, as defined above, is assayed.

In a still further aspect, the invention is related to a method for in vivo diagnosis and prognosis of human malignant disease, whereby the localisation of an antibody, as defined above, to tumour deposits in a human subject is determined. Said antibody is preferably administered to the subject before the determination. In one embodiment said antibody is accumulated in tumour deposits. In a further embodiment, said method is quantitative.

Another aspect of the invention is related to a method for therapy of human malignant disease, whereby an antibody, as defined above, is administered to a human subject. In one embodiment of this method said antibody has been changed by being genetically linked to molecules giving the combined molecule changed pharmacokinetic

WO 01/30854 PCT/SE00/02082

9

properties. In another embodiment said antibody has been changed by being derivatised.

DETAILED DESCRIPTION OF THE INVENTION

The identification of novel tumour associated antigens (TAAs) is pivotal for the progression in the fields of tumour immunotherapy and diagnosis. In relation to the present invention, there was first developed, based on flow cytometric evaluation and use of a minilibrary composed of specific antibody clones linked to different antibiotic resistance markers, methods for positive and subtractive selection of phage antibodies employing intact cells as the antigen source. An scFv phage library (2.7×10⁷) was constructed from a primate (Macaca fascicularis) immunised with pooled human colon carcinomas. This library was selected for three rounds by binding to Colo205 colon adenocarcinoma cells, and proteolytic elution followed by phage amplification.

10

15

20

25

30

35

Several antibodies reactive with colon carcinomas and with restricted reactivity with a few epithelial normal tissues were identified by immunohistochemistry. One clone, A3 scFv, recognised an epitope that was homogeneously expressed in 11/11 of colon and 4/4 pancreatic carcinomas studied and normal tissue expression restricted to subtypes of epithelia in the gastrointestinal tract. The A3 scFv had an apparent overall affinity about 100-fold higher than an A3 Fab, indicating binding of scFv homodimers. The cell surface density of the A3 epitope, calculated on the basis of Fab binding, was exceptionally high, approaching 3 million per cell.

Efficient T cell mediated killing of colon cancer cells coated with A3 scFv fused to the low MHC class II binding superantigen mutant SEA(D227A) is also demonstrated. The identified A3 molecule thus represents a TAA with properties that suggests its use for immunotherapy of colon and pancreatic cancer.

10

DISCUSSION

10

15

20

25

30

In relation to the present invention, efficient protocols for phage selection to be used for the identification of cell phenotype specific antibody fragments from large phage libraries was developed. The target specificities for the applications as exemplified were for colon tumour associated antigens.

First the frequency of pIII-scFv fusion protein surface display in the phage population using the herein presented phagemid construct for phage propagation was analysed. A higher level of C215 scFv display was achieved as compared to previous reports. This should favour subtractive selection efficiency, but also increases the probability of avidity selection of low affinity antibodies from libraries.

Specificity of C215 scFv phage binding to colon adenocarcinoma Colo205 cells was clearly demonstrated. Bound phage could be efficiently eluted by use of the protease Genenase that specifically cleaves a target sequence between the phage protein III and the scFv antibody leaving the cells intact after elution. This non-chemical elution method should equally efficiently elute phage antibodies irrespectively of their binding affinity and only phage bound by scFv interactions, adding to the specificity of the process.

The enrichment achieved after three selection rounds on Colo205 cells (500 000 \times) using this selection protocol was similar to that reported by other investigators for selections on complex antigens.

After verifying the performance of the various methodological steps the combined technology was applied to library selections using Colo205 cells.

The library was constructed from a near human species immunised with human tumours. The antibody pool generated this way would potentially include affinity matured antibodies to tumour specific antigens in a limited background of xeno reactivities to widespread

WO 01/30854 PCT/SE00/02082

10

15

20

25

30

35

11

normal human tissue antigens (6). The antibodies identified recognised tumour and tissue differentiation antigens with restricted normal tissue distribution. All of the selected antibodies identified as colon cancer tissue reactive in the primary screening also reacted with viable Colo205 cells in flow cytometry. This restriction to cell surface specificities should reflect the selection process and not the composition of the library, since a suspension of a mixture of tumour tissue components was used for the immunisation.

In a similar previous study extra- and intracellular specificities were identified in an anti-melanoma library produced the same way and selected using tissue sections as the antigen source (4). Tissue sections of resected human colorectal tumours and normal colon (mounted in the same well) were used for the primary screening using immunohistochemistry to assure the clinical relevance of the selected specificities, to increase the efficiency and to obtain more qualitative information as compared to flow cytometric screening.

The selected antibodies could be classified into four antibody specificity groups, distinguished by their reactivity patterns to epithelia in different organs (see Example 1, Table 1). Among these specificity groups, A3 scFv identified the most tumour selective antigen. This A3 TAA was highly, homogeneously and frequently expressed in samples of primary and metastatic colon cancer and of pancreatic cancer. Furthermore, its cell surface expression level as determined with the A3 Fab fusion protein (3 millions epitopes/cell) was exceptionally high and permissive for cell surface mediated cytotoxic effects.

Few, if any, of the frequently expressed human tumour antigens defined are tumour specific, but are commonly related to tissue differentiation such as A3 and the Ep-CAM. However, upregulated expression of these antigens in tumours should provide a basis for a

5

25

30

35

12

therapeutically active dose window. The availability from the circulation of normal tissue compartments expressing the antigen may also be more restricted due to limited capillary permeability and their site of expression in the body (e.g. the exposure of the apical side of gut epithelial cells to circulating antibodies should be very limited).

The clinical experience with the pan-epithelial EpCAM reactive 17-1A mAb supports the feasibility to

identify an effective non-toxic antibody dose. The
restricted expression in epithelia of all of the selected
scFv clones in this work, indicate that these clones in
principal could be evaluated as candidates for immunotherapeutic applications analogously to the 17-1A, e.g.

as full-length mAbs. However, a particular advantage for
the A3 TAA as compared to the Ep-CAM is the lack of
expression in most normal epithelia such as of the lung
and kidney, although the expression in the colon is
similar.

20 The tissue distribution to subtypes of normal epithelia is supported by the selective expression in subtypes of carcinomas originating from the gastrointestinal tract (see Example 2, Table 2).

Several of the previously well-known colon cancer associated antigens (CEA, CA50, CA19-9, CA242, Tag-72)(3) are expressed equally or more restrictedly in normal tissues as compared to the A3 epitope. However, in contrast to the A3 and the C215 Ep-CAM they are more heterogeneously expressed in tumours.

Use of antibodies to the Ep-CAM has demonstrated good clinical results including a survival advantage for colorectal cancer patients in an adjuvant setting (2). With the objective to induce tumour responses even in more advanced stage patients, the introduction of potent effector molecules in conjunction with this antibody will challenge the "normal tissue resistance" seen in the treatment with the naked 17-1A mAb. Preclinically, this

5

10

15

20

25

30

35

13

could be studied in model systems using toxin-conjugated antibodies specific to the murine version of this antigen or animals transgenic for human colon cancer associated antigens.

Previously, antibody immunotoxins have been successfully used to cure mice in models with metastatically growing tumours expressing xeno (human) tumour antigens not expressed in mouse tissues (10). However, the TAAs used are truly tumour specific and the models do not reflect the potential for normal tissue targeted toxicity.

In previous studies we have reported the potential of superantigens as immunostimulatory toxins for tumour immunotherapy (8). Antibody mediated targeting of superantigens attracted large numbers of cytotoxic and cytokine-producing T cells to the tumour site. The superantigen SEA(D227A), mutated for low MHC class II binding affinity, was genetically linked to tumour targeting antibodies. This "tumour-selective" agent was applied to recruit T cells independent of MHC expression in the tumour, thus short-cutting the problems of MHC down regulation and polymorphism that represent significant obstacles for other active immunotherapeutic approaches.

The mini-library of the established "tumour-selective", 1F scFv phage, the "broadly-reactive" C215 phage and the non-specific D1.3 phage antibody clones was an essential tool for the development of protocols for efficient subtractive cell selection. A requirement for this selection principle is that the negative selection is followed by positive selection before phage rescue and amplification, due to the high frequency of non-displaying phage particles. Alternatively, non-displaying phage can be made non-infective by selective proteolysis (G. Winter, pers. comm.). Such a technique may allow the generation of "inert libraries", i.e. libraries that have been extensively negatively preselected (e.g. towards a

PCT/SE00/02082

14

cell in a resting state or a transfectable parental cell).

In conclusion, the "non-wanted" model phage specificity could selectively be subtracted from the phage population by a factor of approx. 100 for each selection round. Future subtractive selections using the developed protocol in combination with the use of large non-immune phage libraries for identification of differentially expressed cell surface antigens will demonstrate whether such an approach prove to be superior 10 to the strategy we used in this study, i.e. positive selection using an in vivo pre-selected immune repertoire, including restrictions and biases such as immunodominance (4). The low affinity and high epitope density demonstrated for the A3 Fab binding to tumour 15 cells as compared to the A3 scFv fusion protein suggests formation of scFv multimers that interact with epitopes that cluster on cell surfaces. Higher affinity monovalent variants of A3 Fab or alternatively, stable divalent constructs such as full-length A3 Fv grafted mAbs 20 compatible with the putative low immunogenicity of A3 should be developed. Such constructs would be suitable for targeting of appropriate effector molecules to this highly expressed gastro-intestinal tumour associated antigen. 25

The invention is further illustrated in the following nonlimiting experimental part of the description. EXMPERIMENTAL PART

Materials and Methods

30 Animals

35

Cynomolgus Macaque (Macaca fascicularis) monkeys were kept and immunised at the Swedish Institute for Infectious Decease Control (SIIDC), Stockholm. Water and food were always available ad libitum. Four monkeys were immunised subcutaneously with 2 ml of a crude suspension of colon cancer tissues in 10 % normal cynomolgus serum in PBS. Booster doses were given day 21, 35, and 49.

WO 01/30854 PCT/SE00/02082

15

Antibody responses were demonstrated in two monkeys where the antigen had been admixed with alum adjuvant. All animals were kept according to Swedish legislation and the experiments were approved by the local ethical committees.

Tissues and cells

5

10

15

20

30

35

Human tumours and normal tissue samples were obtained from Lund University Hospital and Malmö General Hospital, Sweden. The human colorectal cell line Colo205, the human B cell lymphoma cell line Raji and the murine B16 melanoma cell line were from the American Tissue Culture Collection (ATCC, Rockville, MD). The mouse melanoma B16-C215⁺ cells transfected with the expression vector pKGE839 containing the Ep-CAM-1 gene (C215) has been described previously (9).

The human cells were cultured in RPMI 1640 medium (Gibco, Middlesex, UK) supplemented with 10% heat inactivated foetal bovine serum (Gibco) and 0.1 mg/ml gentamycin sulphate (Biological Industries, Kibbutz Beit Haemek, Israel). The mouse cells were cultured in medium additionally supplemented with 1 mM glutamine (Hyclone, Cramlington, UK), 5×10^{-5} M β -mercaptoethanol (ICN, Costa Mesa, CA), 0.2 % NaHCO₃ (Seromed Biochrome, Berlin, Germany), 1×10^{-2} M HEPES (HyClone, UT) and 1×10^{-3} M sodium pyrovate (HyClone). The cells were repeatedly tested for Mycoplasma contamination with Gene-Probe Mycoplasma T. C. test (San Diego, CA).

Phagemid vector and phage library construction

Total spleen RNA was extracted from one of the responding monkeys using an RNA isolation kit from Promega (Mannheim, Germany) and cDNA was amplified using an RNA PCR kit from PE Biosystems (Stockholm, Sweden). The primers for cDNA synthesis of lambda light chain and heavy chain genes and for the assembly of these genes to scFv genes have been reported previously (4). The scFv cDNA was ligated into a phagemid vector (4) in fusion with the residues 249-406 of the M13 gene III. The scFv-

gIII gene was expressed from a phoA promoter and the resulting protein was directed by the $E.\ coli$ heat stable toxin II signal peptide.

Repeated electroporations of 7 μg library vector with scFv gene inserts resulted in a total of 2.7x107 5 primary transformed E. coli TG-1 growing as colonies on minimal agar plates. The colonies were scraped from the plates and grown in 2xYT at 150 rpm and 37°C for 1h. The culture was superinfected with M13K07 helper phage (Promega) in 50 times excess. Ampicillin to a concentra-10 tion of 100 mg/l was added and the culture grown for a further hour. After addition of kanamycin to a concentration of 70 mg/l, the culture was grown for 15 h at 30°C and 250 rpm. The phage particles were harvested from the culture supernatant using two repeated PEG/NaCl 15 precipitations. The precipitated phage was resolved in PBS 1% BSA.

Western blot analysis

A two-fold dilution series of scFv-C215 phage particles (from an undiluted stock of PEG-precip-20 itated/concentrated phage) was applied to separation on a reducing 12% polyacrylamide gel with 1% SDS and 2% β mercaptoethanol. The proteins were transferred to a nitrocellulose membrane (Bio-Rad, Hercules, CA) by electrophoresis. The membrane was blocked with 5% low-fat 25 milk (Semper AB, Stockholm, Sweden) and then incubated with a rabbit antiserum against a protein III derived peptide sequence, AEGDDPAKAAFNSLQASATEC, conjugated to keyhole limpet hemocyanin. Secondary horse radish peroxidase (HRP) conjugated goat-anti-rabbit antibodies 30 (Bio-Rad) were incubated for 30 min. Between all steps the membrane was washed 3 times during 5 min in PBS/ 0.5% Tween 20. The membrane was incubated in substrate (Amersham Pharmacia Biotech, Little Chalfon Buckinghamshire, UK) for one min. A light sensitive film (ECL 35 hyperfilm, Amersham) was exposed to the membrane and developed for 0.5-5 min.

WO 01/30854 PCT/SE00/02082

17

Similarly, to analyse the integrity of purified Fab (A3, including cynomolgus CH1 and Clambda domains), scFv-and Fab (including murine CH1 and Ckappa)-SEA(D227A) fusion proteins (produced as described previously (9)), 12% SDS-PAGEs were performed. The membranes with transferred proteins were incubated with purified polyclonal rabbit anti-SEA antibodies followed by the reagent steps described above.

Model and library phage selection on cells

5

10

15

20

25

30

35

}

Phage suspensions of the lambda light chain library (or of model phage), 10^{12} in 100 μ l PBS/1% BSA, were incubated with 3 million Colo205 cells for 1h on ice. The cells were washed 3 times including a 10-min incubation using 2 ml PBS/1% BSA for each wash. The phage were eluted by adding 50 μ l of 33 μ q/ml Genenase to the cell pellet and incubated for 15 min. Genenase, which is a subtilisin BPN mutant, S24C/H64A/E156S/G169A/Y217L, was kindly provided by Dr. Poul Carter (San Francisco, CA). After centrifugation the supernatant was transferred to a new tube and 250 μ l 1% BSA in PBS was added. To rescue and amplify the selected library (and the model phage particles in the multi-pass experiment), the eluted phage particles were allowed to infect 1 ml, E. coli DH5αF´ $(OD_{600 \text{ nm}} = 1.0)$. The infected bacterial culture was diluted 100 times with 2xYT supplemented with the proper antibiotic and cultured until an OD >1.0 (up to two days).

Finally, to produce soluble scFv the amber suppressor strain HB2151 of *E. coli* was infected with the selected library from the second and third round. After growth on agar plates containing ampicillin, single colonies were cultured in 96 Micro well plates in 2xYT medium supplemented with ampicillin at 30°C for 17 h. After centrifugation, removal of the supernatant to which an equal volume of PBS/1%BSA was added, individual scFvs were analysed for immunoreactivity to sections of human tumours and normal tissues. Briefly, the C-terminal tag,

WO 01/30854 PCT/SE00/02082

18

ATPAKSE, was detected using a rabbit antiserum followed by biotinylated goat anti-rabbit antibodies (DAKO A/S, Copenhagen, Denmark) and StreptABComplex HRP (DAKO A/S) (see "Immunohistochemistry").

5 Immunohistochemistry

3.0

15

20

35

Frozen cryosections (8 μ m) were air-dried on slides, fixed in acetone at -20°C for 10 min and rehydrated in 20% foetal bovine serum in PBS (FBS). Endogenous biotin was blocked with avidin (diluted 1/6) for 15 min and then with biotin (diluted 1/6) for 15 min (Vector Laboratories, Burlingame, CA). Affinity purified and biotinylated rabbit anti-SEA antibodies, 5 μg/ml, were incubated for 30 min followed by StreptABComplex HRP (DAKO A/S, Copenhagen, Denmark), 1/110 diluted in 50 mM Tris pH 7.6 for 30 min. Between all steps the sections were washed 3 times in TBS. The staining reaction was developed for 8 min in 0.5 mg/ml 3,3'-diaminobenzidine tetrahydrochloride (Sigma) dissolved in Tris pH 7.6 with 0.01 percent H2O2. After 10 min counterstaining in 0.5% methyl green, the slides were rinsed for 10 min in tap water and gradually dehydrated in 70-99% ethanol and xylene before mounting in DPX medium (Sigma). Flow cytometry

The Colo205 colon cancer cells were dissociated with 0.02% w/v EDTA and washed with PBS. To follow the development of an antibody response in the monkeys the cells were incubated consecutively with diluted serum, for 1h at 4°C, biotinylated rabbit anti-human IgG antibodies (Southern Biotechnology Ass. Inc., Al, USA) for 30 min, and finally with avidin-PE (Becton Dickinson, Mountain View, CA) for 30 min.

The binding of model phage to the cells was analysed using rabbit-anti-M13 antibodies (produced by immunisation of rabbits with M13 particles) and FITC conjugated donkey anti-rabbit antibodies (Amersham Pharmacia Biotech). The binding of antibodies fused to SEA(D227A) was detected using biotinylated rabbit anti-

10

15

20

25

35

19

SEA antibodies and avidin-PE. All reagents were diluted in PBS/1% BSA. The cells were washed twice with PBS/1% BSA after incubations with reagents and three times including 10 min incubations after binding of phage particles.

Flow cytometric analysis was performed using a FACSort flow cytometer (Becton Dickinson).

Affinity determination on cultured cells

A3 scFv-SEA(D227A), A3 Fab-SEA(D227A) and 1F scFv SEA(D227A) fusion proteins, 80 μg of each protein, were labelled with iodine as described by Bolton and Hunter to a specific activity of 10-15 $\mu Ci/\mu g$. Colo205 cells and Raji cells, 30 000/sample were incubated with the iodinated fusion protein at 100 $\mu l/t$ ube in a two-fold dilution series in 1% BSA for 1h and then washed three times in PBS before measuring bound activity. The concentration of added and bound fusion protein was used for Scatchard analysis. The background binding to the Raji cells was subtracted to calculate the specific binding to the Colo205 cells.

Cytotoxicity assay

The T cell dependent cytotoxicity of the superantigen fusion protein (superantigen antibody dependent cellular cytotoxicity, SADCC) was measured in a standard 4 h chromium-release assay employing ⁵¹Cr-labelled Colo205 cells as target cells and human T cells as effector cells (9). The percent specific lysis was calculated as:

30 100 x <u>cpm experimental release - cpm background release</u> cpm total release - cpm background release

EXAMPLE 1

Generation of tumour binding monoclonal cynomolgus antibodies

Cynomolgus monkeys, Macaca fascicularis (four individuals) were repeatedly immunised with a suspension

10

15

20

35

20

of human colon carcinomas four times every other week. The gradual development of an antibody response in the monkeys was followed by flow cytometric staining of cultured colorectal cells, Colo205, using dilution series of the preimmune and immune sera. An IgG antibody response was elicited only when alum precipitated tumour tissue suspensions were used (two individuals).

The monkey with the highest binding level of immune to preimmune serum antibodies was used for the construction of a large combinatorial scFv phage library of approximately 2.7×107 (estimated from the number of primary transformants). The primate phage library was selected using Colo205 cells. The total phage yield (eluted/added number of phage counted as colony forming units, CFU) from three consecutive selection rounds increased gradually from 1.9×10^{-7} , 1.4×10^{-5} , to 1.2×10^{-3} . Five percent (12/246) of the monoclonal soluble scFv:s produced from the phage library after the third round of selection were demonstrated to bind to sections of a human colorectal cancer tissue and to intact Colo205 cells by flow cytometry. All of the selected antibodies demonstrated individually unique nucleic acid sequences according to Hinf I restriction patterns analysed by 1% agarose gel electrophoresis.

The antibody genes were amplified by polymerase chain reaction using 5 μ l of bacterial cultures and primers complementary to regions 5'and 3' to the scFv gene in the phagemid vector (regions in the phoA promoter and in the M13 gene III).

30 The selected scFv demonstrate individually unique reactivity with epithelia in normal tissues

The colorectal cancer reactive scFv's were classified into specificity groups based on their immunohistochemical reactivity pattern with normal tissues (Table 1). The antibodies studied in detail were A3 scFv (and A3 scFv-SEA(D227A)), A10 scFv, 3D scFv and 1D scFv. The representative antibodies could be

10

15

20

25

21

distinguished from each other by their fine specificity to epithelia in different organs and by their binding to leukocytes. The 1D scFv strongly reacted with gut epithelia and was the only antibody that reacted with cells of polymorph nuclear granulocyte morphology. The 1D scFv also differed from the other antibodies by staining the luminal surface of kidney tubuli and collecting ducts whereas the A10 scFv reacted homogeneously (non-polarly) with these epithelial cells and 3D scFv and A3 scFv were negative. 1D, A10 and 3D, but not A3 scFv also reacted with macrophage-like cells in the lung.

A fifth group of antibodies, not extensively evaluated and thus not included in Table 1, reacted with colon epithelia, leukocytes and Kuppfer cells in the liver. The A3 scFv stands out as demonstrating the most restricted reactivity with the panel of normal tissues used. The most prominent normal tissue reactivity of the A3 was staining of normal colon epithelium. Weak staining were also detected in small ducts of the pancreas and bile ducts of the liver and of substructures in small bowel epithelia. The surface epithelium of one of the two stomach samples was strongly stained by the A3 antibody.

The reactivity pattern of the A3 scFv was confirmed using the fusion protein A3 scFv-SEA(D227A). This format permitted the use of polyclonal rabbit anti-SEA antibodies for immunohistochemical detection, which is a more sensitive detection system demonstrating lower background and tissue crossreactivity as compared to the use of secondary antibodies to the peptide tag, ATPAKSE,

30 at the C-terminus of the scFvs.

PCT/SE00/02082

Table 1 Immunohistochemical reactivity to normal human tissues of soluble scFv fragments from the selected colorectal cancer phage library scFv clone designation

Sephagus	Tissue / sub-structure	n*	A3 **	AlO	3D	1D
Colon		1	0	ND	ND	ND
/ epithelium / non-epithelial tissue D D D Small bowel / villi epithelium / basal glandulae	/ non-epithelial tissue		0	ND	ND	ND
Small bowel		5	++	+	+	++
/ villi epithelium / basal glandulae / non-epithelial tissue 0	/ non-epithelial tissue		0	0	0	granulocytes ++
/ non-epithelial tissue 0 0 0 0 Ventricle / Surface epithelium 0 0, + ++ / glandular epithelium 0 +, ++ 0 ++ / non-epithelial tissue 0 0 0 0 Pancreas 1 0 (+) + ++ / acini + ++ ++ ++ / large ducts 0 0 0 0 0 / non-epithelial tissue 0 0 0 0 0 0 / endocrine 0 0 ND ND <td< td=""><td></td><td>2 .</td><td>(+)</td><td>heterogenously +</td><td>+</td><td>heterogenously (+)</td></td<>		2 .	(+)	heterogenously +	+	heterogenously (+)
Ventricle	/ basal glandulae		+,	+	+	++
gurface epithelium		·	0	.0		0
mon-epithelial tissue		2	0, ++	0	0, +	++
Pancreas	/ glandular epithelium		0	+, ++	0 .	++
/ small ducts			0	0	0	0
/ large ducts		1	o	(+)	+	++
/ non-epithelial tissue	/ small ducts		(+)	(+)	+	++
/ endocrine 0 0 0 0 Liver / hepatocytes 2 0 ND ND ND ND / Kuppfer cells 0 ND ND ND ND / bile ducts (+) ND ND ND ND Kidney / proximal tubuli 1 0 + 0 luminal surface ++ / collecting ducts 0 + 0 luminal surface ++ / glomeruli 0 0 0 0 / non-epithelial tissue 0 0 0 0 Bladder / spithelial tissue 0 ND ND ND / non-epithelial tissue 0 ND ND ND Prostate / epithelial tissue 0 0 0 0 Lung / bronchial epithelium 0 (+) (+) 0 / alveolar epithelial tissue 0 macrophages + macrophages granulocytes ++, macrophages + mac	/ large ducts		0	(+)	+	++
Liver	The state of the s		0	0	٥	0
/ hepatocytes / Kuppfer cells	/ endocrine		0	0	0	0
bile ducts		2	0	ND	ND	ND
Kidney 1 0 + 0 luminal surface ++ / proximal tubuli 0 + 0 luminal surface ++ / collecting ducts 0 + 0 luminal surface ++ / glomeruli 0 0 0 0 / non-epithelial tissue 0 0 0 0 Bladder 1 0 ND ND ND / epithelial tissue 0 ND ND ND Prostate 1 0 ++ + and secreted material ++ / epithelial tissue 0 0 0 0 Lung 1 0 (+) (+) 0 / bronchial epithelium 0 (+) (+) 0 / alveolar epithelial tissue 0 macrophages + macrophages granulocytes ++, macrophages + CNS 1 0 ND ND ND / gray matter 0 ND ND ND	/ Kuppfer cells		0	ND	ND	ND
/ proximal tubuli / distal tubuli / distal tubuli / collecting ducts 0	/ bile ducts		(+)	ND	ND	ND
/ collecting ducts		1	0	+	0	luminal surface ++
/ glomeruli	/ distal tubuli		0	+	0	luminal surface ++
/ non-epithelial tissue 0 0 0 0 Bladder / epithelial tissue 1 0 ND ND ND / non-epithelial tissue 0 ND ND ND ND Prostate / epithelial tissue 1 0 ++ + and secreted material ++ / non-epithelial tissue 0 0 0 0 Lung / bronchial epithelium 0 (+) (+) 0 / alveolar epithelium 0 (+) (+) 0 / non-epithelial tissue 0 macrophages + macrophages granulocytes ++, macrophages + CNS / gray matter 1 0 ND ND ND / gray matter 0 ND ND ND ND	/ collecting ducts		0	+	0	luminal surface ++
Bladder 1 0 ND	/ glomeruli		0	0	0	0
/ epithelial tissue 0 ND ND ND Prostate 1 0 ++ + and secreted material ++ / non-epithelial tissue 0 0 0 0 0 Lung 1 0 (+) (+) 0 / bronchial epithelium 0 (+) (+) 0 / non-epithelial tissue 0 macrophages + macrophages granulocytes ++, the macrophages + CNS 1 0 ND ND ND ND / gray matter / white matter 0 ND ND ND ND	/ non-epithelial tissue	:	0	0	0	0
Prostate		1	0	ND	ND	ND
/ epithelial tissue	/ non-epithelial tissue	:	0	ND	ND	ND
Lung 1 0 (+) 0 / bronchial epithelium / alveolar epithelium 0 (+) (+) 0 / non-epithelial tissue 0 macrophages + macrophages granulocytes ++, the macrophages + CNS 1 0 ND ND ND / gray matter / white matter 0 ND ND ND		1	0	++	. +	
/ bronchial epithelium / alveolar epithelium 0 (+) (+) 0 / non-epithelial tissue 0 macrophages + macrophages granulocytes ++, to macrophages + CNS 1 0 ND ND ND ND / gray matter / white matter 0 ND ND ND	/ non-epithelial tissue	:	0	0	0	0
/ non-epithelial tissue 0 macrophages + macrophages granulocytes ++, to macrophages + CNS 1 0 ND ND ND / gray matter / white matter 0 ND ND ND		1	0	(+)	(+)	0
/ non-epithelial tissue 0 macrophages + macrophages granulocytes ++, to macrophages + CNS 1 0 ND ND ND / gray matter / white matter 0 ND ND ND ND	/ alveolar epithelium		0	(+)	(+)	0
/ gray matter / white matter 0 ND ND ND	/ non-epithelial tissue	2	0	macrophages +	macrophages	
		1	0	ND	ND	ND
Skeletal muscle 1 0 ND ND ND	/ white matter		0	ND	ND	ND
	Skeletal muscle	1	0	ND	ND	ND

Notes to Table 1

- 0 = negative, (+) = weak, + = moderate, ++ = strong, ND = not determined
- * Number of tissue samples examined
- ** The reactivity of A3 scFv has been confirmed with the A3 scFv SEA(D227A) fusion protein

EXAMPLE 2

The A3 tumour-associated antigen is homogeneously and frequently expressed in colorectal and pancreatic tumours 10 The A3 scFv-SEA(D227A) fusion protein was used for immunohistochemical staining of various tumours of epithelial origin (Table 2 and Figure 1). The fusion protein homogeneously and strongly stained 11/11 samples of primary colon cancer tissues and 4/4 metastatic colon 15 cancer samples resected from the ovary, a lymph node and the liver. Pancreatic cancer tumours, 4/4 samples, were equally strongly positive. In contrast, tissue samples of gastric, prostate, breast and non-small cell lung carcinomas were negative. 20

Tumor tissue reactivity of A3 scFv SEA(D227A) Table 2

Tumor tissue	n	Reactivity
Colon cancer, primary tumors	11	All tumor cells are strongly and homogenously stained
Colon cancer metastasis in lymph node, liver and ovary	4	As above
Pancreas cancer	4	As above
Ventricle cancer	2	Negative
Prostate cancer	2	Negative
Breast cancer	2	Negative
Lung carcinoma (non-small cell)	2	Negative
Malignant melanoma	2	Negative

WO 01/30854 PCT/SE00/02082

24

EXAMPLE 3

25

The A3 TAA is highly expressed on the surface of colon cancer cells

The results from several Scatchard plots for affinity determination, based on the binding of the fusion proteins A3 scFv-SEA(D227A), A3 Fab and 1F scFv-SEA(D227A) (1F was classified to the A3 specificity group) to Colo205 cells, are summarised in Table 3. Specific binding was calculated by subtraction of nonspecific binding to human B cell lymphoma Raji cells, a 10 cell line not expressing the A3 and 1F TAAs, from the binding to Colo205 cells. Linear regression was used to calculate the slope and the intercept of the extrapolated line in the Scatchard plot. The A3 scFv-SEA(D227A) fusion protein saturated approximately 10-fold less binding 15 sites per cell as compared to the A3 Fab (approx. 3 million sites per cell) fusion protein, indicating that divalent (multivalent) binding was involved for the scFv. This is supported by the more than 100-fold higher overall affinity (3.6-5.5 nM) for the A3 scFv fusion 20 protein as compared to the A3 Fab (580-780 nM).

A single experiment performed using the 1F scFv-SEA(D227A) fusion protein, demonstrated similar binding affinity and saturation of binding sites as the A3 scFv-SEA(D227A) fusion protein.

Table 3 Scatchard analysis of iodinated fusion proteins binding to Colo205 cells

Fusion protein		n*	Kd (nM)	million sites /cell
A 3	Fab-SEA(D227A)	2	580-7	80	3.0-3.9
АЗ	scFv-SEA(D227A)	3	3.6-5	. 5	0.11-0.39
1F	scFv-SEA(D227A)	1	4.2		0.18

^{*} Number of experiments performed

15

25

30

35

}

25

EXAMPLE 4

A3 and 1F scFv-SEA(D227A) mediate T cell lysis of Colo205 cells

The capacity of the two fusion proteins A3 and 1F scFv-SEA(D227A) to mediate superantigen antibody dependent cellular cytotoxicity (SADCC) towards Colo205 cells was investigated and compared with the positive control C215 Fab-SEA(D227A) and negative control D1.3 scFv-SEA(D227A) fusion proteins. The A3 scFv-SEA(D227A) fusion protein titration approached a plateau for maximal lysis which was similar, approx. 50 percent in this 4 h assay, to that demonstrated for the C215 Fab-SEA(D227A) fusion protein, although at a ten-fold higher concentration (Figure 2). The 1F scFv-SEA(D227A) mediated a similar level of cytotoxicity at a slightly higher concentration as compared to the A3 scFv-SEA(D227A).

The negative control D1.3 scFv SEA(D227A) fusion protein did not mediate any cytotoxicity. EXAMPLE 5

20 Purification of a tumour associated antigen that is recognised by the colon cancer reactive antibody A3.

A tumour extract was made out of xenografted tumour cell line Colo205. The extract was applied to a precolumn coupled with C215Fab-SEAm9, and a column coupled with A3scFv-SEAm9. The columns were in series, during the application of sample but separated prior to elution under alkaline conditions.

A single peak was detected during elution by UV spectroscopy (Figure 3). This eluted fraction from the latter A3-column was collected, neutralised, concentrated, and then analysed by SDS-PAGE under non-reducing conditions (Figure 4). Two bands visible by silver staining (labelled I and II in Figure 4) of apparent molecular weight of approximately 90-140 kDa were cut out and examined by standard peptid mapping methodologies. These two bands corresponds to bands detected by A3 in Western Blot, see example 8. From band

26

I 47 separate tryptic peptide masses were obtained (see SEQ ID NO: 3, Table 4, and Fig 5 for the sequnces and corresponing mass weights) which completely matched to different tryptic peptide masses. as determined by MALDITOF) of the human $\alpha 6$ integrin or $\beta 4$ integrin (see SEQ ID NOs: 5-51 and 3-4, respectively, and Fig 3A and B, respectively, where in Fig 3A the underlinings correspond to the peptides appearing in Fig 3B/SEQ ID NOs: 5-51). From band II 22 separate tryptic peptide masses were obtained which completely matched to different tryptic peptide masses of $\beta 4$ integrin (data not shown). The data show that the $\alpha 6\beta 4$ integrin heterodimer is specifically isolated with the A3-affinity column.

15 Table 4 Peptides/polypeptides derived from human $\alpha 6 \beta 4$ integrin and masses thereof

Sequence	Sequence	Measured	Calculated
No.	1	Mass	Mass
5	LLLVGAPR	838.568	838.551
6	ANRTGGLYSCDITARGPCTR	2226.131	2226.050
7	VVTCAHRYEK	1262.637	1262.631
8	RQHVNTK	882.524	882.490
9	CYVLSQNLR	1152.618	1152.583
10	FGSCQQGVAATFTK	1501.706	1501.710
11	DFHYIVFGAPGTYNWK	1914.881	1914.917
12	DEITFVSGAPR	1191.625	1191.600
13	ANHSGAVVLLK	1108.600	1108.647
14	DGWQDIVIGAPQYFDR	1879.865	1879.897
15	DGEVGGAVYVYMNQQGR	1842.811	1842.844
16	WNNVKPIR	1026.608	1026.584
17	NIGDINQDGYPDIAVGAPYDDLGK	2520.213	2520.189
18	GISPYFGYSIAGNMDLDR	1975.913	1975.922
19	NSYPDVAVGSLSDSVTIFR	2026.992	2027.008
20	SRPVINIQK	1054.644	1054.637
21	LRPIPITASVEIQEPSSR	1993.066	1993.108
22	VNSLPEVLPILNSDEPK	1863.920	1864.006
23	TAHIDVHFLK	1180.665	1180.647
24	FSYLPIQK	995.601	995.556
25	DIALEITVTNSPSNPR	1726.866	1726.897
26	SEDEVGSLIEYEFR	1672.764	1672.770
27	VESKGLEKVTCEPQK	1731.866	1731.895

15

28	REITEKQIDDNRK	1644.792	1644.866
29	FSLFAER	869.476	869.452
30	YQTLNCSVNVNCVNIR	1954.003	1953.927
31	LNYLDILMR	1150.644	1150.629
32	AFIDVTAAAENIR	1390.739	1390.733
33	LPNAGTQVR	955.523	955.532
34	VSVPQTDMRPEK	1386.727	1386.705
35	EPWPNSDPPFSFK	1547.730	1547.717
36	NVISLTEDVDEFR	1536.744	1536.754
37	TODYPSVPTLVR	1375.718	1375.722
38	RGEVGIYQVQLR	1417.801	1417.791
39	ALEHVDGTHVCQLPEDQK	2075.965	2075.981
40	GNIHLKPSFSDGLK	1512.749	1512.817
41	MDAGIICDVCTCELQK	1928.901	1928.822
42	YEGOFCEYDNFQCPR	2012.795	2012.790
43	SCVQCQAWGTGEKKGR	1879.865	1879.890
44	DEDDDCTYSYTMEGDGAPGPNSTVL	3103.229	3103.278
	VHK	1501 550	1501 710
45	QEVEENLNEVYR	1521.779	1521.718
46	VAPGYYTLTADQDAR	1640.779	1640.791
47	VPLFIRPEDDDEK	1572.778	1572.790
48	DVVSFEQPEFSVSR	1625.758	1625.781
49	LLELQEVDSLLR	1427.760	1427.810
50	VCAYGAQGEGPYSSLVSCR	2060.883	2060.916
51	VLVDNPKNR	1054.644	1054.600

Materials and Methods.

Solubilisation of Tumour Tissue

Human colon cancer tissue expressing the A3 antigen was provided by hospitals in Sweden and stored frozen at -70°C in the tissue bank at ABR. Frozen colon cancer tissues were sliced with a scalpel and transferred into a tube containing cold isotonic sucrose buffer (0.25M sucrose, 10mM KCl, 1.5M MgCl₂, 50mM Tris-HCl pH 7.4 at 25°C) containing 1% (v/v) Nonidet P-40 (NP-40) and protease inhibitors (CompletetTMProtease Inhibitor Cocktail Tablet, Boehringer Mannheim). Tissue was homogenised with an Ultra-Turrax homogeniser and were left to solubilise at 0°C. The solubilised preparation was centrifuged at 11,000 rpm (Hettich centrifuge Universal 30 RF rotor), to remove cell debris. The supernatant was further centrifuged at 108,000g at 4°C

(Beckman Ultracentrifuge Ti-60 rotor), and finally filtered through a 0.2 μm Minisart plus filter (Sartoriuis AG Gottingen Germany).

Affinity Purification of tissue antigens

A3scFv-SEAm9 was coupled to a NHS-activated HiTrap® column (Pharmacia Biotech Uppsala Sweden), according to The control and prethe manufacturer's recommendations. column were coupled with C215Fab-SEAm9, and the control, pre-column and column were set up in series. All columns were washed with pre-wash buffer (20mM Tris HCl pH7.5 at 4°C containing 0.2% NP 40). The extract was loaded onto the column at 0.1ml/min, and the flow through was recirculated. The columns were then washed with start buffer. Bound antigen was eluted in a pH gradient of diethylamine starting at pH 7.5 up to 11.0. 2.5 ml of eluant was collected and concentrated down to 75 μ l. The purification was performed at 4°C using an AKTA FPLC system (Amersham Pharmacia Biotech Uppsala Sweden). Eluted protein was analysed by SDS PAGE and silver staining. Individual bands were excised, digested with trypsin and the masses of the peptide were determined using a MALDI-TOF instrument by Protana A/S (Odense, Denmark). The peptide masses were then compared in a computer search with all tryptic peptide masses for each protein in the SWISSPROT database, a service provided by Protana A/S (Odense Denmark).

EXAMPLE 6

WO 01/30854

5

15

20

25

30

35

A3scFv-SEAm9 detects a novel α6β4 integrin epitope
Commercial antibodies to human α6 integrin and β4
integrin were compared to A3 on normal and malignant
colon sections. The reactivity, shown in Figure 6,
demonstrates that A3 is restricted to the colon
epithelium (Fig 6[i]), and malignant cell in the tumour
(Fig 6 [ii]). Commercial antibody NKI-GoH3 to α6
integrin, also reacted with normal colon (Fig 6 [iii])
and colon cancer (Figure 6 [iv]). Reaction was seen in
epithelial cells of colon and malignant cells (arrows)

10

15

20

25

30

35

29

but also in blood vessels (BV), some stromal components (s) and in muscularis mucosae (mm). The reaction observed with commercial ASC-3 anti- $\beta4$ integrin antibody was similar to that noted with anti- $\alpha6$ antibody but weaker, in both normal colon (v) and colon cancer (vi). Materials and Methods Antibody

A3 scFv was selected from the M fascicularis library. The VH and VL genes from this were released by restriction enzyme digestion and fused to the Staphylococcal Enterotoxin AE chimeric mutant (D227A) to generate the A3scFv-SEAm9. This demonstrated very low levels of non-specific binding and allowed sensitive detection by secondary antibodies. ASC-3 anti-human- β 4 integrin antibody and NKI-GoH3 anti-human- α 6 integrin antibody were from Becton Dickinson (Copenhagen, Denmark) Immunohistochemistry

Tumour and normal tissue samples were obtained from the Department of Surgery Lund Hospital. These were rate-frozen in iso-pentane, which had been pre-cooled in liquid nitrogen. Samples were stored at -70°C until sectioned. After cryosectioning the sections were air dried over night, fixed in cold acetone and blocked with avidin/biotin (Vector Burlingame CA). Primary antibody was then added to the section for one hour.

The secondary antibodies were incubated for 30 minutes followed by streptavidin-biotin/HRP (Dakopatts Copenhagen Denmark) for a further 30 minutes. Extensive washing was perfromed between all these steps with 50mM Tris pH 7.6, 0.15M NaCl. Diaminobenzidine (DAB) was used as chromogen and the sections were counterstained in 0.5% methyl green. Controls included a non-tissue reactive Fab and SEA-D227A or no primary antibody. All antibodies were used at a final concentration of 5 μ g/ml. Results were expressed as negative, weak, moderate or strong staining.

10

15

20

25

30

35

30

EXAMPLE 7

The A3 Tumour Associated Antigen reacted with $\alpha 6$ and $\beta 4$ integrin antibodies in a capture ELISA

Crude tumor extract or A3 antigen purified by A3affinity chromatography (see example 5) was analysed by a capture ELISA. Commercial antibodiy ASC-3 specific for beta 4 integrin were used as capture antibody, to which different dilutions of crude tumor extract was applied. This was then chased with A3scFv-SEAm9. Bound A3scFv-SEAm9 was then detected with anti-SEA-HRP (Fig 7A). In Figure 7B the commercial anti-α6 integrin antibody NKI-GoH3 was used to capture different dilutions of the concentrated A3-affinity purified eluate. In a similar way as in Figure 7A the captured proteins were chased with A3scFv-SEAm9 and detected with anti-SEA-HRP. In both experiments a concentration dependent signal was detected. These results confirm the specificity of A3 to $\alpha 6\beta 4$ intergin heterodimer, which was also shown to be specifically isolated from the A3-affinity column in example 5.

Material and Methods

Commercial antibodies NKI-GoH3 or ASC-3 (Becton Dickinson Copenhagen Denmark) 100 μ l, were used to coat the well of an E.I.A./R.I.A.-plate (Costar) in 0.05 M NaHCO3, pH 9.6. The reaction was allowed to continue overnight at 4°C, after which the plates were washed 4 times in DPBS + 0.05 % Tween 20. Wells were then blocked with 200 μ l 3 % non-fat milk powder in DPBS + 0.05 % Tween 20, for 1-2 h at room temperature (RT) with shaking. Wells were again washed as above and 100 μ l antigen extract diluted in 3 % non-fat milk powder in DPBS + 0.05 % Tween 20, was applied for 2 h at RT with shaking. Wells were again washed (4 x DPBS + 0.05 % Tween 20) after which 100 μ l of the primary antibody diluted in 3 % non-fat milk powder in DPBS + 0.05 % Tween 20 was incuabted for 2 h at RT with shaking. Wells were washed again as above and 100 μ l of the secondary antibody

15

20

25

30

diluted in 3 % non-fat milkpowder in DPBS + 0.05 % Tween 20 was added to each well for 1 h at RT with shaking. Wells were again washed as above and colour developed by the addition of 100 μ l peroxidase substrate (Sigma Fast OPD Peroxidase Substrate Tablet Set P-9187). The reaction was allowed to continue for 30 min at RT, in the dark and shaking before the reaction was stopped by the addition of 50 μ l 3 M $\rm H_2SO_4$. The absorbance was read at 490 nm.

10 EXAMPLE 8

Western Blot analysis of the A3 tumour antigen A3-affinity purified tumour antigen extracts were separated by SDS-PAGE and transferred to membranes for Western blot analysis. Extracts were applied directly or heated to 100°C for 5 minutes or heated to 100°C for 5 minutes but in the presence of mercaptoethanol (BME) (Figure 8). The membranes were then probed with A3scFv-SEAm9 and anti-SEA-HRP or anti-human-α6 integrin or anti-human- $\beta4$ integrin antibodies. The anti- $\beta4$ integrin antibody did not react with any protein on the membrane (Fig 8[ii]). The anti-human- α 6 integrin reacted with a major specie with apparent molecular weight between 90 - 140 kDa in the A3-affinity purified tumour antigen extract (Figure 8[iii]). The same species was also detected by A3scFv-SEAm9, which also was detected after heating but was much weaker under reduced conditions (with BME present) (Figure 8[i]). The major band detected in the 90 - 140 kDa interval corresponds to the bands in example 5, that were analysed by peptide mapping and were found to contain $\alpha 6$ integrin and $\beta 4$

Materials and Methods

integrin.

ASC-3 anti-human-β4 integrin antibody and NKI-GoH3 antihuman-α6 integrin antibody were from Becton Dickinson (Copenhagen, Denmark). Samples were resolved by SDS-PAGE in 0.25M tris-glycine pH 8.9 and 0.1%SDS at 100V through the upper gel, then 170V through the resolving gel.

10

15

32

Molecular weight standards (Biorad broad Range, Biorad) were included on all gels. Resolved samples were transferred to nitrocellulose (Biorad) in transfer buffer (10 mM Tris base, 2M glycine, 40% (v/v) methanol) at 100V Membranes were blocked with 5% (w/v) BSA/TBS for 1 hour. for at least 2 hours at 4°C, then incubated with the appropriate antibody diluted in 5% BSA/TBS/0.2% azide. This reaction was allowed to proceed for at least 2 hours at RT, after which the membrane was washed extensively in TBST-T. Bound antibody was detected by incubation of membranes for 1 hour with HRP conjugated antibody diluted in TSB-T containing 5% milk powder. Membranes were then incubated with enhanced chemiluminescence (ECL) detection reagents (Renaissance $^{^{\!\varpi}}$ NEN $^{^{\rm TM}}$ Life Science Products, Boston MA) for 1 minute and exposed to film for up to 1 hour.

PCT/SE00/02082

33

REFERENCES

15

25

35

- 1. DeCosse JJ, Tsioulias GJ, Jacobson JS. Colorectal cancer: detection, treatment, and rehabilitation. CA Cancer J Clin 1994; 44: 27-42.
- 2. Riethmuller G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998; 16: 1788-1794.
- Kuhn JA, Thomas G. Monoclonal antibodies and
 colorectal carcinoma: a clinical review of diagnostic applications. Cancer Invest 1994; 12: 314-323.
 - 4. Tordsson J, et al. Efficient selection of scFv antibody phage by adsorption to in situ expressed antigens in tissue sections. J Immunol Methods 1997; 210: 11-23.
 - 5. Aujame L, Geoffroy F, Sodoyer R. High affinity human antibodies by phage display. Hum Antibodies 1997; 8: 155-168.
- 6. Clark RK, Trainer DL, Bailey DS, Greig RG
 Immunohistochemical analysis of antiserum from rhesus
 monkeys immunized with human colon carcinoma. Cancer Res
 1989; 49: 3656-3661.
 - 7. Lewis AP, et al. Cloning and sequence analysis of kappa and gamma cynomolgus monkey immunoglobulin cDNAs.

 Dev Comp Immunol 1993; 17: 549-560.
 - 8. Brodin TN, et al. Man-made superantigens: Tumor-selective agents for T-cell-based therapy. Adv Drug Deliv Rev 1998; 31: 131-142.
- 9. Dohlsten M, et al. Monoclonal antibody30 superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci U S A 1994; 91: 8945-8949.
 - 10. Liu C, et al. Eradication of large colon tumor xenografts by targeted delivery of maytansinoids. Proc Natl Acad Sci USA 1996; 93: 8618-8623.

10

15

20

25

30

35

34

LEGENDS TO FIGURES

Figure 1 The A3 tumour-associated antigen is homogeneously expressed in primary and metastatic tumours

Immunohistochemical staining of frozen and acetone fixed sections of human tumour tissues using A3 scFv-SEA(D227A) and C215 Fab-SEA(D227A) at 70 nM. The A3 scFv fusion protein reacted strongly and homogeneously with both primary colon and pancreatic carcinoma resected from tumour patients. A representative staining of a primary colon cancer is shown for C215 Fab-SEA(D227A) in (A) and for A3 scFv-SEA(D227A) in (B). Staining by A3 scFv-SEA(D227A) of a colon cancer liver metastasis is shown in (C) and of a primary pancreatic cancer in (D).

Figure 2 A3 scFv-SEA(D227A) coated Colo205 tumour cells are efficiently killed by T cells.

Superantigen antibody dependent cellular cytotoxicity (SADCC) towards Colo205 cells mediated by A3 scFv-SEA(D227A) reached the same maximal cytotoxicity as the anti-Ep-CAM fusion protein C215 Fab-SEA(D227A), although at a ten-fold higher concentration. The absence of cytotoxicity mediated by the D1.3 scFv-SEA(D227A) demonstrates the need of a tumour targeting antibody moiety in the fusion protein.

Figure 3

Immunoaffinity chromatography of tumor extract on a A3scFv-SEAm9 coupled column. Protein bound to A3 coupled columns was washed extensively then eluted as described in Materials and Methods in Example 5. The eluted fractions were examined by UV spectroscopy (arrow) and a single peak identified. The sample was eluted with a pH gradient as indicated by an x.

Figure 4

A3 antigen preparation was separated on a non-reduced SDS PAGE and silver-stained. Previous Western analysis had defined a molecular weight range in which the A3 antigen was believed to reside. The bands evident

within this region (Labelled I and II) were excised for peptide mapping analysis

Figure 5A and 5B

Epithelial integrin $\alpha6\beta4$: complete primary structure of $\alpha6$ and variant forms of $\beta4$ (precursor) (Tamura et al J Cell Biol 111:1593-1604 (1990)). The matched peptides shown in SEQ ID NOs: 5-51 are underlined in the sequences of human $\alpha6$ (Fig 5A) integrin and $\beta4$ (precursor) (Fig 5B) integrin as published.

10 Figure 6

15

20

25

30

Immunohistochemistry of normal and malignant colon using A3scFv and commercial anti-human $\alpha 6$ and $\beta 4$ integrin monoclonal antibodies.

Figure 7A and 7B

Capture ELISA. In fig 7A monoclonal antibody ASC-3 specific for β4 integrin was used as capture antibody, to which different dilutions of crude tumor extract was applied. In fig 7B the anti-α6 integrin monoclonal antibody NKI-GoH3 was used to capture different dilutions of the concentrated A3-affinity purified eluate. In both fig 7A and 7B the captured integrin antigen was then successfully detected with A3scFv-SEAm9.

Figure 8A and 8B

Western blot analysis of the eluate from the A3-affinity column. The primary antibodies used are (i) and (ii) A3scFv-SEAm9, (iii) ASC-3 anti-human- β 4 integrin antibody and (iv) NKI-GoH3 anti-human- α 6 integrin antibody. Lane A - the eluate was applied directly, lane B - the eluate was heated to 100°C for 5 minutes, and lane C - the eluate was heated to 100°C for 5 minutes but in the presence of mercaptoethanol. Positions of molecular weight standards are indicated.

PCT/SE00/02082

36

CLAIMS

- 1. An antibody, or a derivative or a fragment 5 thereof, having a binding structure for a target structure displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells, said binding structure comprising the complementarity determining region (CDR) sequences in the 10 light chain comprising essentially the amino acids number 23-33 (CDR1), 49-55 (CDR2), 88-98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158-162 (CDR1), 177-193 (CDR2), 226-238 (CDR3) of 15 the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties.
- An antibody according to claim 1, which is phage
 selected.
 - 3. An antibody according to claim 1, wherein the sequences are of Macaca fascicularis origin.
 - 4. A derivative of an antibody according to claim 1, which is of human origin.
- 5. An antibody according to claim 1, wherein the sequences have an identity of at least 84% to corresponding sequences of human origin.
 - 6. An antibody according to claim 1, which has low immunogenicity or non-immunogenicity in humans.
- 7. An antibody according to claim 1, which has been derivatised by genetically linking to other polypeptides, and/or by chemical conjugation to organic or non-organic chemical molecules, and/or by di-, oligo- or multimerisation.
- 8. An antibody according to claim 1, which is genetically linked or chemically conjugated to cytotoxic

polypeptides or to cytotoxic organic or non-organic chemical molecules.

- 9. An antibody according to claim 1, which is genetically linked or chemically conjugated to biologically active molecules.
- 10. An antibody according to claim 1, which is genetically linked or chemically conjugated to immune activating molecules.
- 11. An antibody according to claim 1, which has been changed to increase or decrease the avidity and/or affinity thereof.
 - 12. An antibody according to claim 1, which has been changed to increase the production yield thereof.
- 13. An antibody according to claim 1, which has been changed to influence the pharmacokinetic properties thereof.
 - 14. An antibody according to claim 1, which has been changed to give new pharmacokinetic properties thereto.
- 15. An antibody according to claim 1, which is
 labeled and the binding thereof is inhibited by an
 unlabeled form of said antibody and not by other binding
 structures, and not inhibiting the binding of other binding structures having other binding specificities.
- 16. An antibody according to claim 1, wherein said binding structure recognises a non-reduced form of $\alpha6\beta4$ integrin.
 - 17. A target structure displayed in, or on the surface of, tumour cells, said target structure
- a) having the ability of being specifically blocked 30 by and to specifically block the binding structure of an antibody as defined in any one of claims 1-14, and other binding structures with similar binding properties,
 - b) being displayed in, and on the surface of, human gastrointestinal epithelial cells,
 - c) having substantial homology with $\alpha 6$ and/or $\beta 4$ integrin chains or variants thereof, representing a shared or unique epitope,

38

- d) being highly expressed on the surface of tumour cells, and
 - e) being a target for cytotoxic effector mechanisms.
- 18. A target structure according to claim 17,

 wherein the binding structure is labeled and the binding thereof is inhibited by an unlabeled form of said binding structure and not by other binding structures, and not inhibiting the binding of other binding structures having other binding specificities.
- 19. A target structure according to claim 17, wherein said binding structure comprises one or more of the complementarity determining region (CDR) sequences comprising essentially the amino acids number 23-33, 49-55, 88-98, 158-162, 177-193, 226-238 of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties.
 - 20. A target sturcture according to claim 17, wherein said binding structure is an antibody.
- 21. A target structure according to claim 20,
 20 wherein said antibody comprises the variable region of a
 light chain comprising essentially the amino acids number
 1-109 of the amino acid sequence shown in SEQ ID NO:2,
 and the variable region of a heavy chain comprising
 essentially the amino acids number 128-249 of the amino
 25 acid sequence shown in SEQ ID NO: 2.
 - 22. A target structure according to any one of claims 17-21, which is expressed homogenously in human colonic epithelial cells and less in pancreatic duct and bile duct cells.
- 23. A target structure according to any one of claims 17-22, the expression of which is correlated to gastrointestinal epithelial differentiation.
 - 24. A target structure according to any one of claims 17-23, which comprises essentially the amino acid sequence of $\alpha6$ integrin shown in SEQ ID NO: 3 and/or of $\beta4$ integrin shown in SEQ ID NO: 4, and/or one or more

35

39

fragments, and/or variants or splice variants, and or subunits, thereof.

- 25. A target structure according to claim 24, which comprises homo- or hetero-monomers or homo- or hetero-multimers of said $\alpha 6\beta 4$ integrin and/or of said one or more fragments and/or variants and/or subunits thereof.
- 26. A target structure according to claim 24, which has an apparent molecular weight in its non-reduced form of from 90 to 140 kDa, most preferred from 80 to 160 kDa.
- 27. A target structure according to claim 24, which comprises a peptide or polypeptide(s) comprising essentially any one of the amino acid sequences shown in SEQ ID NOs: 5-51, or comprises a molecule complexed to said polypeptide(s).
- 28. A target structure according to any one of claims 24-27 recognised, exclusively or not, in its non-reduced form by the binding structure comprised by the antibody as defined in any one of claims 1-16.
- 29. A substance which brinds to the target structure as defined in any one of claims 17-28, which substance is an organic chemical molecule or a peptide.
 - 30. A substance, which is an anti-idiotype of a binding structure to said target structure as defined in anyone of claims 17-28.
- 31. A substance according to claim 30, which antiidiotype is specifically blocked by and specifically blocks a binding structure having binding specificity for said target structure.
- 32. A substance which blocks the function of the target structure as defined in any one of claims 17-28, which substance is an organic chemical molecule or a peptide.
 - 33. A binding structure which recognizes a target structure as defined in any one of claims 17-28, and which is of an organic chemical nature.

- 34. A pharmaceutical composition comprising as an active principle an antibody as defined in any one of claims 1-16.
- 35. A pharmaceutical composition comprising as an active principle a target structure as defined in any one of claims 17-28.
 - 36. A pharmaceutical composition comprising as an active principle a substance as defined in any one of claims 29-32.
- or a target structure as defined in any one of claims 1-16, or a target structure as defined in any one of claims 17-28, or a substance as defined in any one of claims 29-32.
- 38. A method of therapy for treating conditions based on an anti-angiogenic mechanism, whereby an antibody as defined in any one of claims 1-16, or a target structure as defined in any one of claims 17-28, or a substance as defined in any one of claims 29-32, is administered to a human subject.
 - 39. A method of treating human metastatic diseases, wherein an antibody as defined in any one of claims 1-16 is administered to a human subject.
- 40. A method of in vitro histopathological diagnosis and prognosis of human malignant desease, whereby a sample is contacted with an antibody as defined in any one of claims 1-17 and an indicator.
 - 41. A method according to claim 40, which method comprises tumour typing.
- 42. A method according to claim 40, which method comprises tumour screening.
 - 43. A method according to claim 40, which method comprises tumour diagnosis and prognosis.
- 44. A method according to claim 40, which method comprises monitoring premalignant conditions.
 - 45. A method for in vitro diagnosis and prognosis of human malignant disease, whereby concentrations in bodily

10

30

41

fluids of an antigen comprising a target structure, as defined in any one of claims 17-28,

- 46. A method for in vitro diagnosis and prognosis of human malignant disease, whereby concentrations in bodily fluids of an antibody as defined in any one of claims 1-16 is assayed.
- 47. A method for in vitro diagnosis and prognosis of human malignant disease, whereby concentrations in bodily fluids of a complex of a) an antigen comprising a target structure, as defined in any one of claims 17-28, or a structure, as defined in any one of claims 29-32, is assayed, and b) an antibody, as defined in any one of claims 1-16, is assayed.
- 48. A method for in vivo diagnosis and prognosis of human malignant disease, whereby the localisation of an antibody, as defined in any one of claims 1-16, to tumour deposits in a human subject is determined.
- 49. A method according to claim 48, whereby said antibody is administered to the subject before the deter-20 mination.
 - 50. A method according to claim 48, whereby said antibody is accumulated in tumour deposits.
 - 51. A method according to any one of claims 48-50, which is quantitative.
- 52. A method for therapy of human malignant disease, whereby an antibody, as defined in any one of claims 1-16, is administered to a human subject.
 - 53. A method according to claim 52, whereby said antibody has been changed by being genetically linked to molecules giving the combined molecule changed pharmacokinetic properties.
 - 54. A method according to claim 52, whereby said antibody has been changed by being derivatised.

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 3 May 2001 (03.05.2001)

PCT

(10) International Publication Number WO 01/30854 A2

(51) International Patent Classification⁷: G01N 33/574, A61K 39/00

C07K 16/30,

(21) International Application Number: PCT/SE00/02082

(22) International Filing Date: 26 October 2000 (26.10.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 9903895-2

28 October 1999 (28.10.1999) SH

(71) Applicant (for all designated States except US): ACTIVE BIOTECH AB [SE/SE]; Box 724, S-220 07 Lund (SE).


(72) Inventors; and

(75) Inventors/Applicants (for US only): BRODIN, Thomas; N. [SE/SE]; Lidängsgatan 10, S-252 71 Råå (SE). KARL-STRÖM, Pia, J. [SE/SE]; Fjelievägen 10A, S-227 36 Lund (SE). OHLSSON, Lennart, G. [SE/SE]; Rude-boksvägen 898, S-226 55 Lund (SE). TORDSSON, M., Jesper [SE/SE]; Flöjtvägen 20B, S-224 68 Lund (SE). KEARNEY, Phillip, P. [AU/SE]; Kulgränden 15C, S-226 49 Lund (SE). NILSON, Bo, H., K. [SE/SE]; Sölvegatan 11, S-223 62 Lund (SE).

- (74) Agent: AWAPATENT AB; Box 5117, S-200 71 Malmö (SE).
- (81) Designated States (national): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: NOVEL COMPOUNDS



(57) Abstract: An antibody, or a derivate or a fragment thereof, having a binding structure for a target structure is described. The antibody is displayed in, and on the cell surface of, human gastrointestinal epithelial tumour cells and in a subpopulation of normal human gastrointestinal epithelial cells. Said binding structure comprises the complementarity determining region (CDR) sequences in the light chain comprising essentially the amino acids number 23-33 (CDR1), 49-55 (CDR2), 88-98 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, and the CDR sequences in the heavy chain comprising essentially the amino acids number 158-162 (CDR1), 177-193 (CDR2), 226-238 (CDR3) of the amino acid sequence shown in SEQ ID NO:2, or other binding structures with similar unique binding properties. There is also described a target structure displayed in, or on the surface of tumour cells, vaccine compositions, pharmaceutical compositions as well as methods related to human malignant diseases.

VO 01/30854 A




Published:

 Without international search report and to be republished upon receipt of that report. For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


PCT/SE00/02082

FIG. 1



WO 01/30854

FIG. 2







FIG. 3

FIG. 4



WO 01/30854

PCT/SE00/02082

5/10

FIG. 5A

TA6-Human integrin ALPHA-6A

MAAAGQLCLLYLSAGLLSRLGAAFNLDTREDNVIRKYGDPGSLFGFSLAMHWQLQP EDKRLLLVGAPRGEALPLQRANRTGGLYSCDITARGPCTRIEFDNDADPTSESKEDQ WMGVTVOSOGPGGKVVTCAHRYEKROHVNTKOESRDIFGRCYVLSONLRIEDDMD GGDWSFCDGRLRGHEK<u>FGSCQQGVAATFTKDFHYIVFGAPGTYNWK</u>GIVRVEQKN NTFFDMNIFEDGPYEVGGETEHDESLVPVPANSYLGFSLDSGKGIVSKDEITFVSGAPR ANHSGAVVLLKRDMKSAHLLPEHIFDGEGLASSFGYDVAVVDLNKDGWQDIVIGAP <u>OYFDRDGEVGGAVYVYMNQQGRWNNVKPIRLNGTKDSMFGIAVKNIGDINQDGYP</u> <u>DIAVGAPYDDLGK</u>VFIYHGSANGINTKPTQVLK<u>GISPYFGYSIAGNMDLDRNSYPDV</u> <u>AVGSLSDSVTIFRSRPVINIQK</u>TITVTPNRIDLRQKTACGAPSGICLQVKSCFEYTANPA GYNPSISIVGTLEAEKERRKSGLSSRVOFRNOGSEPKYTOELTLKROKOKVCMEETL WLQDNIRDKLRPIPITASVEIQEPSSRRRVNSLPEVLPILNSDEPKTAHIDVHFLKEGCG DDNVCNSNLKLEYKFCTREGNQDKFSYLPIQKGVPELVLKDQKDIALEITVTNSPSNP RNPTKDGDDAHEAKLIATFPDTLTYSAYRELRAFPEKQLSCVANQNGSQADCELGNP FKRNSNVTFYLVLSTTEVTFDTPDLDINLKLETTSNODNLAPITAKAKVVIELLLSVSG VAKPSQVYFGGTVVGEQAMK<u>SEDEVGSLIEYEFR</u>VINLGKPLTNLGTATLNIQWPKEI SNGKWLLYLVK<u>VESKGLEKVTCEPQ</u>KEINSLNLTESHNSRKKREITEKQIDDNRKFSL FAERKYOTLNCSVNVNCVNIRCPLRGLDSKASLILRSRLWNSTFLEEYSKLNYLDILM RAFID<u>VTAAAENIRLPNAGTOVR</u>VTVFPSKTVAQYSGVPWWIILVAILAGILMLALLV FILWKCGFFKRNKKDHYDATYHKAEIHAQPSDKERLTSDA

WO 01/30854

PCT/SE00/02082

6/10

FIG. 5B


INTEGRIN BETA-4 (PRECURSOR)

MAGPRPSPWARLLLAALISVSLSGTLANRCKKAPVKSCTECVRVDKDCAYCTDEMF RDRRCNTOAELLAAGCORESIVVMESSFQITEETQIDTTLRRSQMSPQGLRVRLRPGE ERHFELEVFEPLESPVDLYILMDFSNSMSDDLDNLKKMGQNLARVLSQLTSDYTIGFG KFVDKVSVPOTDMRPEKLKEPWPNSDPPFSFKNVISLTEDVDEFRNKLQGERISGNLD **APEGGFDAILQTAVCTRDIGWRPDSTHLLVFSTESAFHYEADGANVLAGIMSRNDER** CHLDTTGTYTQYRTQDYPSVPTLVRLLAKHNIIPIFAVTNYSYSYYEKLHTYFPVSSLG VLQEDSSNIVELLEEAFNRIRSNLDIRALDSPRGLRTEVTSKMFQKTRTGSFHIRRGEV GIYOVOLRALEHVDGTHVCOLPEDOKGNIHLKPSFSDGLKMDAGIICDVCTCELOKE VRSARCSFNGDFVCGOCVCSEGWSGOTCNCSTGSLSDIOPCLREGEDKPCSGRGECQ CGHCVCYGEGR<u>YEGOFCEYDNFQCPR</u>TSGFLCNDRGRCSMGQCVCEPGWTGPSCDC PLSNATCIDSNGGICNGRGHCECGRCHCHQQSLYTDTICEINYSAIHPGLCEDLRSCVQ COAWGTGEKKGRTCEECNFKVKMVDELKRAEEVVVRCSFRDEDDDCTYSYTMEGD GAPGPNSTVLVHKKKDCPPGSFWWLIPLLLLLLLLLLLLCWKYCACCKACLALL PCCNRGHMVGFKEDHYMLRENLMASDHLDTPMLRSGNLKGRDVVRWKVTNNMQR PGFATHAASINPTELVPYGLSLRLARLCTENLLKPDTRECAOLROEVEENLNEVYROI SGVHKLQOTKFRQOPNAGKKQDHTIVDTVLMAPRSAKPALLKLTEKQVEQRAFHDL **KVAPGYYTLTADQDARGMVEFQEGVELVDVRVPLFIRPEDDDEKQLLVEAIDVPAG** TATLGRRLVNITIIKEQARDVVSFEQPEFSVSRGDQVARIPVIRRVLDGGKSQVSYRTQ DGTAOGNRDYIPVEGELLFOPGEAWKELOVKLLELOEVDSLLRGRQVRRFHVQLSNP KFGAHLGQPHSTTIIIRDPDELDRSFTSQMLSSQPPPHGDLGAPQNPNAKAAGSRKIHF NWLPPSGKPMGYRVKYWIQGDSESEAHLLDSKVPSVELTNLYPYCDYEMK<u>VCAYG</u> AQGEGPYSSLVSCRTHQEVPSEPGRLAFNVVSSTVTQLSWAEPAETNGEITAYEVCY GLVNDDNRPIGPMKKVLVDNPKNRMLLIENLRESOPYRYTVKARNGAGWGPEREAII NLATQPKRPMSIPIIPDIPIVDAQSGEDYDSFLMYSDDVLRSPSGSQRPSVSDDTGCGW KFEPLLGEELDLRRVTWRLPPELIPRLSASSGRSSDAEAPTAPRTTAARAGRAAAVPR SATPGPPGEHLVNGRMDFAFPGSTNSLHRMTTTSAAAYGTHLSPHVPHRVLSTSSTLT RDYNSLTRSEHSHSTTLPRDYSTLTSVSSHGLPPIWEHGRSRLPLSWALGSRSRAQMK GFPPSRGPRDSIILAGRPAAPSWGPDSRLTAGVPDTPTRLVFSALGPTSLRVSWQEPRC ERPLQGYSVEYQLLNGGELHRLNIPNPAQTSVVVEDLLPNHSYVFRVRAQSQEGWGR EREGVITIESQVHPQSPLCPLPGSAFTLSTPSAPGPLVFTALSPDSLQLSWERPRRPNGD IVGYLVTCEMAQGGGPATAFRVDGDSPESRLTVPGLSENVPYKFKVQARTTEGFGPE REGIITIESQDGGPFPQLGSRAGLFQHPLQSEYSSITTTHTSATEPFLVDGPTLGAQHLE AGGSLTRHVTQEFVSRTLTTSGTLSTHMDQQFFQT

PCT/SE00/02082

7/10

FIG. 6



8/10

FIG. 7A





FIG. 7B




PCT/SE00/02082

9/10


FIG. 8A (i)

scFvA3FabSEAm9 (4 μg/ml) αSEA-HRP (1/2000)



•

10/10



		ENT APPLICATION AND POWER tional (PCT) Applications)	OF ATTORNEY (Includes	Attorney's Docket No. 003300-920									
My residence, I BELIEVE I ORIGINAL, I	As a below named inventor, I hereby declare that: My residence, post office address and citizenship are as stated below next to my name; I BELIEVE I AM THE ORIGINAL, FIRST AND SOLE INVENTOR (IF ONLY ONE NAME IS LISTED BELOW) OR AN ORIGINAL, FIRST AND JOINT INVENTOR (IF PLURAL NAMES ARE LISTED BELOW) OF THE SUBJECT MATTER WHICH IS CLAIMED AND FOR WHICH A PATENT IS SOUGHT ON THE INVENTION ENTITLED:												
		NOVEL COMPOUNDS	<u>S</u>										
The specificat		one item below): es Patent Application Number											
	on and was amended on		(if applicable).										
\boxtimes	was filed as Internationa	al (PCT) Application Number <u>SI</u>											
	and was amended on		(if applicable).										
		TAND THE CONTENTS OF THE ENDED BY ANY AMENDMENT		FICATION,									
I ACKNOWLEDGE THE DUTY TO DISCLOSE TO THE U.S. PATENT AND TRADEMARK OFFICE ALL INFORMATION KNOWN TO ME TO BE MATERIAL TO PATENTABILITY AS DEFINED IN TITLE 37, CODE OF FEDERAL REGULATIONS, Sec. 1.56 (as amended effective March 16, 1992);													
invention ther more than one America more inventor's cert application fil I hereby claim patent or inve United States certificate or a	I do not know and do not believe the said invention was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to said application; that said invention was not in public use or on sale in the United States of America more than one year prior to said application; that said invention has not been patented or made the subject of an inventor's certificate issued before the date of said application in any country foreign to the United States of America on any application filed by me or my legal representatives or assigns more than six months prior to said application; I hereby claim foreign priority benefits under Title 35, United States Code, §§ 119 (a)-(e) of any foreign application(s) for patent or inventor's certificate or of any International (PCT) Application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT International (PCT) Application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is												
PRIOR FOR	EIGN/PCT APPLICATI	ON(S) AND ANY PRIORITY CL	AIMS UNDER 35 U.S.C. §11	9:									
(if PC	COUNTRY T, indicate "PCT")	APPLICATION NUMBER	(day, month, year)	RIORITY CLAIMED NDER 35 U.S.C. §119									
	Sweden	9903895-2	28 October 1999	⊠Yes □No									
				☐Yes ☐No									
				Yes No									
				Yes No									
				Yes No									
I hereby clain below.	the benefit under Title 3	5, United States Code § 119(e) of a	ny United States provisional app	plication(s) listed									
(APPLICATION	NUMBER)	(FILING DATE)											
(APPLICATION	NUMBER)	(FILING DATE)											

COMBINED DECLARATION FOR PATENT APPLICATION AND POWER OF ATTORNEY (CONT'D) (Includes Reference to Provisional and International (PCT) Applications)

Attorney's Docket No. 003300-920

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States applications(s) or International (PCT) Application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to the patentability as defined in Title 37, Code of Federal Regulations § 1.56, which became available between the filing date of the prior application(s) and the national or international filing date of this application:

PRIOR U.S. APPLICATIONS OR INTERNATIONAL (PCT) APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. §

PLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONED
				\
				ļ
DESIGNATING				
ING DATE	U.S. APPLICATION NUMBERS ASSIGNED (if any)			
ober 2000				
-	ING DATE	NUMBERS ASSIGNED (if any)	ING DATE U.S. APPLICATION NUMBERS ASSIGNED (if any)	ING DATE U.S. APPLICATION NUMBERS ASSIGNED (if any)

I hereby appoint the following attorneys and agent(s) to prosecute said application and to transact all business in the U.S. Patent and Trademark Office connected therewith and to file, prosecute and to transact all business in connection with international applications directed to said invention:

William L. Mathis	17,337	Eric H. Weisblatt	30,505
Robert S. Swecker	19,885	James W. Peterson	26,057
Platon N. Mandros	22,124	Teresa Stanek Rea	30,427
Benton S. Duffett, Jr.	22,030	Robert E. Krebs	25,885
Norman H. Stepno	22,716	William C. Rowland	30,888
Ronald L. Grudziecki	24,970	T. Gene Dillahunty	25,423
Frederick G. Michaud, Jr.	26,003	Patrick C. Keane	32,858
Alan E. Kopecki	25,813	B. Jefferson Boggs, Jr.	32,344
Regis E. Slutter	26,999	William H. Benz	25,952
Samuel C. Miller, III	27,360	Peter K. Skiff	31,917
Robert G. Mukai	28,531	Richard J. McGrath	29,195
George A. Hovanec, Jr.	28,223	Matthew L. Schneider	32,814
James A. LaBarre	28,632	Michael G. Savage	32,596
	28,510	Gerald F. Swiss	30,113
E. Joseph Gess	27,903	Charles F. Wieland III	33,096
R. Danny Huntington	21,303	Charles 1. Wichard III	,

Bruce T. Wieder	33,815
Todd R. Walters	34,040
Ronni S. Jillions	31,979
Harold R. Brown III	36,341
Allen R. Baum	36,086
Steven M. duBois	35,023
Brian P. O'Shaughnessy	32,747
Kenneth B. Leffler	36,075
Fred W. Hathaway	32,236
Wendi L. Weinstein	34,456
Mary Ann Dillahunty	34,576
•	



and: ______

Address all correspondence to:

BURNS, DOANE, SWECKER & MATHIS, L.L.P. P.O. Box 1404

Alexandria, Virginia 22313-1404



Address all telephone calls to: ______ at (703) 836-6620.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

		111		D. A form
7	FULL NAME OF SOLE OR FIRST INVENTOR CHOMAS BRODIN	SIGNATURE SIGNATURE		DATE 13 February
	RESIDENCE (CITY & STATE/COUNTRY) Råå, Sweden Sex		CITIZE Swedist	
	POST OFFICE ADDRESS (HOME ADDRESS) Lidängsgatan 10, 252 71 RÅÅ, SWEDEN			
	TULL NAME OF SECOND JOINT INVENTOR, IF ANY Pia J. KARLSTRÖM	SIGNATURE KANSA	9	DATE 11 February
Ĩ	RESIDENCE (CITY & STATE/COUNTRY) .und, Sweden らミン		CITIZE Swedisl	
	POST OFFICE ADDRESS (HOME ADDRESS) Fjelievägen 10A, 227 36 LUND, SWEDEN			
	FULL NAME OF THIRD JOINT INVENTOR, IF ANY Lennart G. OHLSSON	SIGNATURE SUMMERS OF		DATE 12 February
	RESIDENCE (CITY & STATE/COUNTRY) .und, Sweden SEX	7	CITIZE Swedist	
	POST OFFICE ADDRESS (HOME ADDRESS) Rudeboksvägen 898, 226 55 LUND, SWEDEN			
J	FULL NAME OF FOURTH JOINT INVENTOR, IF ANY esper M. TORDSSON	SIGNATURE TOYNERS	in	12 February
Į	RESIDENCE (CITY & STATE/COUNTRY) .und, Sweden SEX		CITIZE Swedish	NSHIP
I	POST OFFICE ADDRESS (HOME ADDRESS) liongränden K120, 224 74 LUND, SWEDEN	_		
Ę	FULL NAME OF FIFTH JOINT INVENTOR, IF ANY Philip P. KEARNEY	SIGNATURE POC	7	DATE 12 February
	RESIDENCE (CITY & STATE/COUNTRY) Lind, Sweden Sex	0	(CITIZE Australi	
	POST OFFICE ADDRESS (HOME ADDRESS) Kulgränden 15C, 226 49 LUND, SWEDEN	_		
Ē	FULL NAME OF SIXTH JOINT INVENTOR, IF ANY 30 H. K. Nilson	SIGNATURE	}	11 February
	RESIDENCE (CITY & STATE/COUNTRY) und, Sweden Sex		CITIZE Swedisl	
	POST OFFICE ADDRESS (HOME ADDRESS) Sölvegatan 11, 223 62 LUND, SWEDEN			
F	FULL NAME OF SEVENTH JOINT INVENTOR, IF ANY	SIGNATURE	1	DATE
F	RESIDENCE (CITY & STATE/COUNTRY)		CITIZE	NSHIP
F	POST OFFICE ADDRESS (HOME ADDRESS)			
F	ULL NAME OF EIGHTH JOINT INVENTOR, IF ANY	SIGNATURE		DATE
f	RESIDENCE (CITY & STATE/COUNTRY)		CITIZE	NSHIP
F	POST OFFICE ADDRESS (HOME ADDRESS)			
F	FULL NAME OF NINTH JOINT INVENTOR, IF ANY	SIGNATURE		DATE
F	RESIDENCE (CITY & STATE/COUNTRY)	- 	CITIZE	NSHIP
F	OST OFFICE ADDRESS (HOME ADDRESS)			
F	ULL NAME OF TENTH JOINT INVENTOR, IF ANY	SIGNATURE		DATE
F	RESIDENCE (CITY & STATE/COUNTRY)		CITIZE	NSHIP

10000039107088639

WO 01/30854

JC13 Rec'd PCT/SE00/02082 JC13 Rec'd PCT/PTO 2 0 MAR 2002

SEQUENCE LISTING

<110> Active Biotech AB												
<120> Novel compounds												
<130> 2002163												
<150> SE 9903895-2 <151> 1999-10-28												
<160> 51												
<170> PatentIn Ver. 2.1												
<210> 1												
<211> 747 <212> DNA												
<213> Macaca fascicularis												
<221> CDS <222> (1)(747)												
<223> Coding sequence VL (1-109) - modified Huston linker (110-127) - VH (128-249)												
<400> 1												
tot tot gag ctg act cag gge cot gca ttg tot gtg gcc ttg gga cat	48											
Ser Ser Glu Leu Thr Gln Gly Pro Ala Leu Ser Val Ala Leu Gly His												
1 5 10 15												
aca gtc agg atg acc tgc caa gga gac agc ctc aaa acc tat tat gca	96											
Thr Val Arg Met Thr Cys Gln Gly Asp Ser Leu Lys Thr Tyr Tyr Ala 20 25 30												
	144											
agc tgg tac cag cag aag cca ggc cag gtc cct gtg ctg gtc atc tat Ser Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Val Leu Val Ile Tyr	144											
35 40 45												
ggt aac aac tac egg eec tea ggg atc eea gge ega tte tet gge tee	192											
Gly Asn Asn Tyr Arg Pro Ser Gly Ile Pro Gly Arg Phe Ser Gly Ser												
50 55 60												
tgg tca gga aac aca gct tcc ttg acc atc act gcg gct cag gtg gaa	240											
Trp Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Ala Ala Gln Val Glu												
65 70 75 80												
gat gag get gae tat tae tgt aae tee tgg gae age age ggt ace cat	28B											
Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Trp Asp Ser Ser Gly Thr His												
85 90 95												
ccg gta ttc ggc gga ggg acc cgg gtg acc gtc cta ggt caa gcc aac	336											
Pro Val Phe Gly Gly Gly Thr Arg Val Thr Val Leu Gly Gln Ala Asn 100 105 110												
	201											
ggt gaa ggc ggc tct ggt ggc ggg gga tcc gga ggc ggt tct gag Gly Glu Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Glu	384											
115 120 . 125												
·												





Patent Attorney's Docket No. 003300-920

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Thomas BRODIN et al.) Group Art Unit: Not yet assigned
Serial No.: 10/088,639) Examiner: Not yet assigned
Filed: March 20, 2002) Confirmation No.: 7152
For: NOVEL COMPOUNDS) ATTENTION: BOX SEQUENCE

DECLARATION PURSUANT TO 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

- I, Deborah H. Yellin, declare as follows:
- That the content of the paper and computer readable copies of the 1. Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same in compliance with § 1.821(f).
- That the submission, filed in accordance with 37 C.F.R. § 1.821(g)[or 2. (h)], herein does not include new matter [or go beyond the disclosure in the international application].
- That the substitute copy of the computer readable form, submitted in 3. accordance with 37 C.F.R. § 1.825(d), is identical to that originally filed.

10088639,032002

Patent

Serial No.: 10/088,639

Attorney's Docket No. 003300-920

I hereby declare that all statements made herein of my own knowledge are true and that all statements were made on information and belief and are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

September 16, 2002

Date

Registration No. 45,904

gtg cag ttg gtg gag tct ggg gga ggc ttg gta aag cct ggg ggg tcc Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser 130 135 140	432											
ctg aga ctc tct tgt gta gcc tct ggg tcc atc ttc agt agc tct gtt Leu Arg Leu Ser Cys Val Ala Ser Gly Ser Ile Phe Ser Ser Ser Val 145 150 155 160	480											
atg cac tgg gtc cgc cag gct cca gga aag ggt ctg gag tgg gtc tca Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser 165 170 175	528											
gtt att agt gaa aat ggg cgt acc att aac tac gca gac tct gtg aag Val Ile Ser Glu Asn Gly Arg Thr Ile Asn Tyr Ala Asp Ser Val Lys 180 185 190	576											
ggc cga ttc acc atc tcc aga gac aac gcc aag aac tca ctg ttt ctg Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe Leu 195 200 205	624											
cag atg aac agc ctg aca ggc gag gac acg gcc gtc tat tac tgt agt Gln Met Asn Ser Leu Thr Gly Glu Asp Thr Ala Val Tyr Tyr Cys Ser 210 215 220	672											
aga gag ggg gga cct gga aca acg tcc aac cgg ctc gat gcc tgg ggc Arg Glu Gly Gly Pro Gly Thr Thr Ser Asn Arg Leu Asp Ala Trp Gly 225 230 235 240	720											
ccg gga gtc ctg gtc acc gtt tcc tca Pro Gly Val Leu Val Thr Val Ser Ser 245	747											
<210> 2 <211> 249 <212> PRT <213> Macaca fascicularis <223> Coding sequence VL (1-109) - modified Huston linker (110-127) - VH (128-249)												
<pre><400> 2 Ser Ser Glu Leu Thr Gln Gly Pro Ala Leu Ser Val Ala Leu Gly His 1 5 10 15</pre>												
Thr Val Arg Met Thr Cys Gln Gly Asp Ser Leu Lys Thr Tyr Tyr Ala 20 25 30												
Ser Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Val Leu Val Ile Tyr 35 40 45												
Gly Asn Asn Tyr Arg Pro Ser Gly Ile Pro Gly Arg Phe Ser Gly Ser												
50 55 60												
Trp Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Ala Ala Gln Val Glu 65 70 75 80												
50 55 60 Trp Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Ala Ala Gln Val Glu												

PCT/SE00/02082

WO 01/30854

Gly Glu Gly Gly Ser Gly Gly Gly Gly Gly Gly Gly Gly Ser Glu 115 120 125

Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser 130 135 140

Leu Arg Leu Ser Cys Val Ala Ser Gly Ser Ile Phe Ser Ser Ser Val 145 150 155 160

Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser 165 170 175

Val Ile Ser Glu Asn Gly Arg Thr Ile Asn Tyr Ala Asp Ser Val Lys 180 185 190

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe Leu 195 200 205

Gln Met Asn Ser Leu Thr Gly Glu Asp Thr Ala Val Tyr Tyr Cys Ser 210 215 220

Arg Glu Gly Gly Pro Gly Thr Thr Ser Asn Arg Leu Asp Ala Trp Gly 225 230 235 240

Pro Gly Val Leu Val Thr Val Ser Ser 245

<210> 3

<211> 1073

<212> PRT

<213> Human

<223> TA6-Human integrin alpha-6A

<400> 3

Met Ala Ala Gly Gln Leu Cys Leu Leu Tyr Leu Ser Ala Gly Leu

1 5 10 15

Leu Ser Arg Leu Gly Ala Ala Phe Asn Leu Asp Thr Arg Glu Asp Asn 20 25 30

Val Ile Arg Lys Tyr Gly Asp Pro Gly Ser Leu Phe Gly Phe Ser Leu
35 40 45

Ala Met His Trp Gln Leu Gln Pro Glu Asp Lys Arg Leu Leu Val 50 55 60

Gly Ala Pro Arg Gly Glu Ala Leu Pro Leu Gln Arg Ala Asn Arg Thr
65 70 75 80

Gly Gly Leu Tyr Ser Cys Asp Ile Thr Ala Arg Gly Pro Cys Thr Arg

Ile Glu Phe Asp Asn Asp Ala Asp Pro Thr Ser Glu Ser Lys Glu Asp 100 105 110

Gln Trp Met Gly Val Thr Val Gln Ser Gln Gly Pro Gly Gly Lys Val 115 120 125

Val Thr Cys Ala His Arg Tyr Glu Lys Arg Gln His Val Asn Thr Lys 135 Gln Glu Ser Arg Asp Ile Phe Gly Arg Cys Tyr Val Leu Ser Gln Asn 155 150 Leu Arg Ile Glu Asp Asp Met Asp Gly Gly Asp Trp Ser Phe Cys Asp 165 Gly Arg Leu Arg Gly His Glu Lys Phe Gly Ser Cys Gln Gln Gly Val Ala Ala Thr Phe Thr Lys Asp Phe His Tyr Ile Val Phe Gly Ala Pro Gly Thr Tyr Asn Trp Lys Gly Ile Val Arg Val Glu Gln Lys Asn Asn Thr Phe Phe Asp Met Asn Ile Phe Glu Asp Gly Pro Tyr Glu Val Gly 235 Gly Glu Thr Glu His Asp Glu Ser Leu Val Pro Val Pro Ala Asn Ser Tyr Leu Gly Phe Ser Leu Asp Ser Gly Lys Gly Ile Val Ser Lys Asp 265 Glu Ile Thr Phe Val Ser Gly Ala Pro Arg Ala Asn His Ser Gly Ala 275 Val Val Leu Leu Lys Arg Asp Met Lys Ser Ala His Leu Leu Pro Glu 295 His Ile Phe Asp Gly Glu Gly Leu Ala Ser Ser Phe Gly Tyr Asp Val Ala Val Val Asp Leu Asn Lys Asp Gly Trp Gln Asp Ile Val Ile Gly 330 Ala Pro Gln Tyr Phe Asp Arg Asp Gly Glu Val Gly Gly Ala Val Tyr Val Tyr Met Asn Gln Gln Gly Arg Trp Asn Asn Val Lys Pro Ile Arg 360 Leu Asn Gly Thr Lys Asp Ser Met Phe Gly Ile Ala Val Lys Asn Ile 375 370 Gly Asp Ile Asn Gln Asp Gly Tyr Pro Asp Ile Ala Val Gly Ala Pro Tyr Asp Asp Leu Gly Lys Val Phe Ile Tyr His Gly Ser Ala Asn Gly Ile Asn Thr Lys Pro Thr Gln Val Leu Lys Gly Ile Ser Pro Tyr Phe 425 Gly Tyr Ser Ile Ala Gly Asn Met Asp Leu Asp Arg Asn Ser Tyr Pro 435 440

	Val 450	Ala	Val	Gly	Ser 1	Leu 455	Ser	qaA	Ser	Val	Thr 460	Ile	Phe	Arg	Ser
Arg 465	Pro	Val	Ile	Asn	Ile 470	Gln	Lys	Thr	Ile	Thr 475	Val	Thr	Pro	Asn	Arg 480
Ile	Asp	Leu	Arg	Gln 485	Lys	Thr	Ala	Cys	Gly 490	Ala	Pro	Ser	Gly	Ile 495	Cys
Leu	Gln	Val	Lys 500	Ser	Cys	Phe	Glu	Tyr 505	Thr	Ala	Asn	Pro	Ala 510	Gly	Tyr
Asn	Pro	Ser 515	Ile	Ser	Ile	Val	Gly 520	Thr	Leu	Glu	Ala	Glu 525	ГЛЗ	Glu	Arg
Arg	Lys 530	Ser	Gly	Leu	Ser	Ser 535	Arg	Val	Gln	Phe	Arg 540	Asn	Gln	Gly	ser
Glu 545	Pro	Lys	Tyr	Thr	Gln 550	Glu	Leu	Thr	Leu	Lys 555	Arg	Gln	Lys	Gln	Lys 560
Val	Cys	Met	Glu	Glu 565	Thr	Leu	Trp	Leu	Gln 570		Asn	Ile	Arg	Asp 575	Lys
Leu	Arg	Pro	1le 580		Ile	Thr	Ala	Ser 585		Glu	Ile	Gln	Glu 590	Pro	Ser
Ser	Arg	Arg 595		Val	Asn	Ser	Leu 600	Pro	Glu	(Val	. Leu	Pro 605	Ile	Leu	Asn
Ser	Asp 610		Prc	Lys	Thr	Ala 615		Ile	Asp	Val	. His 620	Phe	Leu	Lys	Glu
Gly 625		Gly	y Asp	Asp	Asn 630	Val	. Cys	Asn	Ser	635	Leu S	Lys	Let	ı Glu	Tyr 640
Lys	Phe	e Cys	s Thi	645	g Glu	Gly	Asn	Glī	Asp 650		s Phe	Ser	ту1	655	Pro
Ile	e Glr	ı Ly:	s Gly 660		l Pro	Glı	ı Lev	Va! 66!	L Lei	ı Ly	s Asp	Glı	670	a Asp O	lle
Ala	a Lei	u Gl: 67		e Thi	r Val	Thi	c Asr 680		r Pr	o Se	r Ası	n Pro 68	o Arg	g Ası	n Pro
Th	r Ly:		p Gl	y Ası	p Asp	Ala 69		s Gl	u Al	а Ьу	s Let 70	ı Il O	e Al	a Th	r Phe
Pre 70		p Th	r Le	u Th	r Tyr 710		r Ala	а Ту	r Ar	g Gl 71	u Lei 5	u Ar	g Al	a Ph	Pro 720
Gl	u Ly	s Gl	n Le	u Se 72		s Va	l Ala	a As	n Gl 73		n Gl	y Se	r Gl	n Al 73	a Asp 5
Су	s Gl	u Le	u Gl 74		n Pro	o Ph	e Ly	s Ar 74		n Se	r As	n Va	1 Th 75	r Ph	e Tyr
Le	u Va	1 Le 75		er Th	r Th	r Gl	u Va 76		ır Ph	ne As	sp Th	r Pr 76	O As	sp Le	u Asp

Ile Asn Leu Lys Leu Glu Thr Thr Ser Asn Gln Asp Asn Leu Ala Pro 770 775 780

Ile Thr Ala Lys Ala Lys Val Val Ile Glu Leu Leu Leu Ser Val Ser 785 790 795 800

Gly Val Ala Lys Pro Ser Gln Val Tyr Phe Gly Gly Thr Val Val Gly 805 810 815

Glu Gln Ala Met Lys Ser Glu Asp Glu Val Gly Ser Leu Ile Glu Tyr 820 825 830

Glu Phe Arg Val Ile Asn Leu Gly Lys Pro Leu Thr Asn Leu Gly Thr

Ala Thr Leu Asn Ile Gln Trp Pro Lys Glu Ile Ser Asn Gly Lys Trp

Leu Leu Tyr Leu Val Lys Val Glu Ser Lys Gly Leu Glu Lys Val Thr 865 870 875 880

Cys Glu Pro Gln Lys Glu Ile Asn Ser Leu Asn Leu Thr Glu Ser His 885 890 895

Asn Ser Arg Lys Lys Arg Glu Ile Thr Glu Lys Gln Ile Asp Asp Asn 900 905 910

Arg Lys Phe Ser Leu Phe Ala Glu Arg Lys Tyr Gln Thr Leu Asn Cys 915 , 920 925

Ser Val Asn Val Asn Cys Val Asn Ile Arg Cys Pro Leu Arg Gly Leu 930 935 940

Asp Ser Lys Ala Ser Leu Ile Leu Arg Ser Arg Leu Trp Asn Ser Thr 945 950 955 960

Phe Leu Glu Glu Tyr Ser Lys Leu Asn Tyr Leu Asp Ile Leu Met Arg 965 970 975

Ala Phe Ile Asp Val Thr Ala Ala Ala Glu Asn Ile Arg Leu Pro Asn 980 985 990

Ala Gly Thr Gln Val Arg Val Thr Val Phe Pro Ser Lys Thr Val Ala 995 1000 1005

Gln Tyr Ser Gly Val Pro Trp Trp Ile Ile Leu Val Ala Ile Leu Ala 1010 1015 1020

Gly Ile Leu Met Leu Ala Leu Leu Val Phe Ile Leu Trp Lys Cys Gly 1025 1030 1035 1040

Phe Phe Lys Arg Asn Lys Lys Asp His Tyr Asp Ala Thr Tyr His Lys
1045 1050 1055

Ala Glu Ile His Ala Gln Pro Ser Asp Lys Glu Arg Leu Thr Ser Asp 1060 1065 1070

Ala

<210> 4

<211> 1875

<212> PRT

<213> Human

<223> Integrin beta-4 (precursor)

<400> 4

Met Ala Gly Pro Arg Pro Ser Pro Trp Ala Arg Leu Leu Ala Ala 1 5 10 15

Leu Ile Ser Val Ser Leu Ser Gly Thr Leu Ala Asn Arg Cys Lys Lys 20 25 30

Ala Pro Val Lys Ser Cys Thr Glu Cys Val Arg Val Asp Lys Asp Cys
35 40 45

Ala Tyr Cys Thr Asp Glu Met Phe Arg Asp Arg Cys Asn Thr Gln
50 55 60

Ala Glu Leu Leu Ala Ala Gly Cys Gln Arg Glu Ser Ile Val Val Met 65 70 75 80

Glu Ser Ser Phe Gln Ile Thr Glu Glu Thr Gln Ile Asp Thr Thr Leu 85 90 95

Arg Arg Ser Gln Met Ser Pro Gln Gly Leu Arg Val Arg Leu Arg Pro
100 105 110

Gly Glu Glu Arg His Phe Glu Leu Glu Val Phe Glu Pro Leu Glu Ser 115 120 125

Pro Val Asp Leu Tyr Ile Leu Met Asp Phe Ser Asn Ser Met Ser Asp 130 135 140

Asp Leu Asp Asn Leu Lys Lys Met Gly Gln Asn Leu Ala Arg Val Leu 145 150 155 160

Ser Gln Leu Thr Ser Asp Tyr Thr Ile Gly Phe Gly Lys Phe Val Asp 165 170 175

Lys Val Ser Val Pro Gln Thr Asp Met Arg Pro Glu Lys Leu Lys Glu 180 185 190

Pro Trp Pro Asn Ser Asp Pro Pro Phe Ser Phe Lys Asn Val Ile Ser 195 200 205

Leu Thr Glu Asp Val Asp Glu Phe Arg Asn Lys Leu Gln Gly Glu Arg 210 215 220

Ile Ser Gly Asn Leu Asp Ala Pro Glu Gly Gly Phe Asp Ala Ile Leu 225 230 235 240

Gln Thr Ala Val Cys Thr Arg Asp Ile Gly Trp Arg Pro Asp Ser Thr 245 250 255

His Leu Leu Val Phe Ser Thr Glu Ser Ala Phe His Tyr Glu Ala Asp 260 265 270

Gly Ala Asn Val Leu Ala Gly Ile Met Ser Arg Asn Asp Glu Arg Cys 275 280 285

His	Leu 290	Asp	Thr	Thr	Gly	Thr 295	Tyr	Thr	Gln	Tyr	Arg 300	Thr	Gln	qaA	Tyr
Pro 305	Ser	Val	Pro	Thr	Leu 310	Val	Arg	Leu	Leu	Ala 315	Lys	His	Asn	Ile	Ile 320
Pro	Ile	Phe	Ala	Val 325	Thr	Asn	Tyr	Ser	Tyr 330	Ser	Tyr	Tyr	Glu	Lys 335	Leu
His	Thr	Tyr	Phe 340	Pro	Val	Ser	Ser	Leu 345	Gly	Val	Leu	Gln	Glu 350	Asp	Ser
Ser	Asn	Ile 355	Val	Glu	Leu	Leu	Glu 360	Glu	Ala	Phe	Asn	Arg 365	Ile	Arg	Ser
Asn	Leu 370	Asp	Ile	Arg	Ala	Leu 375	Asp	Ser	Pro	Arg	Gly 380	Leu	Arg	Thr	Glu
Val 385	Thr	Ser	Lys	Met	Phe 390	Gln	Lys	Thr	Arg	Thr 395	Gly	Ser	Phe	His	Ile 400
Arg	Arg	Gly	Glu	Val 405	Gly	Ile	туr	Gln	Val 410	Gln	Leu	Arg	Ala	Leu 415	Glu
His	Val	Asp	Gly 420	Thr	His	Val	Cys	Gln 425	Leu	Pro	Glu	Asp	Gln 430	Lys	Gly
Asn	Ile	His 435	Leu	Lys	Pro	Ser	Phe 440	Ser	Asp	Gly	Leu	Lys 445	Met	Asp	Ala
Gly	Ile 450	Ile	Суз	Asp	Val	Сув 455	Thr	Cys	Glu	Leu	Gln 460	-	Glu	Val	Arg
Ser 465	Ala	Arg	Суз	Ser	Phe 470	Asn	Gly	Asp	Phe	Val 475	Сув	Gly	Gln	Cys	Val 480
465					470					475				Cys Gly 495	480
465 Cys	Ser	Glu	Gly	Trp 485	470 Ser	Gly	Gln	Thr	Cys 490	475 Asn	Cys	Ser	Thr	Gly 495	480
465 Cys Leu	Ser	Glu Asp	Gly Ile 500	Trp 485 Gln	470 Ser Pro	Gly Cys	Gln Leu	Thr Arg 505	Cys 490 Glu	475 Asn Gly	Cys Glu	Ser	Thr Lys 510	Gly 495 Pro	480 Ser
465 Cys Leu Ser	Ser Ser Gly	Glu Asp Arg 515	Gly Ile 500	Trp 485 Gln Glu	470 Ser Pro Cys	Gly Cys Gln	Gln Leu Cys 520	Thr Arg 505 Gly	Cys 490 Glu His	Asn Gly Cys	Cys Glu Val	Ser Asp Cys 525	Thr Lys 510 Tyr	Gly 495 Pro	480 Ser Cys
465 Cys Leu Ser Gly	Ser Ser Gly Arg	Glu Asp Arg 515	Gly Ile 500 Gly Glu	Trp 485 Gln Glu	470 Ser Pro Cys	Gly Cys Gln Phe 535	Gln Leu Cys 520 Cys	Thr Arg 505 Gly	Cys 490 Glu His	Asn Gly Cys Asp	Cys Glu Val Asn 540	Ser Asp Cys 525 Phe	Thr Lys 510 Tyr	Gly 495 Pro Gly Cys	480 Ser Cys Glu
465 Cys Leu Ser Gly Arg 545	Ser Ser Gly Arg 530	Glu Asp Arg 515 Tyr	Gly Ile 500 Gly Glu Gly	Trp 485 Gln Glu Gly	470 Ser Pro Cys Gln Leu 550	Gly Cys Gln Phe 535 Cys	Gln Leu Cys 520 Cys	Thr Arg 505 Gly Glu Asp	Cys 490 Glu His Tyr	Asn Gly Cys Asp Gly 555	Cys Glu Val Asn 540	Ser Asp Cys 525 Phe Cys	Thr Lys 510 Tyr Gln Ser	Gly 495 Pro Gly Cys	480 Ser Cys Glu Pro
465 Cys Leu Ser Gly Arg 545 Gln	Ser Gly Arg 530 Thr	Glu Asp Arg 515 Tyr Ser	Gly Ile 500 Gly Glu Gly Cys	Trp 485 Gln Glu Gly Phe Glu 565	470 Ser Pro Cys Gln Leu 550	Gly Cys Gln Phe 535 Cys	Gln Leu Cys 520 Cys Asn Trp	Thr Arg 505 Gly Glu Asp	Cys 490 Glu His Tyr Arg Gly 570	Asn Gly Cys Asp Gly 555 Pro	Cys Glu Val Asn 540 Arg	Ser Asp Cys 525 Phe Cys	Thr Lys 510 Tyr Gln Ser	Gly 495 Pro Gly Cys Met	480 Ser Cys Glu Pro Gly 560
465 Cys Leu Ser Gly Arg 545 Gln Leu	Ser Gly Arg 530 Thr Cys	Glu Asp Arg 515 Tyr Ser Val	Gly Ile 500 Gly Glu Gly Cys Ala 580	Trp 485 Gln Glu Gly Phe Glu 565	470 Ser Pro Cys Gln Leu 550 Pro Cys	Gly Cys Gln Phe 535 Cys Gly	Gln Leu Cys 520 Cys Asn Trp	Thr Arg 505 Gly Glu Asp Thr	Cys 490 Glu His Tyr Arg Gly 570 Asn	Asn Gly Cys Asp Gly 555 Pro	Cys Glu Val Asn 540 Arg Ser	Ser Asp Cys 525 Phe Cys Cys	Thr Lys 510 Tyr Gln Ser Asp Cys 590 Gln	Gly 495 Pro Gly Cys Met Cys 575 Asn	480 Ser Cys Glu Pro Gly 560 Pro

Tyr '	Thr .	Asp	Thr	Ile		Glu 615	Ile	Asn	Tyr	Ser	Ala 620	Ile	His :	Pro '	Gly
Leu. 625	Cys	Glu	Asp		Arg 630	Ser	Cys	Val	Gln	Сув 635	Gln	Ala	Trp	Gly	Thr 640
Gly	Glu	Lys	Lys	Gly 645	Arg	Thr	Cys	Glu	Glu 650		Asn	Phe	Lys	Val 655	Lys
Met	Val	Asp	Glu 660	Leu	Lys	Arg	Ala	Glu 665	Glu	Val	Val	Val	Arg 670	Cys	Ser
Phe	Arg	Asp 675	Glu	Asp	Asp	Asp	Cys 680	Thr	Tyr	Ser	Tyr	Thr 685	Met	Glu	Gly
Asp	Gly 690	Ala	Pro	Gly	Pro	Asn 695	Ser	Thr	Val	Leu	Val 700	His,	ГÀЗ	Lys	Lys
Asp 705	Cys	Pro	Pro	Gly	Ser 710	Phe	Trp	Trp	Leu	11e 715	Pro	Leu	Leu	Leu	Leu 720
Leu	Leu	Pro	Leu	Leu 725	Ala	Leu	Leu	Leu	Leu 730		Cys	Trp	Lys	Tyr 735	Суз
Ala	Cys	Cys	Lys 740	Ala	Cys	Leu	Ala	Leu 745		Pro	Cys	Cys	Asn 750	Arg	Gly
His	Met	Val 755	Gly	Phe	Lys	Glu	Asp 760		туr	Met	Leu	Arg 765	Glu	Asn	Leu
Met	Ala 770	Ser	Asp	His	Leu	Asp 775	Thr	Pro	Met	Leu	Arg 780		Gly	Asn	Leu
Lys 785	Gly	Arg	Asp	Val	Val 790	Arg	Trp	Lys	Val	795		Asn	Met	Gln	Arg 800
Pro	Gly	Phe	Ala	Thr 805	His	Ala	Ala	Ser	11e		Pro	Thr	Glu	Leu 815	Val
Pro	туг	Gly	Leu 820	Ser	Leu	Arg	Leu	825		g Leu	ı Cys	Thr	Glu 830	Asn	Leu
Leu	Lys	835		Thr	Arg	Glu	840		a Glr	ı Lev	ı Arç	g Gln 845	Glu	Val	Glu
Glu	Asn 850		Asn	Glu	Val	Tyr 855		g Glr	ı Ile	e Sei	860		. His	Lys	Leu
Gln 865		Thr	Lys	Phe	Arg 870		ı Glr	n Pro) Ası	n Ala 87!		/ Lys	. Lys	Gln	Asp 880
His	Thr	: Ile	e Val	. Asp 885		· Val	L Lei	ı Met	890		o Arg	g Sei	c Ala	Lys 895	Pro
Ala	Let	ı Le	1 Lys 900		Thr	Gl	ı Ly:	90:		l Gl	u Gli	n Arg	910		His
Asp	Le	ı Ly: 91		l Ala	Pro	Gly	92°		r Th	r Le	u Th	r Ala 92		Glr	qaA r

Ala Arg Gly Met Val Glu Phe Gln Glu Gly Val Glu Leu Val Asp Val 930 935 940

Arg Val Pro Leu Phe Ile Arg Pro Glu Asp Asp Asp Glu Lys Gln Leu 945 950 955 960

Leu Val Glu Ala Ile Asp Val Pro Ala Gly Thr Ala Thr Leu Gly Arg
965 970 975

Arg Leu Val Asn Ile Thr Ile Ile Lys Glu Gln Ala Arg Asp Val Val 980 985 990

Ser Phe Glu Gln Pro Glu Phe Ser Val Ser Arg Gly Asp Gln Val Ala 995 1000 1005

Arg Ile Pro Val Ile Arg Arg Val Leu Asp Gly Gly Lys Ser Gln Val
1010 1020

Ser Tyr Arg Thr Gln Asp Gly Thr Ala Gln Gly Asn Arg Asp Tyr Ile 1025 1030 1035 1040

Pro Val Glu Gly Glu Leu Leu Phe Gln Pro Gly Glu Ala Trp Lys Glu . 1045 1050 1055

Leu Gln Val Lys Leu Leu Glu Leu Gln Glu Val Asp Ser Leu Leu Arg 1060 1065 1070

Gly Arg Gln Val Arg Arg Phe His Val Gln Leu Ser Asn Pro Lys Phe 1075 1080 1085

Gly Ala His Leu Gly Gln Pro His Ser Thr Thr Ile Ile Ile Arg Asp 1090 1095 1100

Pro Asp Glu Leu Asp Arg Ser Phe Thr Ser Gln Met Leu Ser Ser Gln 1105 1110 1115 1120

Pro Pro Pro His Gly Asp Leu Gly Ala Pro Gln Asn Pro Asn Ala Lys 1125 1130 1135

Ala Ala Gly Ser Arg Lys Ile His Phe Asn Trp Leu Pro Pro Ser Gly
1140 1145 1150

Lys Pro Met Gly Tyr Arg Val Lys Tyr Trp Ile Gln Gly Asp Ser Glu 1155 1160 1165

Ser Glu Ala His Leu Leu Asp Ser Lys Val Pro Ser Val Glu Leu Thr 1170 , 1175 1180

Asn Leu Tyr Pro Tyr Cys Asp Tyr Glu Met Lys Val Cys Ala Tyr Gly 1185 1190 1195 1200

Ala Gln Gly Glu Gly Pro Tyr Ser Ser Leu Val Ser Cys Arg Thr His 1205 1210 1215

Gln Glu Val Pro Ser Glu Pro Gly Arg Leu Ala Phe Asn Val Val Ser 1220 1225 1230

Ser Thr Val Thr Gln Leu Ser Trp Ala Glu Pro Ala Glu Thr Asn Gly 1235 1240 1245

- Glu Ile Thr Ala Tyr Glu Val Cys Tyr Gly Leu Val Asn Asp Asp Asn 1250 1255 1260
- Arg Pro Ile Gly Pro Met Lys Lys Val Leu Val Asp Asn Pro Lys Asn 1265 1270 1280
- Arg Met Leu Ieu Ile Glu Asn Leu Arg Glu Ser Gln Pro Tyr Arg Tyr 1285 1290 1295
- Thr Val Lys Ala Arg Asn Gly Ala Gly Trp Gly Pro Glu Arg Glu Ala 1300 1305 1310
- Ile Ile Asn Leu Ala Thr Gln Pro Lys Arg Pro Met Ser Ile Pro Ile 1315 1320 1325
- Ile Pro Asp Ile Pro Ile Val Asp Ala Gln Ser Gly Glu Asp Tyr Asp 1330 1335 1340
- Ser Phe Leu Met Tyr Ser Asp Asp Val Leu Arg Ser Pro Ser Gly Ser 1345 1350 1355 1360
- Gln Arg Pro Ser Val Ser Asp Asp Thr Gly Cys Gly Trp Lys Phe Glu 1365 1370 1375
- Pro Leu Gly Glu Glu Leu Asp Leu Arg Arg Val Thr Trp Arg Leu 1380 1385 1390
- Pro Pro Glu Leu Ile Pro Arg Leu Ser Ala Ser Ser Gly Arg Ser Ser 1395 1400 1405
- Asp Ala Glu Ala Pro Thr Ala Pro Arg Thr Thr Ala Ala Arg Ala Gly
 1410 1415 1420
- Arg Ala Ala Val Pro Arg Ser Ala Thr Pro Gly Pro Pro Gly Glu 1425 1430 1435 1440
- His Leu Val Asn Gly Arg Met Asp Phe Ala Phe Pro Gly Ser Thr Asn 1445 1450 1455
- Ser Leu His Arg Met Thr Thr Ser Ala Ala Ala Tyr Gly Thr His 1460 1465 1470
- Leu Ser Pro His Val Pro His Arg Val Leu Ser Thr Ser Ser Thr Leu 1475 1480 1485
- Thr Arg Asp Tyr Asn Ser Leu Thr Arg Ser Glu His Ser His Ser Thr 1490 1495 1500
- Thr Leu Pro Arg Asp Tyr Ser Thr Leu Thr Ser Val Ser Ser His Gly
 1505 1510 1515 1520
- Leu Pro Pro Ile Trp Glu His Gly Arg Ser Arg Leu Pro Leu Ser Trp
 1525 1530 1535
- Ala Leu Gly Ser Arg Ser Arg Ala Gln Met Lys Gly Phe Pro Pro Ser 1540 1545 1550
- Arg Gly Pro Arg Asp Ser Ile Ile Leu Ala Gly Arg Pro Ala Ala Pro 1555 1560 1565

Ser Trp Gly Pro Asp Ser Arg Leu Thr Ala Gly Val Pro Asp Thr Pro 1570 1575 1580

Thr Arg Leu Val Phe Ser Ala Leu Gly Pro Thr Ser Leu Arg Val Ser 1585 1590 1595 1600

Trp Gln Glu Pro Arg Cys Glu Arg Pro Leu Gln Gly Tyr Ser Val Glu
1605 1610 1615

Tyr Gln Leu Leu Asn Gly Gly Glu Leu His Arg Leu Asn Ile Pro Asn 1620 1625 1630

Pro Ala Gln Thr Ser Val Val Glu Asp Leu Pro Asn His Ser 1635 1640 1645

Tyr Val Phe Arg Val Arg Ala Gln Ser Gln Glu Gly Trp Gly Arg Glu 1650 1660

Arg Glu Gly Val Ile Thr Ile Glu Ser Gln Val His Pro Gln Ser Pro 1665 1670 1675 1680

Leu Cys Pro Leu Pro Gly Ser Ala Phe Thr Leu Ser Thr Pro Ser Ala 1685 1690 1695

Pro Gly Pro Leu Val Phe Thr Ala Leu Ser Pro Asp Ser Leu Gln Leu 1700 1705 1710

Ser Trp Glu Arg Pro Arg Pro Asn Gly Asp Ile Val Gly Tyr Leu 1715 1720 1725

Val Thr Cys Glu Met Ala Gln Gly Gly Gly Pro Ala Thr Ala Phe Arg 1730 1735 1740

Val Asp Gly Asp Ser Pro Glu Ser Arg Leu Thr Val Pro Gly Leu Ser 1745 1750 1755 1760

Glu Asn Val Pro Tyr Lys Phe Lys Val Gln Ala Arg Thr Thr Glu Gly
1765 1770 1775

Phe Gly Pro Glu Arg Glu Gly Ile Ile Thr Ile Glu Ser Gln Asp Gly 1780 1785 1790

Gly Pro Phe Pro Gln Leu Gly Ser Arg Ala Gly Leu Phe Gln His Pro 1795 1800 1805

Leu Gln Ser Glu Tyr Ser Ser Ile Thr Thr His Thr Ser Ala Thr 1810 1815 1820

Glu Pro Phe Leu Val Asp Gly Pro Thr Leu Gly Ala Gln His Leu Glu 1825 1830 1835 1840

Ala Gly Gly Ser Leu Thr Arg His Val Thr Gln Glu Phe Val Ser Arg 1845 1850 1855

Thr Leu Thr Thr Ser Gly Thr Leu Ser Thr His Met Asp Gln Gln Phe 1860 1865 1870

Phe Gln Thr 1875

PCT/SE00/02082

```
<210> 5
<211> 8
<212> PRT
<213> Human
<223> Amino acids 61-68 of SEQ ID NO: 3
<400> 5
Leu Leu Val Gly Ala Pro Arg
                  5
<210> 6
<211> 20
<212> PRT
<213> Human
<223> Amino acids 77-96 of SEQ ID NO: 3
<400> 6
Ala Asn Arg Thr Gly Gly Leu Tyr Ser Cys Asp Ile Thr Ala Arg Gly
                                      10
Pro Cys Thr Arg
             20
<210> 7
 <211> 10
 <212> PRT
 <213> Human
 <223> Amino acids 128-137 of SEQ ID NO: 3
 <400> 7
 Val Val Thr Cys Ala His Arg Tyr Glu Lys
 <210> B
 <211> 7
 <212> PRT
 <213> Human
 <223> Amino acids 138-144 of SEQ ID NO: 3
 <400> 8
 Arg Gln His Val Asn Thr Lys
 <210> 9
  <211> 9
  <212> PRT
  <213> Human
  <223> Amino acids 154-162 of SEQ ID NO: 3
  <400> 9
  Cys Tyr Val Leu Ser Gln Asn Leu Arg
```

5

WO 01/30854

```
<210> 10
<211> 14
<212> PRT
<213> Human
<223> Amino acids 185-198 of SEQ ID NO: 3
<400> 10
Phe Gly Ser Cys Gln Gln Gly Val Ala Ala Thr Phe Thr Lys
                                      10
<210> 11
<211> 16
<212> PRT
<213> Human
<223> Amino acids 199-214 of SEQ ID NO: 3
<400> 11
Asp Phe His Tyr Ile Val Phe Gly Ala Pro Gly Thr Tyr Asn Trp Lys
<210> 12
<211> 11
<212> PRT
<213> Human
<223> Amino acids 272-282 of SEQ ID NO: 3
 <400> 12
Asp Glu Ile Thr Phe Val Ser Gly Ala Pro Arg
                   5
 1
 <210> 13
 <211> 11
 <212> PRT
 <213> Human
 <223> Amino acids 283-293 of SEQ ID NO: 3
 <400> 13
 Ala Asn His Ser Gly Ala Val Val Leu Leu Lys
                   5
  1
 <210> 14
 <211> 16
 <212> PRT
 <213> Human
 <223> Amino acids 328-343 of SEQ ID NO: 3
 <400> 14
 Asp Gly Trp Gln Asp Ile Val Ile Gly Ala Pro Gln Tyr Phe Asp Arg
```

```
<210> 15
<211> 17
<212> PRT
<213> Human
<223> Amino acids 344-360 of SEQ ID NO: 3
Asp Gly Glu Val Gly Gly Ala Val Tyr Val Tyr Met Asn Gln Gln Gly
Arg
<210> 16
<211> 8
 <212> PRT
 <213> Human
<223> Amino acids 361-368 of SEQ ID NO: 3
 <400> 16
 Trp Asn Asn Val Lys Pro Ile Arg
  1
 <210> 17
 <211> 24
 <212> PRT
 <213> Human
 <223> Amino acids 383-406 of SEQ ID NO: 3
 Asn Ile Gly Asp Ile Asn Gln Asp Gly Tyr Pro Asp Ile Ala Val Gly
                                       10
                   5
  Ala Pro Tyr Asp Asp Leu Gly Lys
               20
  <210> 18
  <211> 18
  <212> PRT
  <213> Human
  <223> Amino acids 427-444 of SEQ ID NO: 3
  Gly Ile Ser Pro Tyr Phe Gly Tyr Ser Ile Ala Gly Asn Met Asp Leu
                                         10
                     5
    1
   Asp Arg
```

PCT/SE00/02082

WO 01/30854

```
<210> 19
<211> 19
<212> PRT
<213> Human
<223> Amino acids 445-463 of SEQ ID NO: 3
Asn Ser Tyr Pro Asp Val Ala Val Gly Ser Leu Ser Asp Ser Val Thr
<400> 19
Ile Phe Arg
<210> 20
<211> 9
 <212> PRT
 <213> Human
 <223> Amino acids 464-472 of SEQ ID NO: 3
 <400> 20
 Ser Arg Pro Val Ile Asn Ile Gln Lys
                   5
 1
 <210> 21
 <211> 18
 <212> PRT
 <213> Human
 <223> Amino acids 577-594 of SEQ ID NO: 3
 Leu Arg Pro Ile Pro Ile Thr Ala Ser Val Glu Ile Gln Glu Pro Ser
                                       10
                    5
   1
  Ser Arg
  <210> 22
  <211> 17
  <212> PRT
  <213> Human
  <223> Amino acids 597-613 of SEQ ID NO: 3
  <400> 22
  Val Asn Ser Leu Pro Glu Val Leu Pro Ile Leu Asn Ser Asp Glu Pro
                                        10
   Lys
```

```
<210> 23
 <211> 10
 <212> PRT
 <213> Human
<223> Amino acids 614-623 of SEQ ID NO: 3
 <400> 23
 Thr Ala His Ile Asp Val His Phe Leu Lys
 <210> 24
 <211> 8
 <212> PRT
 <213> Human
 <223> Amino acids 652-659 of SEQ ID NO: 3
 <400> 24
 Phe Ser Tyr Leu Pro Ile Gln Lys
  1
 <210> 25
 <211> 16
 <212> PRT
 <213> Human
 <223> Amino acids 671-686 of SEQ ID NO: 3
 <400> 25
 Asp Ile Ala Leu Glu Ile Thr Val Thr Asn Ser Pro Ser Asn Pro Arg
                                       10
 <210> 26
 <211> 14
 <212> PRT
 <213> Human
  <223> Amino acids 822-835 of SEQ ID NO: 3
  <400> 26
 Ser Glu Asp Glu Val Gly Ser Leu Ile Glu Tyr Glu Phe Arg
                   5
  <210> 27
  <211> 15
  <212> PRT
  <213> Human
  <223> Amino acids 871-885 of SEQ ID NO: 3
  Val Glu Ser Lys Gly Leu Glu Lys Val Thr Cys Glu Pro Gln Lys
   1
                    5
                                       10
```

```
<210> 28
<211> 13
<212> PRT
<213> Human
<223> Amino acids 902-914 of SEQ ID NO: 3
<400> 28
Arg Glu Ile Thr Glu Lys Gln Ile Asp Asp Asn Arg Lys
<210> 29
<211> 7
<212> PRT
<213> Human
<223> Amino acids 915-921 of SEQ ID NO: 3
<400> 29
Phe Ser Leu Phe Ala Glu Arg
1
<210> 30
<211> 16
<212> PRT
<213> Human
<223> Amino acids 923-938 of SEQ ID NO: 3
<400> 30
Tyr Gln Thr Leu Asn Cys Ser Val Asn Val Asn Cys Val Asn Ile Arg
                 5
                                      10
<210> 31
<211> 9
<212> PRT
<213> Human
<223> Amino acids 968-976 of SEQ ID NO: 3
<400> 31
Leu Asn Tyr Leu Asp Ile Leu Met Arg
                  5
<210> 32
<211> 13
<212> PRT
<213> Human
<223> Amino acids 977-989 of SEQ ID NO: 3
<400> 32
Ala Phe Ile Asp Val Thr Ala Ala Ala Glu Asn Ile Arg
                  5
```

PCT/SE00/02082

WO 01/30854

```
<210> 33
<211> 9
<212> PRT
<213> Human
<223> Amino acids 990-998 of SEQ ID NO: 3
<400> 33
Leu Pro Asn Ala Gly Thr Gln Val Arg
<210> 34
<211> 12
<212> PRT
<213> Human
<223> Amino acids 178-189 of SEQ ID NO: 4
<400> 34
Val Ser Val Pro Gln Thr Asp Met Arg Pro Glu Lys
<210> 35
<211> 13
<212> PRT
<213> Human
<223> Amino acids 192-204 of SEQ ID NO: 4
 <400> 35
Glu Pro Trp Pro Asn Ser Asp Pro Pro Phe Ser Phe Lys
 <210> 36
 <211> 13
 <212> PRT
.<213> Human
 <223> Amino acids 205-217 of SEQ ID NO: 4
 <400> 36
 Asn Val Ile Ser Leu Thr Glu Asp Val Asp Glu Phe Arg
 <210> 37
 <211> 12
 <212> PRT
 <213> Human
 <223> Amino acids 301-312 of SEQ ID NO: 4
 <400> 37
 Thr Gln Asp Tyr Pro Ser Val Pro Thr Leu Val Arg
                                       10
                   5
```

```
<210> 38
<211> 12
<212> PRT
<213> Human
<223> Amino acids 402-413 of SEQ ID NO: 4
<400> 38
Arg Gly Glu Val Gly Ile Tyr Gln Val Gln Leu Arg
<210> 39
<211> 18
<212> PRT
<213> Human
<223> Amino acids 414-431 of SEQ ID NO: 4
<400> 39
Ala Leu Glu His Val Asp Gly Thr His Val Cys Gln Leu Pro Glu Asp
                                      10
Gln Lys
<210> 40
<211> 14
<212> PRT
<213> Human
<223> Amino acids 432-445 of SEQ ID NO: 4
<400> 40
Gly Asn Ile His Leu Lys Pro Ser Phe Ser Asp Gly Leu Lys
                  5
<210> 41
<211> 16
<212> PRT
<213> Human
<223> Amino acids 446-461 of SEQ ID NO: 4
Met Asp Ala Gly Ile Ile Cys Asp Val Cys Thr Cys Glu Leu Gln Lys
  1
                                      10
<210> 42
<211> 15
<212> PRT
<213> Human
<223> Amino acids 531-545 of SEQ ID NO: 4
<400> 42
Tyr Glu Gly Gln Phe Cys Glu Tyr Asp Asn Phe Gln Cys Pro Arg
```

مر د به سر

```
<210> 43
<211> 16
<212> PRT
<213> Human
<223> Amino acids 631-646 of SEQ ID NO: 4
<400> 43
Ser Cys Val Gln Cys Gln Ala Trp Gly Thr Gly Glu Lys Lys Gly Arg
                                      10
<210> 44
 <211> 28
 <212> PRT
 <213> Human
 <223> Amino acids 675-702 of SEQ ID NO: 4
<400> 44
 Asp Glu Asp Asp Asp Cys Thr Tyr Ser Tyr Thr Met Glu Gly Asp Gly
                                     10
Ala Pro Gly Pro Asn Ser Thr Val Leu Val His Lys
             20
 <210> 45
 <211> 12
 <212> PRT
 <213> Human
 <223> Amino acids 845-856 of SEQ ID NO: 4
 <400> 45
 Gln Glu Val Glu Glu Asn Leu Asn Glu Val Tyr Arg
                   5
 <210> 46
 <211> 15
 <212> PRT
 <213> Human
 <223> Amino acids 916-930 of SEQ ID NO: 4
 Val Ala Pro Gly Tyr Tyr Thr Leu Thr Ala Asp Gln Asp Ala Arg
                   5
```

pa 1 2 74

```
<210> 47
<211> 13
<212> PRT
<213> Human
<223> Amino acids 946-958 of SEQ ID NO: 4
<400> 47
Val Pro Leu Phe Ile Arg Pro Glu Asp Asp Asp Glu Lys
                                      10
             . 5
<210> 48
<211> 14
<212> PRT
<213> Human
<223> Amino acids 990-1003 of SEQ ID NO: 4
 <400> 48
Asp Val Val Ser Phe Glu Gln Pro Glu Phe Ser Val Ser Arg
                                       10
                   5
 <210> 49
 <211> 12
 <212> PRT
 <213> Human
 <223> Amino acids 1061-1072 of SEQ ID NO: 4
 <400> 49
 Leu Leu Glu Leu Gln Glu Val Asp Ser Leu Leu Arg
                    5
   1
  <210> 50
  <211> 19
  <212> PRT
  <213> Human
  <223> Amino acids 1196-1214 of SEQ ID NO: 4
  Val Cys Ala Tyr Gly Ala Gln Gly Glu Gly Pro Tyr Ser Ser Leu Val
   1
  Ser Cys Arg
  <210> 51
   <211> 9
   <212> PRT
   <213> Human
   <223> Amino acids 1273-1281 of SEQ ID NO: 4
   <400> 51
   Val Leu Val Asp Asn Pro Lys Asn Arg
```

5

1





SEQUENCE LISTING

Ohlsso Tordss Kearne	, Thomas rom, Pia n, Lenna on, Jesp y, Phili , Bo H.K	J. rt G. er M. p P.												
<120> Novel	Novel Compounds													
<130> 003300	003300-920													
<140> US 10/ <141> 2002-0	> US 10/088,639 > 2002-03-20													
	<150> SE 9903895-2 <151> 1999-10-28													
<160> 51														
<170> Patent	In Ver.	2.1												
<210> 1 <211> 747 <212> DNA <213> Macaca	fascicu	laris												
<220> <221> CDS <222> (1)(<223> Coding linker						Eied	Hust	con						
<400> 1 tct tct gag Ser Ser Glu 1												48		
aca gtc agg Thr Val Arg												96		
agc tgg tac Ser Trp Tyr 35												144		
ggt aac aac Gly Asn Asn 50												192		
tgg tca gga Trp Ser Gly 65												240		
gat gag gct Asp Glu Ala												288		

90 95 85 ccg gta ttc ggc gga ggg acc cgg gtg acc gtc cta ggt caa gcc aac Pro Val Phe Gly Gly Gly Thr Arg Val Thr Val Leu Gly Gln Ala Asn 100 ggt gaa ggc ggc tct ggt ggc ggg gga tcc gga ggc ggc ggt tct gag 384 Gly Glu Gly Gly Ser Gly Gly Gly Ser Gly Gly Gly Ser Glu 120 125 gtg cag ttg gtg gag tct ggg gga ggc ttg gta aag cct ggg ggg tcc 432 Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser 135 ctg aga ctc tct tgt gta gcc tct ggg tcc atc ttc agt agc tct gtt Leu Arg Leu Ser Cys Val Ala Ser Gly Ser Ile Phe Ser Ser Ser Val 155 atg cac tgg gtc cgc cag gct cca gga aag ggt ctg gag tgg gtc tca 528 Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser gtt att agt gaa aat ggg cgt acc att aac tac gca gac tct gtg aag 576 Val Ile Ser Glu Asn Gly Arg Thr Ile Asn Tyr Ala Asp Ser Val Lys 180 185 190 ggc ega ttc acc atc tcc aga gac aac gcc aag aac tca ctg ttt ctg 624 Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe Leu 200 195 cag atg aac agc ctg aca ggc gag gac acg gcc gtc tat tac tgt agt 672 Gln Met Asn Ser Leu Thr Gly Glu Asp Thr Ala Val Tyr Tyr Cys Ser 215 720 aga gag ggg gga cct gga aca acg tcc aac cgg ctc gat gcc tgg ggc Arg Glu Gly Gly Pro Gly Thr Thr Ser Asn Arg Leu Asp Ala Trp Gly 230 235 747 ccg gga gtc ctg gtc acc gtt tcc tca Pro Gly Val Leu Val Thr Val Ser Ser 245 <210> 2 <211> 249 <212> PRT <213> Macaca fascicularis <223> Coding sequence VL (1-109) - modified Huston linker (110-127) - VH (128-249) <400> 2 Ser Ser Glu Leu Thr Gln Gly Pro Ala Leu Ser Val Ala Leu Gly His Thr Val Arg Met Thr Cys Gln Gly Asp Ser Leu Lys Thr Tyr Tyr Ala 20

Ser Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Val Leu Val Ile Tyr 35 40 45

Gly Asn Asn Tyr Arg Pro Ser Gly Ile Pro Gly Arg Phe Ser Gly Ser 50 60

Trp Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Ala Ala Gln Val Glu 65 70 75 80

Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Trp Asp Ser Ser Gly Thr His $85 \hspace{1.5cm} 90 \hspace{1.5cm} 95$

Pro Val Phe Gly Gly Gly Thr Arg Val Thr Val Leu Gly Gln Ala Asn $100 \hspace{1cm} 105 \hspace{1cm} 110$

Gly Glu Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu 115 120 125

Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser 130 135 140

Leu Arg Leu Ser Cys Val Ala Ser Gly Ser Ile Phe Ser Ser Ser Val 145 150 155 160

Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser 165 170 175

Val Ile Ser Glu Asn Gly Arg Thr Ile Asn Tyr Ala Asp Ser Val Lys 180 185 190

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe Leu 195 200 205

Gln Met Asn Ser Leu Thr Gly Glu Asp Thr Ala Val Tyr Tyr Cys Ser 210 215 220

Arg Glu Gly Gly Pro Gly Thr Thr Ser Asn Arg Leu Asp Ala Trp Gly 225 230 235

Pro Gly Val Leu Val Thr Val Ser Ser 245

<210> 3

<211> 1073

<212> PRT

<213> Human

<220>

<223> TA6-Human integrin alpha-6A

<100> 3

Met Ala Ala Ala Gly Gln Leu Cys Leu Leu Tyr Leu Ser Ala Gly Leu 1 10 15

Leu Ser Arg Leu Gly Ala Ala Phe Asn Leu Asp Thr Arg Glu Asp Asn 20 25 30

Val Ile Arg Lys Tyr Gly Asp Pro Gly Ser Leu Phe Gly Phe Ser Leu Ala Met His Trp Gln Leu Gln Pro Glu Asp Lys Arg Leu Leu Val Gly Ala Pro Arg Gly Glu Ala Leu Pro Leu Gln Arg Ala Asn Arg Thr Gly Gly Leu Tyr Ser Cys Asp Ile Thr Ala Arg Gly Pro Cys Thr Arg Ile Glu Phe Asp Asn Asp Ala Asp Pro Thr Ser Glu Ser Lys Glu Asp Gln Trp Met Gly Val Thr Val Gln Ser Gln Gly Pro Gly Gly Lys Val 120 Val Thr Cys Ala His Arg Tyr Glu Lys Arg Gln His Val Asn Thr Lys Gln Glu Ser Arg Asp Ile Phe Gly Arg Cys Tyr Val Leu Ser Gln Asn Leu Arg Ile Glu Asp Asp Met Asp Gly Gly Asp Trp Ser Phe Cys Asp Gly Arg Leu Arg Gly His Glu Lys Phe Gly Ser Cys Gln Gln Gly Val Ala Ala Thr Phe Thr Lys Asp Phe His Tyr Ile Val Phe Gly Ala Pro Gly Thr Tyr Asn Trp Lys Gly Ile Val Arg Val Glu Gln Lys Asn Asn Thr Phe Phe Asp Met Asn Ile Phe Glu Asp Gly Pro Tyr Glu Val Gly Gly Glu Thr Glu His Asp Glu Ser Leu Val Pro Val Pro Ala Asn Ser Tyr Leu Gly Phe Ser Leu Asp Ser Gly Lys Gly Ile Val Ser Lys Asp 265 Glu Ile Thr Phe Val Ser Gly Ala Pro Arg Ala Asn His Ser Gly Ala Val Val Leu Leu Lys Arg Asp Met Lys Ser Ala His Leu Leu Pro Glu 295 His Ile Phe Asp Gly Glu Gly Leu Ala Ser Ser Phe Gly Tyr Asp Val Ala Val Val Asp Leu Asn Lys Asp Gly Trp Gln Asp Ile Val Ile Gly 330 Ala Pro Gln Tyr Phe Asp Arg Asp Gly Glu Val Gly Gly Ala Val Tyr 340 345

10088639.032002

003300-920.ST25

Val Tyr Met Asn Gln Gln Gly Arg Trp Asn Asn Val Lys Pro Ile Arg Leu Asn Gly Thr Lys Asp Ser Met Phe Gly Ile Ala Val Lys Asn Ile Gly Asp Ile Asn Gln Asp Gly Tyr Pro Asp Ile Ala Val Gly Ala Pro 390 Tyr Asp Asp Leu Gly Lys Val Phe Ile Tyr His Gly Ser Ala Asn Gly 405 Ile Asn Thr Lys Pro Thr Gln Val Leu Lys Gly Ile Ser Pro Tyr Phe 425 Gly Tyr Ser Ile Ala Gly Asn Met Asp Leu Asp Arg Asn Ser Tyr Pro 435 440 445 Asp Val Ala Val Gly Ser Leu Ser Asp Ser Val Thr Ile Phe Arg Ser 455 Arg Pro Val Ile Asn Ile Gln Lys Thr Ile Thr Val Thr Pro Asn Arg Ile Asp Leu Arg Gln Lys Thr Ala Cys Gly Ala Pro Ser Gly Ile Cys Leu Gln Val Lys Ser Cys Phe Glu Tyr Thr Ala Asn Pro Ala Gly Tyr Asn Pro Ser Ile Ser Ile Val Gly Thr Leu Glu Ala Glu Lys Glu Arg 520 Arg Lys Ser Gly Leu Ser Ser Arg Val Gln Phe Arg Asn Gln Gly Ser 535 Glu Pro Lys Tyr Thr Gln Glu Leu Thr Leu Lys Arg Gln Lys Gln Lys Val Cys Met Glu Glu Thr Leu Trp Leu Gln Asp Asn Ile Arg Asp Lys Leu Arg Pro Ile Pro Ile Thr Ala Ser Val Glu Ile Gln Glu Pro Ser 585 Ser Arg Arg Arg Val Asn Ser Leu Pro Glu Val Leu Pro Ile Leu Asn Ser Asp Glu Pro Lys Thr Ala His Ile Asp Val His Phe Leu Lys Glu 615 Gly Cys Gly Asp Asp Asn Val Cys Asn Ser Asn Leu Lys Leu Glu Tyr Lys Phe Cys Thr Arg Glu Gly Asn Gln Asp Lys Phe Ser Tyr Leu Pro 645 650 Ile Gln Lys Gly Val Pro Glu Leu Val Leu Lys Asp Gln Lys Asp Ile 665 660

Ala Leu Glu Ile Thr Val Thr Asn Ser Pro Ser Asn Pro Arg Asn Pro 680 Thr Lys Asp Gly Asp Asp Ala His Glu Ala Lys Leu Ile Ala Thr Phe Pro Asp Thr Leu Thr Tyr Ser Ala Tyr Arg Glu Leu Arg Ala Phe Pro 710 715 Glu Lys Gln Leu Ser Cys Val Ala Asn Gln Asn Gly Ser Gln Ala Asp Cys Glu Leu Gly Asn Pro Phe Lys Arg Asn Ser Asn Val Thr Phe Tyr Leu Val Leu Ser Thr Thr Glu Val Thr Phe Asp Thr Pro Asp Leu Asp 760 765 Ile Asn Leu Lys Leu Glu Thr Thr Ser Asn Gln Asp Asn Leu Ala Pro Ile Thr Ala Lys Ala Lys Val Val Ile Glu Leu Leu Ser Val Ser Gly Val Ala Lys Pro Ser Gln Val Tyr Phe Gly Gly Thr Val Val Gly Glu Gln Ala Met Lys Ser Glu Asp Glu Val Gly Ser Leu Ile Glu Tyr Glu Phe Arg Val Ile Asn Leu Gly Lys Pro Leu Thr Asn Leu Gly Thr Ala Thr Leu Asn Ile Gln Trp Pro Lys Glu Ile Ser Asn Gly Lys Trp Leu Leu Tyr Leu Val Lys Val Glu Ser Lys Gly Leu Glu Lys Val Thr Cys Glu Pro Gln Lys Glu Ile Asn Ser Leu Asn Leu Thr Glu Ser His 890 Asn Ser Arg Lys Lys Arg Glu Ile Thr Glu Lys Gln Ile Asp Asn 905 Arg Lys Phe Ser Leu Phe Ala Glu Arg Lys Tyr Gln Thr Leu Asn Cys Ser Val Asn Val Asn Cys Val Asn Ile Arg Cys Pro Leu Arg Gly Leu 935 Asp Ser Lys Ala Ser Leu Ile Leu Arg Ser Arg Leu Trp Asn Ser Thr Phe Leu Glu Glu Tyr Ser Lys Leu Asn Tyr Leu Asp Ile Leu Met Arg Ala Phe Ile Asp Val Thr Ala Ala Ala Glu Asn Ile Arg Leu Pro Asn 985

Ala Gly Thr Gln Val Arg Val Thr Val Phe Pro Ser Lys Thr Val Ala 995 $1000\,$ 1005

Gln Tyr Ser Gly Val Pro Trp Trp Ile Ile Leu Val Ala Ile Leu Ala 1010 1015 1020

Gly Ile Leu Met Leu Ala Leu Leu Val Phe Ile Leu Trp Lys Cys Gly 1025 1030 1035 1040

Phe Phe Lys Arg Asn Lys Lys Asp His Tyr Asp Ala Thr Tyr His Lys
1045 1050 1055

Ala Glu Ile His Ala Gln Pro Ser Asp Lys Glu Arg Leu Thr Ser Asp 1060 1065 1070

Ala

<210> 4

<211> 1875

<212> PRT

<213> Human

<220>

<223> Integrin beta-4 precursor

<400> 4

Met Ala Gly Pro Arg Pro Ser Pro Trp Ala Arg Leu Leu Ala Ala 1 5 10 15

Leu Ile Ser Val Ser Leu Ser Gly Thr Leu Ala Asn Arg Cys Lys 20 25 30

Ala Pro Val Lys Ser Cys Thr Glu Cys Val Arg Val Asp Lys Asp Cys 35 40 45

Ala Tyr Cys Thr Asp Glu Met Phe Arg Asp Arg Arg Cys Asn Thr Gln 50 55 60

Ala Glu Leu Leu Ala Ala Gly Cys Gln Arg Glu Ser Ile Val Val Met 65 70 75 80

Glu Ser Ser Phe Gln Ile Thr Glu Glu Thr Gln Ile Asp Thr Thr Leu 85 90 95

Arg Arg Ser Gln Met Ser Pro Gln Gly Leu Arg Val Arg Leu Arg Pro 100 . 105 110

Gly Glu Glu Arg His Phe Glu Leu Glu Val Phe Glu Pro Leu Glu Ser 115 120 125

Pro Val Asp Leu Tyr Ile Leu Met Asp Phe Ser As
n Ser Met Ser Asp 130 135 140

Asp Leu Asp Asn Leu Lys Lys Met Gly Gln Asn Leu Ala Arg Val Leu 145 150 155 160

Ser Gln Leu Thr Ser Asp Tyr Thr Ile Gly Phe Gly Lys Phe Val Asp 165 170 175

Lys Val Ser Val Pro Gln Thr Asp Met Arg Pro Glu Lys Leu Lys Glu Pro Trp Pro Asn Ser Asp Pro Pro Phe Ser Phe Lys Asn Val Ile Ser Leu Thr Glu Asp Val Asp Glu Phe Arg Asn Lys Leu Gln Gly Glu Arg Ile Ser Gly Asn Leu Asp Ala Pro Glu Gly Gly Phe Asp Ala Ile Leu Gln Thr Ala Val Cys Thr Arg Asp Ile Gly Trp Arg Pro Asp Ser Thr His Leu Leu Val Phe Ser Thr Glu Ser Ala Phe His Tyr Glu Ala Asp 265 Gly Ala Asn Val Leu Ala Gly Ile Met Ser Arg Asn Asp Glu Arg Cys His Leu Asp Thr Thr Gly Thr Tyr Thr Gln Tyr Arg Thr Gln Asp Tyr 295 Pro Ser Val Pro Thr Leu Val Arg Leu Leu Ala Lys His Asn Ile Ile Pro Ile Phe Ala Val Thr Asn Tyr Ser Tyr Ser Tyr Tyr Glu Lys Leu 325 His Thr Tyr Phe Pro Val Ser Ser Leu Gly Val Leu Gln Glu Asp Ser 345 Ser Asn Ile Val Glu Leu Leu Glu Glu Ala Phe Asn Arg Ile Arg Ser 360 Asn Leu Asp Ile Arg Ala Leu Asp Ser Pro Arg Gly Leu Arg Thr Glu Val Thr Ser Lys Met Phe Gln Lys Thr Arg Thr Gly Ser Phe His Ile 395 390 Arg Arg Gly Glu Val Gly Ile Tyr Gln Val Gln Leu Arg Ala Leu Glu His Val Asp Gly Thr His Val Cys Gln Leu Pro Glu Asp Gln Lys Gly Asn Ile His Leu Lys Pro Ser Phe Ser Asp Gly Leu Lys Met Asp Ala 440 Gly Ile Ile Cys Asp Val Cys Thr Cys Glu Leu Gln Lys Glu Val Arg Ser Ala Arg Cys Ser Phe Asn Gly Asp Phe Val Cys Gly Gln Cys Val Cys Ser Glu Gly Trp Ser Gly Gln Thr Cys Asn Cys Ser Thr Gly Ser 485

Leu Ser Asp Ile Gln Pro Cys Leu Arg Glu Gly Glu Asp Lys Pro Cys Ser Gly Arg Gly Glu Cys Gln Cys Gly His Cys Val Cys Tyr Gly Glu Gly Arg Tyr Glu Gly Gln Phe Cys Glu Tyr Asp Asn Phe Gln Cys Pro Arg Thr Ser Gly Phe Leu Cys Asn Asp Arg Gly Arg Cys Ser Met Gly Gln Cys Val Cys Glu Pro Gly Trp Thr Gly Pro Ser Cys Asp Cys Pro Leu Ser Asn Ala Thr Cys Ile Asp Ser Asn Gly Gly Ile Cys Asn Gly Arg Gly His Cys Glu Cys Gly Arg Cys His Cys His Gln Gln Ser Leu 600 Tyr Thr Asp Thr Ile Cys Glu Ile Asn Tyr Ser Ala Ile His Pro Gly 615 Leu Cys Glu Asp Leu Arg Ser Cys Val Gln Cys Gln Ala Trp Gly Thr Gly Glu Lys Lys Gly Arg Thr Cys Glu Glu Cys Asn Phe Lys Val Lys Met Val Asp Glu Leu Lys Arg Ala Glu Glu Val Val Val Arg Cys Ser Phe Arg Asp Glu Asp Asp Cys Thr Tyr Ser Tyr Thr Met Glu Gly 680 Asp Gly Ala Pro Gly Pro Asn Ser Thr Val Leu Val His Lys Lys Lys Asp Cys Pro Pro Gly Ser Phe Trp Trp Leu Ile Pro Leu Leu Leu Leu 710 715 Leu Leu Pro Leu Leu Ala Leu Leu Leu Leu Cys Trp Lys Tyr Cys Ala Cys Cys Lys Ala Cys Leu Ala Leu Leu Pro Cys Cys Asn Arg Gly His Met Val Gly Phe Lys Glu Asp His Tyr Met Leu Arg Glu Asn Leu 760 Met Ala Ser Asp His Leu Asp Thr Pro Met Leu Arg Ser Gly Asn Leu Lys Gly Arg Asp Val Val Arg Trp Lys Val Thr Asn Asn Met Gln Arg Pro Gly Phe Ala Thr His Ala Ala Ser Ile Asn Pro Thr Glu Leu Val 810

Pro Tyr Gly Leu Ser Leu Arg Leu Ala Arg Leu Cys Thr Glu Asn Leu Leu Lys Pro Asp Thr Arg Glu Cys Ala Gln Leu Arg Gln Glu Val Glu Glu Asn Leu Asn Glu Val Tyr Arg Gln Ile Ser Gly Val His Lys Leu Gln Gln Thr Lys Phe Arg Gln Gln Pro Asn Ala Gly Lys Lys Gln Asp His Thr Ile Val Asp Thr Val Leu Met Ala Pro Arg Ser Ala Lys Pro Ala Leu Leu Lys Leu Thr Glu Lys Gln Val Glu Gln Arg Ala Phe His Asp Leu Lys Val Ala Pro Gly Tyr Tyr Thr Leu Thr Ala Asp Gln Asp 915 920 Ala Arg Gly Met Val Glu Phe Gln Glu Gly Val Glu Leu Val Asp Val 935 Arg Val Pro Leu Phe Ile Arg Pro Glu Asp Asp Asp Glu Lys Gln Leu Leu Val Glu Ala Ile Asp Val Pro Ala Gly Thr Ala Thr Leu Gly Arg 970 965 Arg Leu Val Asn Ile Thr Ile Ile Lys Glu Gln Ala Arg Asp Val Val 985 Ser Phe Glu Gln Pro Glu Phe Ser Val Ser Arg Gly Asp Gln Val Ala 1000 Arg Ile Pro Val Ile Arg Arg Val Leu Asp Gly Gly Lys Ser Gln Val 1015 Ser Tyr Arg Thr Gln Asp Gly Thr Ala Gln Gly Asn Arg Asp Tyr Ile 1035 1030 Pro Val Glu Gly Glu Leu Leu Phe Gln Pro Gly Glu Ala Trp Lys Glu 1050 Leu Gln Val Lys Leu Leu Glu Leu Gln Glu Val Asp Ser Leu Leu Arg Gly Arg Gln Val Arg Arg Phe His Val Gln Leu Ser Asn Pro Lys Phe 1080 Gly Ala His Leu Gly Gln Pro His Ser Thr Thr Ile Ile Arg Asp 1095 Pro Asp Glu Leu Asp Arg Ser Phe Thr Ser Gln Met Leu Ser Ser Gln 1115 1110 Pro Pro Pro His Gly Asp Leu Gly Ala Pro Gln Asn Pro Asn Ala Lys 1125 1130

- Ala Ala Gly Ser Arg Lys Ile His Phe Asn Trp Leu Pro Pro Ser Gly 1140 1145 1150
- Lys Pro Met Gly Tyr Arg Val Lys Tyr Trp Ile Gln Gly Asp Ser Glu 1155 1160 1165
- Ser Glu Ala His Leu Leu Asp Ser Lys Val Pro Ser Val Glu Leu Thr 1170 1175 1180
- Asn Leu Tyr Pro Tyr Cys Asp Tyr Glu Met Lys Val Cys Ala Tyr Gly 1185 1190 1195 1200
- Ala Gl
n Gly Glu Gly Pro Tyr Ser Ser Leu Val Ser Cys Arg Th
r His 1205 1210 1215
- Gln Glu Val Pro Ser Glu Pro Gly Arg Leu Ala Phe Asn Val Val Ser 1220 1225 1230
- Ser Thr Val Thr Gln Leu Ser Trp Ala Glu Pro Ala Glu Thr Asn Gly 1235 1240 1245
- Glu Ile Thr Ala Tyr Glu Val Cys Tyr Gly Leu Val Asn Asp Asp Asn 1250 1260
- Arg Pro Ile Gly Pro Met Lys Lys Val Leu Val Asp Asn Pro Lys Asn 1265 1270 1275 1280
- Arg Met Leu Leu Ile Glu Asn Leu Arg Glu Ser Gln Pro Tyr Arg Tyr $1285 \hspace{1.5cm} 1290 \hspace{1.5cm} 1295$
- Thr Val Lys Ala Arg Asn Gly Ala Gly Trp Gly Pro Glu Arg Glu Ala 1300 1305 1310
- Ile Ile Asn Leu Ala Thr Gln Pro Lys Arg Pro Met Ser Ile Pro Ile 1315 1320 1325
- Ile Pro Asp Ile Pro Ile Val Asp Ala Gln Ser Gly Glu Asp Tyr Asp 1330 1340
- Ser Phe Leu Met Tyr Ser Asp Asp Val Leu Arg Ser Pro Ser Gly Ser 1345 1350 1355 1360
- Gln Arg Pro Ser Val Ser Asp Asp Thr Gly Cys Gly Trp Lys Phe Glu 1365 1370 1375
- Pro Leu Leu Gly Glu Glu Leu Asp Leu Arg Arg Val Thr Trp Arg Leu 1380 1385 1390
- Pro Pro Glu Leu Ile Pro Arg Leu Ser Ala Ser Ser Gly Arg Ser Ser 1395 1400 1405
- Asp Ala Glu Ala Pro Thr Ala Pro Arg Thr Thr Ala Ala Arg Ala Gly 1410 1420
- Arg Ala Ala Val Pro Arg Ser Ala Thr Pro Gly Pro Pro Gly Glu 1425 1430 1435 1440
- His Leu Val Asn Gly Arg Met Asp Phe Ala Phe Pro Gly Ser Thr Asn 1445 1450 1455

- Ser Leu His Arg Met Thr Thr Thr Ser Ala Ala Ala Tyr Gly Thr His 1460 1465 1470
- Leu Ser Pro His Val Pro His Arg Val Leu Ser Thr Ser Ser Thr Leu 1475 1480 1485
- Thr Arg Asp Tyr Asn Ser Leu Thr Arg Ser Glu His Ser His Ser Thr 1490 1495 1500
- Thr Leu Pro Arg Asp Tyr Ser Thr Leu Thr Ser Val Ser Ser His Gly 1505 1510 1515 1520
- Leu Pro Pro Ile Trp Glu His Gly Arg Ser Arg Leu Pro Leu Ser Trp
 1525 1530 1535
- Ala Leu Gly Ser Arg Ser Arg Ala Gln Met Lys Gly Phe Pro Pro Ser
- Arg Gly Pro Arg Asp Ser Ile Ile Leu Ala Gly Arg Pro Ala Ala Pro 1555 1560 1565
- Ser Trp Gly Pro Asp Ser Arg Leu Thr Ala Gly Val Pro Asp Thr Pro 1570 1575 1580
- Thr Arg Leu Val Phe Ser Ala Leu Gly Pro Thr Ser Leu Arg Val Ser 1585 1590 1595 1600
- Trp Gln Glu Pro Arg Cys Glu Arg Pro Leu Gln Gly Tyr Ser Val Glu 1605 1610 1615
- Tyr Gln Leu Leu Asn Gly Gly Glu Leu His Arg Leu Asn Ile Pro Asn 1620 1630
- Pro Ala Gln Thr Ser Val Val Val Glu Asp Leu Leu Pro Asn His Ser 1635 1640 1645
- Tyr Val Phe Arg Val Arg Ala Gln Ser Gln Glu Gly Trp Gly Arg Glu 1650 1660
- Arg Glu Gly Val Ile Thr Ile Glu Ser Gln Val His Pro Gln Ser Pro 1665 1670 1675 1680
- Leu Cys Pro Leu Pro Gly Ser Ala Phe Thr Leu Ser Thr Pro Ser Ala 1685 1690 1695
- Pro Gly Pro Leu Val Phe Thr Ala Leu Ser Pro Asp Ser Leu Gln Leu 1700 1705 1710
- Ser Trp Glu Arg Pro Arg Pro Asn Gly Asp Ile Val Gly Tyr Leu 1715 1720 1725
- Val Thr Cys Glu Met Ala Gln Gly Gly Gly Pro Ala Thr Ala Phe Arg 1730 1735 1740
- Val Asp Gly Asp Ser Pro Glu Ser Arg Leu Thr Val Pro Gly Leu Ser 1745 1750 1760
- Glu Asn Val Pro Tyr Lys Phe Lys Val Gln Ala Arg Thr Thr Glu Gly 1765 1770

```
Phe Gly Pro Glu Arg Glu Gly Ile Ile Thr Ile Glu Ser Gln Asp Gly
                              1785
Gly Pro Phe Pro Gln Leu Gly Ser Arg Ala Gly Leu Phe Gln His Pro
                          1800
Leu Gln Ser Glu Tyr Ser Ser Ile Thr Thr His Thr Ser Ala Thr
                                           1820
Glu Pro Phe Leu Val Asp Gly Pro Thr Leu Gly Ala Gln His Leu Glu
                  1830
1825
Ala Gly Gly Ser Leu Thr Arg His Val Thr Gln Glu Phe Val Ser Arg
                                   1850
Thr Leu Thr Thr Ser Gly Thr Leu Ser Thr His Met Asp Gln Gln Phe
                               1865
         1860
Phe Gln Thr
  1875
<210> 5
<211> 8
<212> PRT
<213> Human
<220>
<223> Amino acids 61-68 of SEQ ID NO: 3
<400> 5
Leu Leu Val Gly Ala Pro Arg
<210> 6
 <211> 20
 <212> PRT
 <213> Human
 <223> Amino acids 77-96 of SEQ ID NO: 3
 Ala Asn Arg Thr Gly Gly Leu Tyr Ser Cys Asp Ile Thr Ala Arg Gly
                                     10
 Pro Cys Thr Arg
 <210> 7
 <211> 10
 <212> PRT
 <213> Human
 <220>
 <223> Amino acids 127-137 of SEQ ID NO: 3
 <400> 7
```

```
Val Val Thr Cys Ala His Arg Tyr Glu Lys
<210> 8
<211> 7
<212> PRT
<213> Human
<220>
<223> Amino acids 138-144 of SEQ ID NO: 3
<400> 8
Arg Gln His Val Asn Thr Lys
<210> 9
<211> 9
<212> PRT
<213> Human
<220>
<223> Amino acids 154-162 of SEQ ID NO: 3
<400> 9
Cys Tyr Val Leu Ser Gln Asn Leu Arg
<210> 10
<211> 14
<212> PRT
<213> Human
<220>
<223> Amino acids 185-198 of SEQ ID NO: 3
Phe Gly Ser Cys Gln Gln Gly Val Ala Ala Thr Phe Thr Lys
<210> 11
<211> 16
<212> PRT
<213> Human
<223> Amino acids 198-214 of SEQ ID NO: 3
 Asp Phe His Tyr Ile Val Phe Gly Ala Pro Gly Thr Tyr Asn Trp Lys
              5 10
 <210> 12
 <211> 11
 <212> PRT
 <213> Human
```

```
<220>
<223> Amino acids 272-282 of SEQ ID NO: 3
<400> 12
Asp Glu Ile Thr Phe Val Ser Gly Ala Pro Arg
<210> 13
<211> 11
<212> PRT
<213> Human
<220>
<223> Amino acids 283-293 of SEQ ID NO: 3
<400> 13
Ala Asn His Ser Gly Ala Val Val Leu Leu Lys
<210> 14
<211> 16
<212> PRT
<213> Human
<220>
<223> Amino acids 328-343 of SEQ ID NO: 3
Asp Gly Trp Gln Asp Ile Val Ile Gly Ala Pro Gln Tyr Phe Asp Arg
 <210> 15
 <211> 17
 <212> PRT
 <213> Human
 <220>
 <223> Amino acids 344-360 of SEQ ID NO: 3
 <400> 15
 Asp Gly Glu Val Gly Gly Ala Val Tyr Val Tyr Met Asn Gln Gly
 Arg
 <210> 16
 <211> 8
 <212> PRT
 <213> Human
 <223> Amino acids 361-368 of SEQ ID NO: 3
 <400> 16
 Trp Asn Asn Val Lys Pro Ile Arg
```

```
5
 1
<210> 17
<211> 24
<212> PRT
<213> Human
<223> Amino acids 383-406 of SEQ ID NO: 3
<400> 17
Asn Ile Gly Asp Ile Asn Gln Asp Gly Tyr Pro Asp Ile Ala Val Gly
Ala Pro Tyr Asp Asp Leu Gly Lys
            20
<210> 18
<211> 18
<212> PRT
<213> Human
<220>
<223> Amino acids 427-444 of SEQ ID NO: 3
<400> 18
Gly Ile Ser Pro Tyr Phe Gly Tyr Ser Ile Ala Gly Asn Met Asp Leu
Asp Arg
 <210> 19
 <211> 19
 <212> PRT
 <213> Human
 <223> Amino acids 445-463 of SEQ ID NO: 3
 <400> 19
 Asn Ser Tyr Pro Asp Val Ala Val Gly Ser Leu Ser Asp Ser Val Thr
                                     10
 Ile Phe Arg
 <210> 20
 <211> 9
 <212> PRT
 <213> Human
 <220>
 <223> Amino acids 464-472 of SEQ ID NO: 3
 <400> 20
```

```
Ser Arg Pro Val Ile Asn Ile Gln Lys
                  5
<210> 21
<211> 18
<212> PRT
<213> Human
<220>
<223> Amino acids 577-594 of SEQ ID NO: 3
<400> 21
Leu Arg Pro Ile Pro Ile Thr Ala Ser Val Glu Ile Gln Glu Pro Ser
                  5
Ser Arg
<210> 22
<211> 17
<212> PRT
<213> Human
<223> Amino acids 597-613 of SEQ ID NO: 3
<400> 22
Val Asn Ser Leu Pro Glu Val Leu Pro Ile Leu Asn Ser Asp Glu Pro
                                      10
Lys
 <210> 23
 <211> 10
 <212> PRT
 <213> Human
 <220>
 <223> Amino acids 614-623 of SEQ ID NO: 3
 Thr Ala His Ile Asp Val His Phe Leu Lys
 <210> 24
 <211> 8
 <212> PRT
 <213> Human
 <220>
 <223> Amino acids 652-659 of SEQ ID NO: 3
 <400> 24
 Phe Ser Tyr Leu Pro Ile Gln Lys
```

```
<210> 25
<211> 16
<212> PRT
<213> Human
<220>
<223> Amino acids 671-686 of SEQ ID NO: 3
<400> 25
Asp Ile Ala Leu Glu Ile Thr Val Thr Asn Ser Pro Ser Asn Pro Arg
                                       10
<210> 26
<211> 14
<212> PRT
<213> Human
<220>
<223> Amino acids 822-835 of SEQ ID NO: 3
 Ser Glu Asp Glu Val Gly Ser Leu Ile Glu Tyr Glu Phe Arg
                   5
 <210> 27
 <211> 15
 <212> PRT
 <213> Human
 <220>
 <223> Amino acids 871-885 of SEQ ID NO: 3
 <400> 27
 Val Glu Ser Lys Gly Leu Glu Lys Val Thr Cys Glu Pro Gln Lys
  1
 <210> 28
 <211> 13
 <212> PRT
 <213> Human
 <220>
 \stackrel{-}{<}223> Amino acids 902-914 of SEQ ID NO: 3
  <400> 28
  Arg Glu Ile Thr Glu Lys Gln Ile Asp Asp Asn Arg Lys
  <210> 29
  <211> 7
  <212> PRT
  <213> Human
  <220>
  <223> Amino acids 915-921 of SEQ ID NO: 3
```

```
<400> 29
Phe Ser Leu Phe Ala Glu Arg
<210> 30
<211> 16
<212> PRT
<213> Human
<220>
<223> Amino acids 923-938 of SEQ ID NO: 3
<400> 30
Tyr Gln Thr Leu Asn Cys Ser Val Asn Val Asn Cys Val Asn Ile Arg
                                      10
<210> 31
<211> 9
<212> PRT
<213> Human
<220>
<\!223\!> Amino acids 968-976 of SEQ ID NO: 3
<400> 31
Leu Asn Tyr Leu Asp Ile Leu Met Arg
<210> 32
<211> 13
<212> PRT
<213> Human
<220>
<223> Amino acids 977-989 of SEQ ID NO: 3
<400> 32
Ala Phe Ile Asp Val Thr Ala Ala Ala Glu Asn Ile Arg
<210> 33
<211> 9
<212> PRT
<213> Human
<223> Amino acids 990-998 of SEQ ID NO: 3
<400> 33
Leu Pro Asn Ala Gly Thr Gln Val Arg
<210> 34
<211> 12
<212> PRT
```

```
<213> Human
<220>
\stackrel{--}{<}223> Amino acids 178-189 of SEQ ID NO: 4
Val Ser Val Pro Gln Thr Asp Met Arg Pro Glu Lys
                 5
<210> 35
<211> 13
<212> PRT
<213> Human
<220>
<223> Amino acids 192-204 of SEQ ID NO: 4
Glu Pro Trp Pro Asn Ser Asp Pro Pro Phe Ser Phe Lys
<400> 35
 <210> 36
 <211> 13
 <212> PRT
 <213> Human
 <220>
 <223> Amino acids 205-217 of SEQ ID NO: 4
 <400> 36
 Asn Val Ile Ser Leu Thr Glu Asp Val Asp Glu Phe Arg
 <210> 37
 <211> 12
  <212> PRT
 <213> Human
  <220>
 <223> Amino acids 301-312 of SEQ ID NO: 4
  Thr Gln Asp Tyr Pro Ser Val Pro Thr Leu Val Arg
   1
  <210> 38
  <211> 12
  <212> PRT
  <213> Human
  <223> Amino acids 402-413 of SEQ ID NO: 4
  <400> 38
```

Page 20

```
<210> 39
<211> 18
<212> PRT
<213> Human
<220>
<223> Amino acids 414-431 of SEQ ID NO: 4
Ala Leu Glu His Val Asp Gly Thr His Val Cys Gln Leu Pro Glu
Asp Gln Lys
<210> 40
<211> 14
 <212> PRT
 <213> Human
 <220>
 <223> Amino acids 432-445 of SEQ ID NO: 4
 Gly Asn Ile His Leu Lys Pro Ser Phe Ser Asp Gly Leu Lys
 <210> 41
 <211> 16
 <212> PRT
 <213> Human
 <223> Amino acids 446-461 of SEQ ID NO: 4
  <220>
  Met Asp Ala Gly Ile Ile Cys Asp Val Cys Thr Cys Glu Leu Gln Lys
  <210> 42
  <211> 15
  <212> PRT
  <213> Human
  <223> Amino acids 531-545 of SEQ ID NO: 4
   Tyr Glu Gly Gln Phe Cys Glu Tyr Asp Asn Phe Gln Cys Pro Arg
                    5
   <210> 43
   <211> 16
```

```
<220>
<223> Amino acids 946-958 of SEQ ID NO: 4
<400> 47
Val Pro Leu Phe Ile Arg Pro Glu Asp Asp Glu Lys
<210> 48
<211> 14
<212> PRT
<213> Human
<220>
\stackrel{-}{<}223> Amino acids 990-1003 of SEQ ID NO: 4
Asp Val Val Ser Phe Glu Gln Pro Glu Phe Ser Val Ser Arg
                   5
 1.
 <210> 49
 <211> 12
 <212> PRT
 <213> Human
 <220>
 <223> Amino acids 1061-1072 of SEQ ID NO: 4
 <400> 49
 Leu Leu Glu Leu Gln Glu Val Asp Ser Leu Leu Arg
                    5
  <210> 50
  <211> 18
  <212> PRT
  <213> Human
  <220>
  <223> Amino acids 1196-1214 of SEQ ID NO: 4
  Val Cys Ala Tyr Ala Gln Gly Glu Gly Pro Tyr Ser Ser Leu Val Ser
  Cys Arg
   <210> 51
   <211> 9
   <212> PRT
   <213> Human
   <220>
   \stackrel{-}{<}223> Amino acids 1273-1281 of SEQ ID NO: 4
```

SEQUENCE LISTING

<110> Brodin, Thomas Karlstrom, Pia J. Ohlsson, Lennart G. Tordsson, Jesper M. Kearney, Philip P. Nilson, Bo H.K.									
<120> Novel Compounds									
<130> 003300-920									
<140> US 10/088,639 <141> 2002-03-20									
<150> SE 9903895-2 <151> 1999-10-28									
<160> 51									
<170> PatentIn Ver. 2.1									
<210> 1 <211> 747 <212> DNA <213> Macaca fascicularis									
<221> CDS <222> (1)(747)									
<223> Coding sequence VL (1-109) - modified Huston linker (110-127) - VH (128-249)									
<400> 1									
<pre><400> 1 tct tct gag ctg act cag ggc cct gca ttg tct gtg gcc ttg gga cat 48 Ser Ser Glu Leu Thr Gln Gly Pro Ala Leu Ser Val Ala Leu Gly His 1 5</pre>	3								
Ser Ser Glu Leu Thr Gin Gly Pro Ala leu Ser vul III 201									
Ser Ser Glu Leu Thr Gln Gly Pro Ala leu Ser vul Inte 15 1 5 10 15 aca gtc agg atg acc tgc caa gga gac agc ctc aaa acc tat tat gca 96 Thr Val Arg Met Thr Cys Gln Gly Asp Ser Leu Lys Thr Tyr Tyr Ala 20 25 30									
Ser Ser Glu Leu Thr Gln Gly Pro Ala leu Ser vul Tha 15 aca gtc agg atg acc tgc caa gga gac agc ctc aaa acc tat tat gca Thr Val Arg Met Thr Cys Gln Gly Asp Ser Leu Lys Thr Tyr Tyr Ala 20 agc tgg tac cag cag aag cca ggc cag gtc cct gtg ctg gtc atc tat Ser Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Val Leu Val Ile Tyr 45	5								
Ser Ser Glu Leu Thr Gln Gly Pro Ala leu Ser val That 20 15 aca gtc agg atg acc tgc caa gga gac agc ctc aaa acc tat tat gca Thr Val Arg Met Thr Cys Gln Gly Asp Ser Leu Lys Thr Tyr Ala 20 25 agc tgg tac cag cag aag cca ggc cag gtc cct gtg ctg gtc atc tat Ser Trp Tyr Gln Gln Lys Pro Gly Gln Val Pro Val Leu Val Ile Tyr 45 ggt aac aac tac cgg ccc tca ggg atc cca ggc cga ttc tct ggc tcc Gly Asn Asn Tyr Arg Pro Ser Gly Ile Pro Gly Arg Phe Ser Gly Ser 50	5 4 4								

Page 1

003300-920.ST25

				85					90					95		
ccg Pro	gta Val	ttc Phe	ggc Gly 100	gga Gly	ggg Gly	acc Thr	cgg Arg	gtg Val 105	acc Thr	gtc Val	cta Leu	ggt Gly	caa Gln 110	gcc Ala	aac Asn	336
ggt Gly	gaa Glu	ggc Gly 115	ggc Gly	tct Ser	ggt Gly	ggc Gly	ggg Gly 120	gga Gly	tcc Ser	gga Gly	ggc Gly	ggc Gly 125	ggt Gly	tct Ser	gag Glu	384
gtg Val	cag Gln 130	t t a	gtg Val	gag Glu	tct Ser	ggg Gly 135	gga	ggc Gly	ttg Leu	gta Val	aag Lys 140	cct Pro	Gly	gly ggg	tcc Ser	432
ctg Leu 145	aga Arg	ctc Leu	tct Ser	tgt Cys	gta Val 150	gcc Ala	tct Ser	ggg Gly	tcc Ser	atc Ile 155	ttc Phe	agt Ser	agc Ser	tct Ser	gtt Val 160	480
atg Met	cac His	tgg Trp	gtc Val	cgc Arg 165	cag Gln	gct Ala	cca Pro	gga Gly	aag Lys 170	ggt Gly	ctg Leu	gag Glu	tgg Trp	gtc Val 175	tca Ser	528
gtt Val	att Ile	agt Ser	gaa Glu 180	aat Asn	ggg Gly	cgt Arg	acc Thr	att Ile 185	aac Asn	tac Tyr	gca Ala	gac Asp	tct Ser 190	gtg Val	aag Lys	576
ggc Gly	cga Arg	ttc Phe 195	Thr	atc Ile	tcc Ser	aga Arg	gac Asp 200	Asn	gcc Ala	aag Lys	aac Asn	tca Ser 205	ctg Leu	ttt Phe	ctg Leu	624
cag Gln	atg Met 210	Asn	agc Ser	ctg Leu	aca Thr	ggc Gly 215	Glu	gac Asp	acg Thr	gcc Ala	gtc Val 220	. туг	tac Tyr	tgt Cys	agt Ser	672
aga Arg 225	Glu	ggg Gly	gga Gly	cct Pro	gga Gly 230	Thr	acg Thr	tcc Ser	aac Asn	cgg Arg 235	, rer	gat Asp	gcc Ala	tgg Trp	ggc Gly 240	720
ccç Pro	gga Gly	gto Val	c ctg Lev	g gto Val 245	. Thr	gtt Val	tcc Ser	tca Ser	1							747
<210> 2 <211> 249 <212> PRT <213> Macaca fascicularis <223> Coding sequence VL (1-109) - modified Huston linker (110-127) - VH (128-249)																
Se	00> : r Se: 1	2 r Gl	u Le		r Gli	n Gl	y Pr	o Al	a Le	u Se: 0	r Va	l Al	a Lei	Gl د 1	y His 5	
Th	r Va	l Ar	g Me		r Cy	s Gl	n Gl	y As	p Se 5	r Le	u Ly	s Th	r Ty:	r Ту О	r Ala	
Se	r Tr		r Gl 5	n Gl	n Ly	s Pr	o Gl 4	y Gl O	n Va	l Pr	o Va	1 Le 4	u Va 5	l Il	e Tyr	

Page 2

- Gly Asn Asn Tyr Arg Pro Ser Gly Ile Pro Gly Arg Phe Ser Gly Ser
- Trp Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Ala Ala Gln Val Glu
- Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Trp Asp Ser Ser Gly Thr His
- Pro Val Phe Gly Gly Gly Thr Arg Val Thr Val Leu Gly Gln Ala Asn 110
- Gly Glu Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Glu 120
- Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser
- Leu Arg Leu Ser Cys Val Ala Ser Gly Ser Ile Phe Ser Ser Ser Val 155 150
- Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val Ser
- Val Ile Ser Glu Asn Gly Arg Thr Ile Asn Tyr Ala Asp Ser Val Lys 185
- Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Phe Leu 200
- Gln Met Asn Ser Leu Thr Gly Glu Asp Thr Ala Val Tyr Tyr Cys Ser
- Arg Glu Gly Gly Pro Gly Thr Thr Ser Asn Arg Leu Asp Ala Trp Gly 235
- Pro Gly Val Leu Val Thr Val Ser Ser 245
- <210> 3
- <211> 1073
- <212> PRT
- <213> Human
- <223> TA6-Human integrin alpha-6A
- <400> 3
- Met Ala Ala Gly Gln Leu Cys Leu Leu Tyr Leu Ser Ala Gly Leu
- Leu Ser Arg Leu Gly Ala Ala Phe Asn Leu Asp Thr Arg Glu Asp Asn 25
- Val Ile Arg Lys Tyr Gly Asp Pro Gly Ser Leu Phe Gly Phe Ser Leu
- Ala Met His Trp Gln Leu Gln Pro Glu Asp Lys Arg Leu Leu Val

10085639.032008

003300-920.ST25

	50					55					60				
Gly 65	Ala	Pro	Arg	Gly	Glu 70	Ala	Leu	Pro	Leu	Gln 75	Arg	Ala	Asn	Arg	Thr 80
Gly	Gly	Leu	Tyr	Ser 85	Cys	Asp	Ile	Thr	Ala 90	Arg	Gly	Pro	Cys	Thr 95	Arg
Ile	Glu	Phe	Asp 100	Asn	Asp	Ala	Asp	Pro 105	Thr	Ser	Glu	Ser	Lys 110	Glu	Asp
Gln	Trp		Gly	Val	Thr	Val	Gln 120	Ser	Gln	Gly	Pro	Gly 125	Gly	Lys	Val
Val	Thr 130	115 Cys	Ala	His	Arg	Tyr 135	Glu	Lys	Arg	Gln	His 140		Asn	Thr	Lys
Gln 145	Glu	Ser	Arg	Asp	Ile 150	Phe	Gly	Arg	Cys	Tyr 155	Val	Leu	Ser	Gln	Asn 160
Leu	Arg	Ile	Glu	Asp 165	Asp	Met	Asp	Gly	Gly 170	Asp	Trp	Ser	Phe	Cys 175	Asp
Gly	Arg	Leu	Arg 180	Gly	His	Glu	Lys	Phe 185	Gly	Ser	Cys	Gln	Gln 190	Gly	Val
Ala	Ala	Thr 195	Phe	Thr	Lys	Asp	Phe 200	His	Tyr	Ile	Val	Phe 205	Gly	Ala	Pro
Gly	Thr 210	Tyr	Asn	Trp	Lys	Gly 215	Ile	Val	Arg	Val	Glu 220	Gln	Lys	Asn	Asn
Thr 225		Phe	Asp	Met	Asn 230		Phe	Glu	Asp	Gly 235	Pro	Tyr	Glu	Val	Gly 240
Gly	Glu	Thr	Glu	His 245		Glu	Ser	Leu	Val 250	Pro	Val	Pro	Ala	Asn 255	Ser
Tyr	Leu	Gly	Phe 260		Leu	Asp	Ser	Gly 265	Lys	Gly	, Ile	Val	Ser 270	Lys	Asp
Glu	Ile	Thr 275		· Val	Ser	Gly	Ala 280		Arç	, Ala	a Asn	His 285	s Ser	Gly	Ala
Val	. Val		ı Lev	ı Lys	arg	Asp 295		Lys	Ser	Ala	a His	Leu)	ı Lev	Prc	Glu
His 305		e Phe	e Asp	Gly	Glu 310		/ Leu	a Alá	sei	Ser 315	c Phe	e Gly	/ Tyr	Asp	Val 320
Ala	a Val	. Val	l Asp	Leu 325	a Asr	n Lys	s Asp	o Gly	7 Trp 330	o Glr	n Asp	o Ile	e Val	11e 335	e Gly
Ala	a Pro	o Gli	n Tys 340		e Asp	o Aro	g Asp	Gly 345	y Glu 5	ı Va	l Gly	y Gly	y Ala 350	a Val	Tyr
Va.	l Týi	r Met		n Gli	n Glr	n Gly	y Arc 360	g Trp) Ası	n Ası	n Val	1 Ly: 36!	s Pro	o Ile	e Arg

Leu Asn Gly Thr Lys Asp Ser Met Phe Gly Ile Ala Val Lys Asn Ile Gly Asp Ile Asn Gln Asp Gly Tyr Pro Asp Ile Ala Val Gly Ala Pro 390 Tyr Asp Asp Leu Gly Lys Val Phe Ile Tyr His Gly Ser Ala Asn Gly Ile Asn Thr Lys Pro Thr Gln Val Leu Lys Gly Ile Ser Pro Tyr Phe Gly Tyr Ser Ile Ala Gly Asn Met Asp Leu Asp Arg Asn Ser Tyr Pro 440 445 Asp Val Ala Val Gly Ser Leu Ser Asp Ser Val Thr Ile Phe Arg Ser 455 Arg Pro Val Ile Asn Ile Gln Lys Thr Ile Thr Val Thr Pro Asn Arg 475 470 Ile Asp Leu Arg Gln Lys Thr Ala Cys Gly Ala Pro Ser Gly Ile Cys Leu Gln Val Lys Ser Cys Phe Glu Tyr Thr Ala Asn Pro Ala Gly Tyr 505 Asn Pro Ser Ile Ser Ile Val Gly Thr Leu Glu Ala Glu Lys Glu Arg Arg Lys Ser Gly Leu Ser Ser Arg Val Gln Phe Arg Asn Gln Gly Ser 535 Glu Pro Lys Tyr Thr Gln Glu Leu Thr Leu Lys Arg Gln Lys Gln Lys Val Cys Met Glu Glu Thr Leu Trp Leu Gln Asp Asn Ile Arg Asp Lys 570 Leu Arg Pro Ile Pro Ile Thr Ala Ser Val Glu Ile Gln Glu Pro Ser 585 Ser Arg Arg Arg Val Asn Ser Leu Pro Glu Val Leu Pro Ile Leu Asn Ser Asp Glu Pro Lys Thr Ala His Ile Asp Val His Phe Leu Lys Glu 615 Gly Cys Gly Asp Asp Asn Val Cys Asn Ser Asn Leu Lys Leu Glu Tyr 630 635 Lys Phe Cys Thr Arg Glu Gly Asn Gln Asp Lys Phe Ser Tyr Leu Pro Ile Gln Lys Gly Val Pro Glu Leu Val Leu Lys Asp Gln Lys Asp Ile 665 Ala Leu Glu Ile Thr Val Thr Asn Ser Pro Ser Asn Pro Arg Asn Pro 680

Gln Tyr Ser Gly Val Pro Trp Trp Ile Ile Leu Val Ala Ile Leu Ala 1010

Gly Ile Leu Met Leu Ala Leu Leu Val Phe Ile Leu Trp Lys Cys Gly 1035

Phe Phe Lys Arg Asn Lys Lys Asp His Tyr Asp Ala Thr Tyr His Lys 1050

Ala Glu Ile His Ala Gln Pro Ser Asp Lys Glu Arg Leu Thr Ser Asp 1065

Ala

<210> 4

<211> 1875

<212> PRT

<213> Human

<223> Integrin beta-4 precursor

<400> 4

Met Ala Gly Pro Arg Pro Ser Pro Trp Ala Arg Leu Leu Ala Ala

Leu Ile Ser Val Ser Leu Ser Gly Thr Leu Ala Asn Arg Cys Lys Lys

Ala Pro Val Lys Ser Cys Thr Glu Cys Val Arg Val Asp Lys Asp Cys

Ala Tyr Cys Thr Asp Glu Met Phe Arg Asp Arg Arg Cys Asn Thr Gln

Ala Glu Leu Leu Ala Ala Gly Cys Gln Arg Glu Ser Ile Val Val Met

Glu Ser Ser Phe Gln Ile Thr Glu Glu Thr Gln Ile Asp Thr Thr Leu

Arg Arg Ser Gln Met Ser Pro Gln Gly Leu Arg Val Arg Leu Arg Pro

Gly Glu Glu Arg His Phe Glu Leu Glu Val Phe Glu Pro Leu Glu Ser 120

Pro Val Asp Leu Tyr Ile Leu Met Asp Phe Ser Asn Ser Met Ser Asp 135

Asp Leu Asp Asn Leu Lys Lys Met Gly Gln Asn Leu Ala Arg Val Leu

Ser Gln Leu Thr Ser Asp Tyr Thr Ile Gly Phe Gly Lys Phe Val Asp

Lys Val Ser Val Pro Gln Thr Asp Met Arg Pro Glu Lys Leu Lys Glu 185

Pro Trp Pro Asn Ser Asp Pro Pro Phe Ser Phe Lys Asn Val Ile Ser 200 195 Leu Thr Glu Asp Val Asp Glu Phe Arg Asn Lys Leu Gln Gly Glu Arg Ile Ser Gly Asn Leu Asp Ala Pro Glu Gly Gly Phe Asp Ala Ile Leu Gln Thr Ala Val Cys Thr Arg Asp Ile Gly Trp Arg Pro Asp Ser Thr 250 His Leu Leu Val Phe Ser Thr Glu Ser Ala Phe His Tyr Glu Ala Asp 265 Gly Ala Asn Val Leu Ala Gly Ile Met Ser Arg Asn Asp Glu Arg Cys 280 His Leu Asp Thr Thr Gly Thr Tyr Thr Gln Tyr Arg Thr Gln Asp Tyr Pro Ser Val Pro Thr Leu Val Arg Leu Leu Ala Lys His Asn Ile Ile 310 Pro Ile Phe Ala Val Thr Asn Tyr Ser Tyr Ser Tyr Tyr Glu Lys Leu His Thr Tyr Phe Pro Val Ser Ser Leu Gly Val Leu Gln Glu Asp Ser Ser Asn Ile Val Glu Leu Leu Glu Glu Ala Phe Asn Arg Ile Arg Ser Asn Leu Asp Ile Arg Ala Leu Asp Ser Pro Arg Gly Leu Arg Thr Glu Val Thr Ser Lys Met Phe Gln Lys Thr Arg Thr Gly Ser Phe His Ile Arg Arg Gly Glu Val Gly Ile Tyr Gln Val Gln Leu Arg Ala Leu Glu 410 His Val Asp Gly Thr His Val Cys Gln Leu Pro Glu Asp Gln Lys Gly Asn Ile His Leu Lys Pro Ser Phe Ser Asp Gly Leu Lys Met Asp Ala Gly Ile Ile Cys Asp Val Cys Thr Cys Glu Leu Gln Lys Glu Val Arg Ser Ala Arg Cys Ser Phe Asn Gly Asp Phe Val Cys Gly Gln Cys Val Cys Ser Glu Gly Trp Ser Gly Gln Thr Cys Asn Cys Ser Thr Gly Ser Leu Ser Asp Ile Gln Pro Cys Leu Arg Glu Gly Glu Asp Lys Pro Cys 505

Page 8

Ser Gly Arg Gly Glu Cys Gln Cys Gly His Cys Val Cys Tyr Gly Glu 520 Gly Arg Tyr Glu Gly Gln Phe Cys Glu Tyr Asp Asn Phe Gln Cys Pro 535 Arg Thr Ser Gly Phe Leu Cys Asn Asp Arg Gly Arg Cys Ser Met Gly Gln Cys Val Cys Glu Pro Gly Trp Thr Gly Pro Ser Cys Asp Cys Pro Leu Ser Asn Ala Thr Cys Ile Asp Ser Asn Gly Gly Ile Cys Asn Gly 585 Arg Gly His Cys Glu Cys Gly Arg Cys His Cys His Gln Gln Ser Leu 600 Tyr Thr Asp Thr Ile Cys Glu Ile Asn Tyr Ser Ala Ile His Pro Gly Leu Cys Glu Asp Leu Arg Ser Cys Val Gln Cys Gln Ala Trp Gly Thr Gly Glu Lys Lys Gly Arg Thr Cys Glu Glu Cys Asn Phe Lys Val Lys 650 Met Val Asp Glu Leu Lys Arg Ala Glu Glu Val Val Arg Cys Ser 665 Phe Arg Asp Glu Asp Asp Cys Thr Tyr Ser Tyr Thr Met Glu Gly Asp Gly Ala Pro Gly Pro Asn Ser Thr Val Leu Val His Lys Lys 695 Asp Cys Pro Pro Gly Ser Phe Trp Trp Leu Ile Pro Leu Leu Leu Leu Leu Leu Pro Leu Leu Ala Leu Leu Leu Leu Cys Trp Lys Tyr Cys Ala Cys Cys Lys Ala Cys Leu Ala Leu Leu Pro Cys Cys Asn Arg Gly His Met Val Gly Phe Lys Glu Asp His Tyr Met Leu Arg Glu Asn Leu Met Ala Ser Asp His Leu Asp Thr Pro Met Leu Arg Ser Gly Asn Leu Lys Gly Arg Asp Val Val Arg Trp Lys Val Thr Asn Asn Met Gln Arg Pro Gly Phe Ala Thr His Ala Ala Ser Ile Asn Pro Thr Glu Leu Val 810 805 Pro Tyr Gly Leu Ser Leu Arg Leu Ala Arg Leu Cys Thr Glu Asn Leu 825

- Leu Lys Pro Asp Thr Arg Glu Cys Ala Gln Leu Arg Gln Glu Val Glu 835 840 845
- Glu Asn Leu Asn Glu Val Tyr Arg Gln Ile Ser Gly Val His Lys Leu 850 855 860
- Gln Gln Thr Lys Phe Arg Gln Gln Pro Asn Ala Gly Lys Lys Gln Asp 865 870 875 880
- His Thr Ile Val Asp Thr Val Leu Met Ala Pro Arg Ser Ala Lys Pro 885 890 895
- Ala Leu Leu Lys Leu Thr Glu Lys Gln Val Glu Gln Arg Ala Phe His 900 905 910
- Asp Leu Lys Val Ala Pro Gly Tyr Tyr Thr Leu Thr Ala Asp Gln Asp 915 920 925
- Ala Arg Gly Met Val Glu Phe Gln Glu Gly Val Glu Leu Val Asp Val 930 935 940
- Arg Val Pro Leu Phe Ile Arg Pro Glu Asp Asp Glu Lys Gln Leu 945 950 955 960
- Leu Val Glu Ala Ile Asp Val Pro Ala Gly Thr Ala Thr Leu Gly Arg 965 970 975
- Arg Leu Val Asn Ile Thr Ile Ile Lys Glu Gln Ala Arg Asp Val Val 980 985 990
- Ser Phe Glu Gln Pro Glu Phe Ser Val Ser Arg Gly Asp Gln Val Ala 995 1000 1005
- Arg Ile Pro Val Ile Arg Arg Val Leu Asp Gly Gly Lys Ser Gln Val 1010 1015 1020
- Ser Tyr Arg Thr Gln Asp Gly Thr Ala Gln Gly Asn Arg Asp Tyr Ile 1025 1030 1035 1040
- Pro Val Glu Gly Glu Leu Leu Phe Gln Pro Gly Glu Ala Trp Lys Glu 1045 1050 1055
- Leu Gln Val Lys Leu Leu Glu Leu Gln Glu Val Asp Ser Leu Leu Arg 1060 1065 1070
- Gly Arg Gln Val Arg Arg Phe His Val Gln Leu Ser Asn Pro Lys Phe 1075 1080 1085
- Gly Ala His Leu Gly Gln Pro His Ser Thr Thr Ile Ile Ile Arg Asp 1090 1095 1100
- Pro Asp Glu Leu Asp Arg Ser Phe Thr Ser Gln Met Leu Ser Ser Gln 1105 1110 1115 1120
- Pro Pro Pro His Gly Asp Leu Gly Ala Pro Gln Asn Pro Asn Ala Lys 1125 1130 1135
- Ala Ala Gly Ser Arg Lys Ile His Phe Asn Trp Leu Pro Pro Ser Gly 1140 1145 1150

- Lys Pro Met Gly Tyr Arg Val Lys Tyr Trp Ile Gln Gly Asp Ser Glu 1155 1160 1165
- Ser Glu Ala His Leu Leu Asp Ser Lys Val Pro Ser Val Glu Leu Thr 1170 1175 1180
- Asn Leu Tyr Pro Tyr Cys Asp Tyr Glu Met Lys Val Cys Ala Tyr Gly 1185 1190 1195 1200
- Ala Gln Gly Glu Gly Pro Tyr Ser Ser Leu Val Ser Cys Arg Thr His $1205 \hspace{1.5cm} 1210 \hspace{1.5cm} 1215$
- Gln Glu Val Pro Ser Glu Pro Gly Arg Leu Ala Phe Asn Val Val Ser 1220 1225 1230
- Ser Thr Val Thr Gln Leu Ser Trp Ala Glu Pro Ala Glu Thr Asn Gly 1235 1240 1245
- Glu Ile Thr Ala Tyr Glu Val Cys Tyr Gly Leu Val As
n Asp Asp As
n 1250 1260
- Arg Pro Ile Gly Pro Met Lys Lys Val Leu Val Asp Asn Pro Lys Asn 1265 1270 1275 1280
- Arg Met Leu Ile Glu Asn Leu Arg Glu Ser Gln Pro Tyr Arg Tyr 1285 1290 1295
- Thr Val Lys Ala Arg Asn Gly Ala Gly Trp Gly Pro Glu Arg Glu Ala 1300 1305 1310
- Ile Ile Asn Leu Ala Thr Gln Pro Lys Arg Pro Met Ser Ile Pro Ile 1315 1320 1325
- Ile Pro Asp Ile Pro Ile Val Asp Ala Gl
n Ser Gly Glu Asp Tyr Asp 1330 $\,\cdot\,\,$ 1335 $\,$ 1340
- Ser Phe Leu Met Tyr Ser Asp Asp Val Leu Arg Ser Pro Ser Gly Ser 1345 1350 1355 1360
- Gln Arg Pro Ser Val Ser Asp Asp Thr Gly Cys Gly Trp Lys Phe Glu 1365 1370 1375
- Pro Leu Leu Gly Glu Glu Leu Asp Leu Arg Arg Val Thr Trp Arg Leu 1380 1385 1390
- Pro Pro Glu Leu Ile Pro Arg Leu Ser Ala Ser Ser Gly Arg Ser Ser 1395 1400 1405
- Asp Ala Glu Ala Pro Thr Ala Pro Arg Thr Thr Ala Ala Arg Ala Gly 1410 1415 1420
- Arg Ala Ala Ala Val Pro Arg Ser Ala Thr Pro Gly Pro Pro Gly Glu 1425 1430 1435 1440
- His Leu Val Asn Gly Arg Met Asp Phe Ala Phe Pro Gly Ser Thr Asn $1445 \\ \hspace*{1.5cm} 1450 \\ \hspace*{1.5cm} 1455$
- Ser Leu His Arg Met Thr Thr Thr Ser Ala Ala Ala Tyr Gly Thr His 1460 1465 1470

- Leu Ser Pro His Val Pro His Arg Val Leu Ser Thr Ser Ser Thr Leu 1475 1480 1485
- Thr Arg Asp Tyr Asn Ser Leu Thr Arg Ser Glu His Ser His Ser Thr 1490 1495 1500
- Thr Leu Pro Arg Asp Tyr Ser Thr Leu Thr Ser Val Ser Ser His Gly 1505 1510 1515 1520
- Leu Pro Pro Ile Trp Glu His Gly Arg Ser Arg Leu Pro Leu Ser Trp
 1525 1530 1535
- Ala Leu Gly Ser Arg Ser Arg Ala Gln Met Lys Gly Phe Pro Pro Ser 1540 1545 1550
- Arg Gly Pro Arg Asp Ser Ile Ile Leu Ala Gly Arg Pro Ala Ala Pro 1555 1560 1565
- Ser Trp Gly Pro Asp Ser Arg Leu Thr Ala Gly Val Pro Asp Thr Pro 1570 1575 1580
- Thr Arg Leu Val Phe Ser Ala Leu Gly Pro Thr Ser Leu Arg Val Ser 1585 1590 1595 1600
- Trp Gln Glu Pro Arg Cys Glu Arg Pro Leu Gln Gly Tyr Ser Val Glu 1605 1610 1615
- Tyr Gln Leu Leu Asn Gly Gly Glu Leu His Arg Leu Asn Ile Pro Asn 1620 1625 1630
- Pro Ala Gln Thr Ser Val Val Val Glu Asp Leu Leu Pro Asn His Ser 1635 1640 1645
- Tyr Val Phe Arg Val Arg Ala Gln Ser Gln Glu Gly Trp Gly Arg Glu
 1650 1660
- Arg Glu Gly Val Ile Thr Ile Glu Ser Gln Val His Pro Gln Ser Pro 1665 1670 1675 1680
- Leu Cys Pro Leu Pro Gly Ser Ala Phe Thr Leu Ser Thr Pro Ser Ala 1685 1690 1695
- Pro Gly Pro Leu Val Phe Thr Ala Leu Ser Pro Asp Ser Leu Gln Leu 1700 1705 1710
- Ser Trp Glu Arg Pro Arg Pro Asn Gly Asp Ile Val Gly Tyr Leu 1715 1720 1725
- Val Thr Cys Glu Met Ala Gln Gly Gly Gly Pro Ala Thr Ala Phe Arg 1730 1740
- Val Asp Gly Asp Ser Pro Glu Ser Arg Leu Thr Val Pro Gly Leu Ser 1745 1750 1755 1760
- Glu Asn Val Pro Tyr Lys Phe Lys Val Gln Ala Arg Thr Thr Glu Gly 1765 1770 1775
- Phe Gly Pro Glu Arg Glu Gly Ile Ile Thr Ile Glu Ser Gln Asp Gly 1780 1785 1790

```
Gly Pro Phe Pro Gln Leu Gly Ser Arg Ala Gly Leu Phe Gln His Pro
                          1800
Leu Gln Ser Glu Tyr Ser Ser Ile Thr Thr His Thr Ser Ala Thr
                   1815
Glu Pro Phe Leu Val Asp Gly Pro Thr Leu Gly Ala Gln His Leu Glu
Ala Gly Gly Ser Leu Thr Arg His Val Thr Gln Glu Phe Val Ser Arg
              1845
                                  1850
Thr Leu Thr Thr Ser Gly Thr Leu Ser Thr His Met Asp Gln Gln Phe
                               1865
Phe Gln Thr
      1875
<210> 5
<211> 8
<212> PRT
<213> Human
<223> Amino acids 61-68 of SEQ ID NO: 3
<400> 5
Leu Leu Val Gly Ala Pro Arg
<210> 6
<211> 20
<212> PRT
<213> Human
<223> Amino acids 77-96 of SEQ ID NO: 3
Ala Asn Arg Thr Gly Gly Leu Tyr Ser Cys Asp Ile Thr Ala Arg Gly
Pro Cys Thr Arg
             20
<210> 7
<211> 10
<212> PRT
<213> Human
<223> Amino acids 127-137 of SEQ ID NO: 3
<400> 7
```

Val Val Thr Cys Ala His Arg Tyr Glu Lys

5

P,

1

<210> 8 <211> 7

```
<212> PRT
<213> Human
<223> Amino acids 283-293 of SEQ ID NO: 3
<400> 13
Ala Asn His Ser Gly Ala Val Val Leu Leu Lys
<210> 14
<211> 16
<212> PRT
<213> Human
<223> Amino acids 328-343 of SEQ ID NO: 3
<400> 14
Asp Gly Trp Gln Asp Ile Val Ile Gly Ala Pro Gln Tyr Phe Asp Arg
<210> 15
<211> 17
<212> PRT
<213> Human
<223> Amino acids 344-360 of SEQ ID NO: 3
<400> 15
Asp Gly Glu Val Gly Gly Ala Val Tyr Val Tyr Met Asn Gln Gly
 1
                                      10
Arg
<210> 16
<211> 8
<212> PRT
<213> Human
<223> Amino acids 361-368 of SEQ ID NO: 3
<400> 16
Trp Asn Asn Val Lys Pro Ile Arg
<210> 17
<211> 24
<212> PRT
<213> Human
<223> Amino acids 383-406 of SEQ ID NO: 3
<400> 17
Asn Ile Gly Asp Ile Asn Gln Asp Gly Tyr Pro Asp Ile Ala Val Gly
  1
                  5
                                      10
                                                          1.5
```

()

```
Ala Pro Tyr Asp Asp Leu Gly Lys
            20
<210> 18
<211> 18
<212> PRT
<213> Human
<223> Amino acids 427-444 of SEQ ID NO: 3
<400> 18
Gly Ile Ser Pro Tyr Phe Gly Tyr Ser Ile Ala Gly Asn Met Asp Leu
Asp Arg
<210> 19
<211> 19
<212> PRT
<213> Human
<223> Amino acids 445-463 of SEQ ID NO: 3
<400> 19
Asn Ser Tyr Pro Asp Val Ala Val Gly Ser Leu Ser Asp Ser Val Thr
Ile Phe Arg
<210> 20
<211> 9
<212> PRT
<213> Human
<223> Amino acids 464-472 of SEQ ID NO: 3
<400> 20
Ser Arg Pro Val Ile Asn Ile Gln Lys
<210> 21
<211> 18
<212> PRT
<213> Human
<223> Amino acids 577-594 of SEQ ID NO: 3
<400> 21
Leu Arg Pro Ile Pro Ile Thr Ala Ser Val Glu Ile Gln Glu Pro Ser
                                      10
Ser Arg
```

```
1
                   5
                                       10
 <210> 27
 <211> 15
 <212> PRT
 <213> Human
<223> Amino acids 871-885 of SEQ ID NO: 3
Val Glu Ser Lys Gly Leu Glu Lys Val Thr Cys Glu Pro Gln Lys
<210> 28
<211> 13
<212> PRT
<213> Human
<223> Amino acids 902-914 of SEQ ID NO: 3
<400> 28
Arg Glu Ile Thr Glu Lys Gln Ile Asp Asp Asn Arg Lys
<210> 29
<211> 7
<212> PRT
<213> Human
<223> Amino acids 915-921 of SEQ ID NO: 3
<400> 29
Phe Ser Leu Phe Ala Glu Arg
<210> 30
<211> 16
<212> PRT
<213> Human
<223> Amino acids 923-938 of SEQ ID NO: 3
<400> 30
Tyr Gln Thr Leu Asn Cys Ser Val Asn Val Asn Cys Val Asn Ile Arg
<210> 31
<211> 9
<212> PRT
<213> Human
<223> Amino acids 968-976 of SEQ ID NO: 3
<400> 31
Leu Asn Tyr Leu Asp Ile Leu Met Arg
```

```
1
                   5
 <210> 32
 <211> 13
 <212> PRT
 <213> Human
<223> Amino acids 977-989 of SEQ ID NO: 3
<400> 32
Ala Phe Ile Asp Val Thr Ala Ala Ala Glu Asn Ile Arg
 1
                   5
                                      10
<210> 33
<211> 9
<212> PRT
<213> Human
<223> Amino acids 990-998 of SEQ ID NO: 3
<400> 33
Leu Pro Asn Ala Gly Thr Gln Val Arg
<210> 34
<211> 12
<212°> PRT
<213> Human
<223> Amino acids 178-189 of SEQ ID NO: 4
<400> 34
Val Ser Val Pro Gln Thr Asp Met Arg Pro Glu Lys
 1
                  5
                                      10
<210> 35
<211> 13
<212> PRT
<213> Human
<223> Amino acids 192-204 of SEQ ID NO: 4
<400> 35
Glu Pro Trp Pro Asn Ser Asp Pro Pro Phe Ser Phe Lys
 1
                                      10
<210> 36
<211> 13
<212> PRT
<213> Human
<223> Amino acids 205-217 of SEQ ID NO: 4
<400> 36
Asn Val Ile Ser Leu Thr Glu Asp Val Asp Glu Phe Arg
```

(3)

4

```
<223> Amino acids 916-930 of SEQ ID NO: 4
<400> 46
Val Ala Pro Gly Tyr Tyr Thr Leu Thr Ala Asp Gln Asp Asp Ala Arg
                                     10
<210> 47
<211> 13
<212> PRT
<213> Human
<223> Amino acids 946-958 of SEQ ID NO: 4
<400> 47
Val Pro Leu Phe Ile Arg Pro Glu Asp Asp Asp Glu Lys
 1
<210> 48
<211> 14
<212> PRT
<213> Human
<223> Amino acids 990-1003 of SEQ ID NO: 4
<400> 48
Asp Val Val Ser Phe Glu Gln Pro Glu Phe Ser Val Ser Arg
<210> 49
<211> 12
<212> PRT
<213> Human
<223> Amino acids 1061-1072 of SEQ ID NO: 4
<400> 49
Leu Leu Glu Leu Gln Glu Val Asp Ser Leu Leu Arg
                  5
<210> 50
<211> 18
<212> PRT
<213> Human
<223> Amino acids 1196-1214 of SEQ ID NO: 4
<400> 50
Val Cys Ala Tyr Ala Gln Gly Glu Gly Pro Tyr Ser Ser Leu Val Ser
                                      10
```

Cys Arg

<210> 51 <211> 9 <212> PRT <213> Human <223> Amino acids 1273-1281 of SEQ ID NO: 4 <400> 51 Val Leu Val Asp Asn Pro Lys Asn Arg 1 5

United States Patent & Trademark Office Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

Page(s)present	of_ Assi	ignment	were not
for scanning.		(Document title)	
☐ Page(s)present	of		were not
for scanning.		(Document title)	

o Scanned copy is best available. Figure, we dance